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ABSTRACT
DECIPHERING THE ROLE OF HUMAN ARYLAMINE N-ACETYLTRANSFERASE 1 (NAT1) IN
BREAST CANCER CELL METABOLISM USING A SYSTEMS BIOLOGY APPROACH
Samantha Marie Carlisle
July 20, 2018
Background: Human arylamine N-acetyltransferase 1 (NAT1) is a phase II xenobiotic
metabolizing enzyme found in almost all tissues. NAT1 can additionally hydrolyze acetylcoenzyme A (acetyl-CoA) in the absence of an arylamine substrate. NAT1 expression varies
inter-individually and is elevated in several cancers including estrogen receptor positive (ER+)
breast cancers. Additionally, multiple studies have shown the knockdown of NAT1, by both small
molecule inhibition and siRNA methods, in breast cancer cells leads to decreased invasive ability
and proliferation and decreased anchorage-independent colony formation. However, the exact
mechanism by which NAT1 expression affects cancer risk and progression remains unclear.
Additionally, consequences of the hydrolysis of acetyl-CoA by NAT1 on cellular metabolism
remains uninvestigated.

Hypothesis and Rationale: Samples with decreased levels or knockout of NAT1 will have
increased free acetyl-CoA since those cell lines have less NAT1 to hydrolyze acetyl-CoA.
Conversely, samples with increased NAT1 will have decreased free acetyl-CoA since those cell
lines have more NAT1 to hydrolyze acetyl-CoA. These differences in free acetyl-CoA are
hypothesized to lead to alterations in cellular pathways/metabolism when compared to cells with
basal NAT1 that can be measured by global bioenergetics, metabolomics, and transcriptomics
experiments.

Methods: This dissertation utilized a systems biology approach with four layers. The first layer
consists of six constructed MDA-MB-231 cell lines whose only genetic difference (theoretically) is
v

in NAT1. The second, third, and fourth layers are bioenergetics (Chapter 3), metabolomics
(Chapter 4), and transcriptomics (Chapter 5) measurements of the constructed cell lines.
Resulting data were analyzed individually and also integrated and analyzed (Chapter 6).

Results: The manipulation of NAT1 in MDA-MB-231 breast cancer cells severely altered cellular
metabolism as measured by mitochondrial bioenergetics, metabolomics, and transcriptomics.
More differences were observed in the cell lines with decreased levels and knockout NAT1 than
the cell line with increased NAT1.

Conclusions: This dissertation has generated novel hypotheses about the role of NAT1 in breast
cancer, and more generally cellular metabolism. Furthermore, biochemicals that are likely
products of NAT1 N-acetylation, N-acetylasparagine and N-acetylputrescine, have been
identified. This dissertation presents strong evidence that NAT1, whether directly or through an
effect of NAT1 on acetyl-CoA levels, has an effect on acyl-CoA carnitine conjugates, lysine
degradation, and mitochondrial function. While the exact mechanism by which NAT1 affects
cellular metabolism or breast cancer progression has not been identified, the data presented in
this dissertation add important pieces to the puzzle, putting researchers one step closer to that
goal.
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CHAPTER 1

BACKGROUND AND SIGNIFICANCE

Breast Cancer
According to the American Cancer Society (ACS), breast cancer will account for
approximately 30% of new cancer cases and 14% of cancer related deaths in American women
in 20181. Additionally, 1 in 8 women will develop breast cancer in their lifetime1. Breast cancer is
a heterogeneous disease with many underlying genetic transformations that lead to a diseased
state. This heterogeneity makes predicting breast cancer risk and developing one-size-fits-all
treatment strategies difficult. As the cost of genomic profiling has decreased dramatically, the
feasibility of developing personalized treatment strategies based on the genomic profile of an
individual’s tumor has become attainable. For example, the National Cancer Institute (NCI)
presently has a clinical trials program called Molecular Analysis for Therapy Choice (MATCH) in
which DNA of tumors from patients for whom standard treatment has not been successful are
sequenced and the results are utilized to provide personalized treatment2; the program currently
has 14 treatment arms to which patients are assigned based on mutations, including
amplifications, translocations, and fusions, in 14 different genes: EGFR, MET, ALK, ROS1,
HER2, mTOR, TSC1, TSC2, GNAQ/GNA11, SMO/PTCH1, cKIT, NTRK, BRCA1, and BRCA22.
These advances in precision medicine have led to an urgent need to understand and catalogue
gene targets involved in breast cancer initiation, transformation, and metastasis so that
preventative and treatment strategies can be personalized and optimized for each patient.
N-acetyltransferases (NATs)
Overview

1

Arylamine N-acetyltransferase 1 and arylamine N-acetyltransferase 2 (NAT1 and NAT2;
collectively NATs) are polymorphic phase II xenobiotic metabolizing isozymes that catalyze the
acetylation of a wide range of arylamine and hydrazine substrates using acetyl coenzyme A
(acetyl-CoA) as the acetyl group donor via a ping-pong bi-bi reaction mechanism3,4. The human
NAT1 and NAT2 genes are located in close proximity on chromosome 8p225 and share
approximately 87% protein coding sequence and 81% deduced amino acid sequence homology6.
The open reading frame (ORF) regions of NAT1 and NAT2 are both 870 base pairs and
intronless6,7. NAT1 and NAT2 have distinct but overlapping substrate specificities with NAT1
selectively acetylating p-aminobenzoic acid (PABA) and p-aminosalicylate (PAS) while NAT2
selectively acetylates isoniazid, sulfamethazine (SMZ), procainamide, and hydralazine8. Both
isozymes can acetylate a plethora of arylamines including 4-aminobiphenyl (4-ABP) and 2aminoflourene (2-AF)8. Many NAT substrates are known carcinogens found in well-done red
meats, cigarette smoke, and commercial dyes9,10. Additionally, NAT1 and NAT2 have differing
tissue distributions (reviewed in 11); NAT1 is expressed in nearly every tissue12-22 while NAT2
tissue distribution is thought to be much more limited with the highest expression found in the
liver12 and gastrointestinal (GI) tract19.
Regulation of NATs
NAT1 and NAT2 expression also vary inter-individually, but independent of one
another12,23, based on single nucleotide polymorphisms (SNPs)4,23-29. As of the most recent
update (April 2016), 28 different NAT1 alleles30 and 64 (108 including those predicted) different
NAT2 alleles31 have been identified and named in human populations, conferring either rapid,
intermediate, slow, or unknown acetylator phenotypes. NAT1 and NAT2 allelic frequencies vary
by ethnic population32. The effect of SNPs in NAT2 on N-acetylation activity have been well
described and characterized (reviewed in 27) however the effect of SNPs (located both in and
outside the ORF) in NAT1 on N-acetylation activity are not understood as well with conflicting
reports (reviewed in 33). Large inter-individual variation exists in NAT1 activities within single
genotypes suggesting additional regulation mechanisms are present34-36. Additionally, there is
considerable evidence that NAT1 activity is highly regulated by post-transcriptional and post-

2

translational mechanisms, and substrate concentrations (reviewed in 37). Although the ORF of
NAT1 is contained in a single exon (exon 9), there are 8 upstream non-coding exons38 that are
included, in varying patterns, in alternatively spliced transcripts21. NAT1 is also known to have two
alternative promoters, NATa and NATb, that differ in promotor strength and tissue specificity39-41
producing mRNAs with distinct 5’-UTRs. Notably, there are 9 variant NAT1 transcripts known,
each with identical protein coding sequences38,39,41.
Through chemical modifications of the NAT1 active site as well as changes in the
turnover of NAT1 protein, NAT1 activity can be modulated post-translationally. NAT1 substrates,
including PABA, p-aminosalicylic acid, ethyl-p-aminobenzoate, and p-aminophenol, are capable
of down-regulating NAT1 activity and protein expression in cultured human peripheral blood
mononuclear cells42; this phenomenon was also observed in confluent human cell lines incubated
with PABA42. It is hypothesized this occurs because substrate binding causes the cysteine in the
NAT1 active site to become de-acetylated leading to polyubiquitination and degradation of the
protein37. N-hydroxyl metabolites of NAT1 substrates, including PABA and sulfomethoxazole,
have also been shown to irreversibly inhibit NAT143; however, the molecular mechanism remains
unknown. NAT1 gene expression can also be regulated indirectly by androgens44,45. Additionally,
NAT1 is known to be inhibited by many chemically diverse non-substrate compounds including
tamoxifen46, cisplatin47, thiram (a dithiocarbamate pesticide)48, isothiocyanates49, hydrogen
peroxide and peroxynitrite50,51, acrolein52, carbon black nanoparticles53, cadmium54, and
disulfiram55. Additionally, hsa-miRNA-1290, implicated in lung adenocarcinoma56, ovarian
cancer57, non-small cell lung cancer58,59, glioma60, and colorectal cancer61, has been shown to
directly target the 3’UTR region of human NAT1 mRNA leading to dose-dependent downregulation of NAT1 expression62,63.
Brief History of NATs
Arylamine N-acetyltransferase activity was first described in the late 1930’s when
acetylated para-aminobenezenesulfonamide was detected in the urine of humans and rabbits, but
not dogs, after administration of para-aminobenezenesulfonamide64, although it would be nearly
40 years before the specific enzyme(s) responsible for the transformation was/were isolated and
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identified. NAT activity was described for a second time in the mid 1940’s when it was observed
that liver homogenates and extracts could acetylate sulfanilamides65 and again in the mid 1950’s
when it was shown that the enzyme responsible for the acetylation of sulfanilamides was also
responsible for the acetylation of isoniazid66. NATs were first isolated and described kinetically in
1967 by Weber and Cohen in partially purified preparations from rabbit liver67. NAT was shown to
catalyze the acetylation of isoniazid and several sulfonamides via a ping-pong bi-bi reaction
mechanism using acetyl-CoA as the acetyl donor67. It is also important to note that at the times of
those early studies, NAT1 and NAT2 were thought to be a single enzyme that could be
monomorphic or polymorphic depending on the substrate acetylated. It was not realized until
1990 that there were actually two individual N-acetylating isozymes6,12 with distinct but
overlapping substrate specificities.
NATs & Breast Cancer
While NAT1 has been implicated in many cancers, NAT1’s role in breast cancer has
been investigated more frequently than any other cancer. The earliest studies on Nacetyltransferases and breast cancer were epidemiological studies that investigated associations
between acetylator phenotype and breast cancer risk68-72. Since those initial studies there have
been many more looking at the association in various ethnic and regional populations and in
combination with several possible modifying factors with conflicting results leading to multiple
meta-analyses of these data.
Briefly, of the 5 meta-analyses published on NAT2 and breast cancer risk, 4 investigated
the independent effect of NAT2 phenotype (determined by genotype) on breast cancer risk with
none observing a significant association73-77. However, one of the meta-analyses found evidence
of decreased breast cancer risk for women with a slow phenotype when separately analyzing
studies in which NAT2 phenotype was determined by acetylation rate of xenobiotics metabolized
by NAT2 rather than genotype76. Three of the 5 meta-analyses further analyzed data by including
cumulative smoking exposure into the risk calculation as a modifying variable with all 3 studies
observing a significant association between high pack years and increased breast cancer risk in
the slow acetylator group compared to the rapid acetylator group74,75,77. A single meta-analysis
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considered menopausal status as a modifying factor of NAT2 genotype in breast cancer risk and
observed no significant difference in risk74. None of the meta-analyses included intake of welldone meat as a possible modifying factor of NAT2 genotype in breast cancer risk. There has
been one meta-analysis of NAT1 genotype and breast cancer risk which found no significant
association78, however possible modifying factors such as smoking exposure and well-done meat
intake were not considered in the study.
Although NAT1 and NAT2 both catalyze N-acetylation and have been associated with
breast cancer, their roles in etiology may differ. Numerous studies have investigated possible
roles for NAT1 in breast cancer etiology and progression79-84, given the association between
increased expression of NAT1 and estrogen receptor (ER)-positive breast cancers85-91. Notably,
NAT1 expression is not directly regulated by estrogens or dihydrotestosterone92, thus suggesting
that there may be a common regulatory element between NAT1 and ESR1. Furthermore,
congenic rats expressing higher NAT2 activity (orthologous to human NAT1) have been reported
to exhibit greater carcinogen-induced mammary tumor susceptibility independent of carcinogen
metabolism83. Notably, NAT1 is one of fifty genes whose expression is utilized in the PAM50based Prosigna breast cancer gene signature array to determine the intrinsic subtype of breast
cancer tumors93,94. Conversely, SNPs in NAT2 have been well described and revealed to
influence acetylation rates of many known carcinogens; an association between NAT2 genotype
with breast cancer risk among smokers has been reported (reviewed in 95).
The mRNA expression levels of NAT1 and NAT2 have been detected by reverse
transcription-polymerase chain reaction (RT-PCR) in human mammary tissue13,96. NAT1 Nacetylation activity has been widely reported in normal breast tissue and breast tumor
tissue13,14,38,97-99 whereas NAT2 N-acetylation activity has not been observed as consistently;
when NAT2 activity is observed the activity is much lower than NAT1 activity13,97,98. In addition,
since NAT1 and NAT2 have overlapping substrate specificities, activity studies of the two
isozymes can be complex. For example, Deitz probed human mammary tissue samples for NAT1
and NAT2 activities with p-aminobenzoic acid (PABA; selective for NAT1) and sulfamethazine
(SMZ; selective for NAT2), and reported that SMZ was acetylated by NAT1 at very low levels99.
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By normalizing the SMZ N-acetylation activity to NAT1 activity, Deitz demonstrated that the SMZ
N-acetylation activity was most likely catalyzed by NAT1 rather than NAT2. NAT1 and NAT2
activities have also been reported in rat mammary tissues100.
Wakefield et al profiled NAT1 expression and activity in seven breast cancer cell lines
(MCF-7, T47D, ZR-75-1, Cal51, MDA-MB-231, MDA-MB-437 and MDA-MB-453) and detected
NAT1 mRNA expression and activity in all seven cell lines88; however, NAT2 expression and
activity were not co-investigated. In addition, NAT2 mRNA has been detected in MCF-7 breast
cancer cells at very low levels96; however, NAT1 was not measured at the same time preventing
a direct comparison of expression between the two isozymes. Bradshaw et al detected NAT1 and
NAT2 by western blotting in the ER-positive breast cancer cell line MCF-7; however, the
expression levels were not compared between the two proteins101. Based on limited data, it has
been hypothesized that NAT2 expression is very low in breast tissue and negligible in comparison
to NAT1 expression. However, a more comprehensive evaluation of NAT1 and NAT2 coexpression in breast tissues and established breast cancer cell lines is needed.
Minchin and Butcher have recently shown, utilizing the publicly available data repositories
Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and The Cancer
Genome Atlas (TCGA), that NAT1 mRNA expression in primary breast tumors, but not prostate,
cervical, or colorectal tumors, can be segregated into three distinct patient subpopulations,
expressing low, intermediate and high levels of NAT1 mRNA102. Gene correlation analysis with
NAT1 in each subset suggested different regulation mechanisms are in place, given the small
overlap in genes correlated with NAT1 mRNA expression in each subpopulation102. Additionally, a
better 10-year survival rate in patients with high NAT1 was observed compared to patients with
low NAT1102. Notably, patients whose tumors had low NAT1 expression exhibited a distinct poor
response to chemotherapy102. It will be important for future studies on NAT1 to investigate how
NAT1 expression in breast tumors influences chemo-sensitivity.
Possible Endogenous Role of NAT1
Although NAT1 has traditionally been described as a xenobiotic metabolizing enzyme,
there is a wealth of evidence suggesting NAT1 may also have unknown endogenous role(s).
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Phylogenetic analysis of the NATs suggested evolutionarily NAT1 did not tolerate mutations while
NAT2 was predicted to have mostly evolved under positive selection103. NATs are found in all
kingdoms of life, excluding plants104. Additionally, NAT1 activity and mRNA have been detected in
mid-gestational fetal tissues15, placenta105,106, and nearly every adult tissue. NAT1 has been
shown to have redundancy with methylthioribose-1-phosphate isomerase (MRI1) in the
methionine salvage pathway, but this role was not observed in MDA-MB-231 cells since they do
not have a functional methionine salvage pathway due to a lack of methylthioadenosine
phosphorylase (MTAP) activity107. To date, NAT1 is known to acetylate only one endogenous
compound, p-aminobenzoylglutamate (pABG)-- a folate catabolite108,109, with unknown
consequence. However, NAT1 has been linked to folate metabolism110,111. Additionally, it has also
been shown that in the absence of an arylamine substrate NAT1 can catalyze the hydrolysis of
acetyl-CoA using folate as a co-factor112,113. Furthermore, NAT1 expression and activity are highly
regulated by many diverse mechanisms whereas NAT2 expression and activity appear to be less
regulated. Taken together, these facts lead to the hypothesis that NAT1 is not just a xenobiotic
metabolizing enzyme. It remains to be determined whether that role is through a NAT1 catalyzed
reaction or a result of NAT1’s ability to catalyze the hydrolysis of acetyl-CoA, a central molecule
in metabolism and cellular energetics.
Construction of MDA-MB-231 Breast Cancer Cell Lines Expressing Varying NAT1
To better investigate NAT1’s role in breast cancer a single established breast cancer cell
line was genetically modified to vary only in NAT1. The MDA-MB-231 triple negative breast
cancer cell line was selected for modification because it expresses an approximate mid-level of
NAT1 RNA compared to other breast cancer cell lines; NAT1 RNA expression has been shown to
be a suitable predictor of NAT1 activity114. Additionally, two different construction methods were
utilized, siRNA and CRISPR/Cas9, to ensure observed results were due to manipulation of NAT1
rather than the specific construction method utilized.
Construction of siRNA Generated Cell Lines
The construction and characterization of the siRNA generated cell lines has been
described extensively elsewhere82,84,115,116. Briefly, three cell lines were constructed, Scrambled,
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Up, and Down, expressing parental, increased, and decreased NAT1 N-acetylation activity,
respectively (Figure 1.1). Each cell line was constructed from the parent MDA-MB-231 cell line,
purchased from American Type Culture Collection (ATCC), that had a flippase recognition target
(FRT) site inserted, thus ensuring all plasmids were transfected into the same genomic location.
Genetically modified cell lines were characterized for NAT1 PABA N-acetylation, NAT1 mRNA
expression, endogenous acetyl-CoA levels, cell doubling rates, anchorage-independent growth,
anchorage-dependent growth, and relative invasive ability. The Scrambled cell line was included
as a transfection control and expressed approximately the same NAT1 N-acetylation activity and
NAT1 mRNA as the parent MDA-MB-231 cell line. NAT1 PABA N-acetylation activity and NAT1
mRNA in the Up cell line were increased 7-fold and 4-fold, respectively, compared to the
Scrambled cell line. Conversely, NAT1 PABA N-acetylation activity and NAT1 mRNA in the Down
cell line were decreased approximately 35% and 53%, respectively, compared to the Scrambled
cell line. Doubling times, relative invasive ability, and anchorage-dependent growth of the three
constructed cell lines did not significantly vary while anchorage-independent growth was
decreased 7-fold in the Down cell line compared to the Scrambled cell line82.
Construction of CRISPR/Cas9 Generated Cell Lines
The CRISPR/Cas9 constructed cell lines were constructed from the MDA-MB-231 cell
line that had an FRT site inserted to allow direct comparison to a single cell line regardless of the
method used to construct the cell line (Figure 1.2). All cell lines were cultured in high-glucose
Dulbecco's Modified Eagle Medium (DMEM), with 10% fetal bovine serum, 5% glutamine, and
5% penicillin/streptomycin added and grown in a humidified incubator set at 37 °C with 5% CO2.
Horizon Discovery Group (Waterbeach, United Kingdom) designed 5 different guide RNAs
(gRNAs) specific for NAT1 and DNA2.0 Inc. (Newark, CA) cloned the gRNAs into a Cas9
expressing vector that also expressed a dasher-green fluorescent probe (GFP) tag. Separately,
each of the 5 gRNA/Cas9 vectors (gRNA sequences listed in Table 1.1) were transiently
transfected in the Scrambled MDA-MB-231 cell line using the Amaxa Nucleofector II (Lonza,
Allendale, NJ). Forty-eight hours after transfection cells were harvested and DNA isolated.
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Figure 1.1

Parent (MDA-MB-231)
Flp-In™ System (Life
Technologies, Grand Island, NY)

Parent + FRT site

Scrambled
shRNA

Scrambled
Wild-type
NAT1 activity

NAT1
Silencing
shRNA

NAT1 Overexpression
Plasmid
hygromycin
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Down

Up

Decreased
NAT1 activity

Increased
NAT1 activity

Figure 1.1: Construction of MDA-MB-231 Cell Lines via siRNA.
The Flp-In™ System (Life Technologies, Grand Island, NY) was used to insert a single flippase
recognition site (FRT) site into the parent MDA-MB-231 cell line. The MDA-MB-231 cell line
containing the FRT site was then stably transfected with either a plasmid containing a nonspecific
shRNA plasmid into the FRT site (Scrambled), a plasmid containing NAT1 specific shRNA into
the FRT site (Down), or a plasmid containing the NATb/NAT1*4 vector into the FRT site (Up).
Each plasmid contained a hygromycin resistant cassette. Therefore stably transfected cells were
selected for using hygromycin. The resulting MDA-MB-231 cell lines, Scrambled, Down, and Up,
express wild-type, decreased, and increased NAT1 mRNA and PABA N-acetylation activity,
respectively.

9

Figure 1.2

Parent + FRT site

Adapted from
https://www.appliedstemcell.
com/services/cell-linemodels/cell-line-modification

CRISPR 2-12
Heterozygous
NAT1 Knockout

CRISPR 2-19

CRISPR 5-50

Homozygous
NAT1 Knockout

Homozygous
NAT1 Knockout

Figure 1.2: Construction of MDA-MB-231 NAT1 Knockout Cell Lines via CRISPR/Cas9.
The CRISPR/Cas9 system was used to decrease and knockout NAT1 in the parent MDA-MB-231
cell line with a previously inserted flippase recognition target (FRT) site utilizing two different
guide RNAs, 2 and 5. The resulting MDA-MB-231 cell lines, CRISPR 2-12, CRISPR 2-19, and
CRISPR 5-50, express decreased, knockout, and knockout levels of PABA NAT1 N-acetylation
activity, respectively. The CRISPR 2-12 and CRISPR 2-19 cell lines were constructed with guide
RNA 2 while the CRISPR 5-50 cell line was constructed using guide RNA 5.
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Table 1.1
CRISPR/Cas9 Guide RNA Sequences
GUIDE RNA
SEQUENCE
1
GAACCTTAACATCCATTGTG
2
CAAAGGGAACAGCTCGGATC
3
GTTGTGAGAAGAAATCGGGG
4
GGCCTCTAAGCCTAAGTCCA
5
GAATTGGCTATAAGAAGTCT

Guide RNAs 2 and 5 were utilized to construct two homozygous NAT1 knockout MDA-MB-231
cell lines and a heterozygous NAT1 knockout MDA-MB-231 cell line.
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The Transgenomic Inc. (Omaha, NE) SURVEYOR Mutation Detection Kit was used to determine
the effectiveness of each gRNA’s ability to cut the genomic DNA and induce DNA strand breaks
effectively. gRNAs #2 and #5 were the most effective at inducing DNA strand breaks, and were
chosen to separately knockout the function of NAT1 in the following studies.
The Scrambled MDA-MB-231 cell line was transfected with either #2 or #5 gRNA/Cas9
vectors as described above. Forty-eight hours after transfection cells were sorted for GFP
fluorescence. The fluorescent positive cells were collected and plated at very dilute cell
concentrations so that individual clones could be isolated. Once individual cells had grown into
large enough colonies (several weeks), cloning cylinders were utilized to isolate those colonies
using trypsin to release them from the plate and transferred to a 96-well culture plate. Clones
were passaged until there were enough cells to plate in a 10 cm dish. Cells were then tested for
NAT1 activity as previously described117. Activity assays showed NAT1 activity was not
detectable (knocked out) in a low number of clones and these clones were selected for further
characterization. Clones with no detectable NAT1 activity were further screened by sequencing
the NAT1 open reading frame (ORF). We were specifically interested in clones that had
deleted/inserted nucleotides in the NAT1 ORF that resulted in frame-shift mutations and thus
premature protein termination signals resulting in predicted nonfunctional NAT1. Individual
knockout cell lines representing the knockout of NAT1 activity for gRNA #2 or #5 were chosen
based on NAT1 enzymatic activity and genomic sequence.
Sequencing of the NAT1 Gene in the CRISPR/Cas9 Constructed Cell Lines
Genomic DNA was isolated from the MDA-MB-231 CRISPR/Cas9 constructed cell lines.
The NAT1 open reading frame was TOPO cloned using pcDNA™ 3.1/V5-His TOPO® TA
Expression Kit (Invitrogen, California, USA) following manufacturer's recommendations. The
TOPO Cloning reaction for each cell line was transformed into One Shot TOP10 Chemically
Competent E. coli. Five transformed E. coli colonies for each cell line were selected and grown
overnight. Cultures of bacteria were then harvested for plasmid purification. Purified plasmids and
primers were sent for DNA sequencing (Eurofins, Louisville, KY, USA). Sequence data was
analyzed and aligned with SeqMan Pro™ (Version 12.0, DNASTAR, Madison, WI.)
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Characterization of CRISPR/Cas9 constructed cell lines are described in detail
elsewhere115. Briefly, the CRISPR 2-19 and CRISPR 5-50 cell lines had no detectable NAT1
activity while NAT1 N-acetylation activity in the CRISPR 2-12 cell line was decreased
approximately 50% compared to the parent MDA-MB-231 and Scrambled cell lines. Endogenous
acetyl-CoA was increased approximately 2-fold in both NAT1 knockout cell lines compared to the
parent MDA-MB-231 cell line. Doubling times, relative invasive ability, and anchorage-dependent
colony formation did not significantly vary between two NAT1 knockout cell lines and the parent
MDA-MB-231 cell line. Notably, NAT1 knockout cell lines formed less anchorage-independent
colonies compared to the parent MDA-MB-231 cell line115.
Summary and Importance
Colleagues, Mark Doll and Dr. Marcus Stepp, have constructed six MDA-MB-231 cell
lines via two different methodologies that express parental, increased, decreased, and no
detectable (limit of detection = 0.05 nmoles acetylated PABA/min/mg) NAT1 N-acetylation activity
(Figure 1.3). All cell lines have been confirmed by STR-profiling to be MDA-MB-231 breast cancer
cells. NAT1 mRNA has also been quantitated in each cell line (Figure 1.4). The genetic
modification of a single established breast cancer cell line that varies only NAT1 provides an
excellent model for studying the possible role of NAT1 in breast cancer metabolism. While breast
cancer cell lines that endogenously express varying levels of NAT1 could have been selected,
that would also complicate the analysis of results due to the multiple unique mutations each cell
line would have. The approach utilized in this dissertation ensures each cell line has the same
genetic background and only varies in NAT1 allowing a more straightforward comparison
between cell lines.
Cancer Metabolism
Cancer as a disease can be concisely described as a dysregulation of normal cellular
functions leading to increased and uncontrolled growth. Hanahan and Weinberg suggested in
2000 that cancer could be summarized by six basic acquired capabilities or hallmarks: 1. evading
apoptosis, 2. self-sufficiency in growth signals, 3. insensitivity to anti-growth signals, 4. tissue
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Figure 1.3: NAT1 N-Acetylation Activity of the Parent and Genetically Modified MDA-MB231 Cell Lines.
NAT1 N-acetylation activity was measured in the 6 cell lines included in this study. The Parent
and Scrambled cell lines express approximately the same level of NAT1 N-acetylation activity
while NAT1 N-acetylation activity in the Down and CRISPR 2-12 cell lines is decreased by
approximately 50%. NAT1 N-acetylation activity in the Up cell line is increased by approximately
700%. The CRISPR 2-19 and CRISPR 5-50 had no detectable NAT1 N-acetylation activity.
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Figure 1.4
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Figure 1.4: NAT1 mRNA of the Parent and Genetically Modified MDA-MB-231 Cell Lines
Relative to Parent.
NAT1 mRNA was quantitated in the 6 cell lines included in this study. The Parent and Scrambled
cell lines express approximately the same level of NAT1 mRNA while NAT1 mRNA in the Down
CRISPR 2-12, and CRISPR 2-19 cell lines is decreased by approximately 50%. NAT1 mRNA in
the Up cell line is increased by approximately 400%. The CRISPR 5-50 cell line had very low
levels of NAT1 mRNA.
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invasion and metastasis, 5. limitless replicative potential, and 6. sustained angiogenesis118. A
decade later Hanahan and Weinberg updated the hallmarks of cancer to add two new emerging
hallmarks: 1. deregulating cellular energetics and 2. avoiding immune destruction119. Based on
these hallmarks of cancer, the dysregulation of metabolism and energetics plays a crucial role in
cancer risk and progression by enabling uncontrolled cell growth. A better understanding of the
role NAT1 has in metabolism and cellular energetics could help lead to a better understanding of
the connection between NAT1 and breast cancer. Given that NAT1 can catalyze the hydrolysis of
acetyl-CoA, a central biochemical in metabolism and cellular energetics120-122, different levels of
NAT1 are hypothesized to lead to observable differences in mitochondrial function, metabolites,
and transcripts. Acetyl-CoA has a central role in fatty acid synthesis and degradation, ketone
body and isoprenoid synthesis, and feeds into the citric acid cycle.
Systems Biology Approach
There are three concepts, 1. emergence, 2. robustness, and 3. modularity, that are
necessary for understanding complex biological systems123. The first concept, emergence, states
that complex systems display properties as a whole that cannot otherwise be predicted by
studying individual parts. The second concept, robustness, states there are many diverse
mechanisms in place for biological systems to maintain phenotypic stability when presented with
perturbations whether through the environment, stochastic events or genetic variation. The final
concept, modularity, states complex systems are divided into specialized modules allowing
damage to be confined as well as robustness. In many studies of cancer and/or metabolism a
reductionist approach, rather than a systems biology approach, is taken because studies of
cancer biology and cellular metabolism are complex and can be difficult to interpret especially in
multidimensional biological systems; however, a systems biology approach provides many
advantages. Publications of systems biology studies has grown exponentially over the last 15
years (by count of PubMed keyword “systems biology” search by year) as technologies and
methods have developed and grown to allow complex global measurements (Figure 1.5). The
first advantage of a systems biology approach is that there is less of a reliance on what is
currently known than with a reductionist approach, facilitating the identification of previously
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Figure 1.5
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Figure 1.5: Systems Biology Publications by Year.
Systems biology publications have grown exponentially over the last 15 years. The first
publication on “systems biology” was in 1988. Publication count by year with keyword “systems
biology” was downloaded from PubMed on 07/03/2018. Years 1988-2017 are plotted.
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unknown cellular reactions or metabolic functions. A second advantage of a systems biology
approach is that when combined with omics technologies, valuable data on the flow of information
in biological systems can be discerned by studying the interactions between different components
of the system124. A systems biology approach was therefore utilized in an attempt to decipher the
role of NAT1 in breast cancer cell metabolism. The systems biology approach utilized in this
dissertation was three pronged, integrating bioenergetics, metabolomics, and transcriptomics with
an added genomics dimension (by using the newly constructed MDA-MB-231 cell lines that vary
only in NAT1) to gain a global view of the role of NAT1 in metabolism and cellular energetics
(Figure 1.6).
Combining Datasets
A comprehensive understanding of a specific biological system cannot be accurately
predicted by that system’s individual parts, even with full understanding of the parts alone124.
Combining information from bioenergetics, metabolomics, and transcriptomics experiments
allows a holistic systems biology view of metabolism in samples that vary only in NAT1.
Integrating all three datasets allows maximization of observations of the system at different points
of regulation and varying complexities. Utilizing a systems biology approach has many
advantages: 1. confidence in conclusions in increased because of the overlap in data at multiple
levels of regulation and 2. combining multiple omics techniques can help overcome the limitations
of a specific omics technique. One potential limitation of these studies is the complexity of
metabolism; metabolism is very highly regulated but many of the regulation mechanisms are
either poorly understood or undefined.
Dissertation Aims
Given human NAT1 both hydrolyzes acetyl-CoA and utilizes acetyl-CoA as a cofactor in
metabolic reactions, increased and decreased levels of NAT1 are hypothesized to contribute to
reprogramming of cellular metabolism by altering the levels of free acetyl-CoA. Increased NAT1
activity would lead to increased hydrolysis of acetyl-CoA and/or increased use of acetyl-CoA for
acetylation, therefore less free acetyl-CoA would be available. Conversely, decreased NAT1
activity would lead to decreased hydrolysis of acetyl-CoA and/or decreased use of acetyl-CoA for
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Figure 1.6

Figure 1.6: Systems Biology Approach.
The work presented in this dissertation utilizes a systems biology approach with four layers. The
first layer consists of the six genetically modified MDA-MB-231 cell lines whose only genetic
difference (theoretically) is in NAT1. The second, third, and fourth layers are bioenergetics,
metabolomics, and transcriptomics measurements of the constructed cell lines and represent
Specific Aim 1, Specific Aim 2. and Specific Aim 3, respectively. Progressing from the genome to
the transcriptome to the proteome to the metabolome, regulatory mechanisms as well as
complexity increase.
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acetylation, therefore more free acetyl-CoA would be available (Figure 1.7). As discussed above,
acetyl-CoA is involved in many cellular pathways, such as fatty acid synthesis and the citric acid
cycle (TCA), which produce important membrane lipids and substrates for cellular energy
metabolism125. Cancer cells characteristically exhibit rapid, uncontrolled growth therefore
requiring increased levels of energy and cellular components when compared to normal cells.
Although, the exact mechanism by which cellular metabolism is reprogrammed remains unclear,
it is likely specific to each cancer and is also influenced by a combination of factors. Varying
levels of NAT1 N-acetylation activity in the MDA-MB-231 breast cancer cell line are predicted to
lead to measurable changes in bioenergetics, metabolite abundances, and transcripts. The
overall goal of this dissertation is to evaluate the effect of varying levels of NAT1 on breast cancer
cell metabolism via a systems biology approach. The Specific Aims of this project are:
Aim 1: To identify bioenergetic changes induced by altering the levels of human NAT1
through mitochondrial stress test profiling using the Seahorse XF24 Bioanalyzer.
Varying levels of NAT1 are expected to lead to differences in mitochondrial energetics
since acetyl-CoA is central to energy metabolism.
Aim 2: To identify metabolic changes induced by altering the levels of human NAT1
through a comprehensive untargeted metabolomics approach.
Differing levels of acetyl-CoA are predicted to lead to differences in the abundances of
metabolites found in the fatty acid synthesis and amino acid degradation pathways. We
additionally predict the abundance of total fatty acids and energy metabolism intermediate
subclasses of metabolites will be altered when compared to samples of cells with ‘parental’ levels
of NAT1 activity.
Aim 3: To identify differential changes in gene expression induced by altering the levels
of human NAT1 through a RNA-seq analysis of the transcriptome.
The expression profile of genes involved in acetyl-CoA containing pathways are expected
to be differentially expressed. Given metabolism is highly regulated we expect altered acetyl-CoA
levels will have an effect on the genes that encode proteins/enzymes that utilize acetyl-CoA. The
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Figure 1.7

Figure 1.7: Dissertation Hypothesis.
The overall hypothesis and rationale for this dissertation is that cell lines with decreased levels or
knockout NAT1 will have increased free acetyl-CoA since those cell lines have less NAT1 to
hydrolyze acetyl-CoA; Conversely, the cell line with increased NAT1 will have decreased free
acetyl-CoA since that cell line has more NAT1 to hydrolyze acetyl-CoA. These differences in free
acetyl-CoA are hypothesized to lead to alterations in cellular pathways/metabolism when
compared to the cell line with basal NAT1 that can be measured by global bioenergetics,
metabolomics, and transcriptomics experiments.
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data collected in this aim will build upon the data generated in Specific Aim 2 by collecting
complementary transcriptomics data from the same biological samples. Differences in the
expression of genes involved in fatty acid and membrane lipid synthesis are expected because
cancer cells have an increased demand for these cellular building blocks.
Significance
This study is the first to investigate the effect of varying human NAT1 activity on the
bioenergetics profile, metabolome, and transcriptome of a breast cancer cell line. Methods for the
evaluation of the bioenergetic profile of living cells in real-time have recently been developed to
identify fluxes in energy pathways and have yet to be utilized when studying the effect varying
levels of NAT1 have on breast cancer cells. The omics disciplines have developed into an
extremely beneficial and information-rich area of research but have been under-utilized in
research on human NAT1. Analysis of metabolomics and transcriptomics data can help reveal
what pathways are altered as a result of varying levels of NAT1 activity thus providing insights
about NAT1’s effect on cellular metabolism and into the role of NAT1 in breast cancer disease
and progression. A greater understanding of the role of NAT1 in breast cancer could lead to
better detection and treatment methods and impact the development of drugs that target NAT1.

22

CHAPTER 2

NAT EXPRESSION IN ESTABLISHED BREAST CANCER CELL LINES & BREAST TISSUES

Background
Based on limited data, it has been hypothesized that NAT2 expression is very low in
breast tissue and negligible in comparison to NAT1 expression. However, a more comprehensive
evaluation of NAT1 and NAT2 co-expression in breast tissues and established breast cancer cell
lines is needed. Additionally, while many studies have reported an association between NAT1
and ESR1 expression85-91, NAT2 and ESR1 association has not been evaluated even though
NAT1 and NAT2 are isozymes that have overlapping substrate specificities and very similar
protein structure. There are many publicly available data repositories of cancer samples that offer
a wealth of gene expression data. These data repositories have been under-utilized in NAT
research.
Materials and Methods
Acquisition of publicly available data from the Cancer Cell Line Encyclopedia (CCLE) and
TCGA data repositories
RNA expression (RNA-Seq) data for ESR1, NAT1 and NAT2 in established breast cancer
cell lines were accessed on 8/11/17 (n=57) from the CCLE126; RNA expression values were
reported in Reads Per Kilobase of transcript per Million mapped reads (RPKM). A total of 15
breast cancer cell lines had no detectable NAT2 gene expression. Data from TCGA127 for the
breast invasive carcinoma (BRCA) cohort were accessed on 2/4/18 (primary breast tumor tissue,
n=1,043; normal breast tissue, n=99) via FirebrowseR128, an R client to the Broad Institute’s
RESTful Firehose Pipeline; RNA expression values were reported in RNA-Seq by Expectation-
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Maximization (RSEM). A total of 59 of the breast tumor samples and seven of the normal tissue
samples did not have gene expression data for NAT2.
Established breast cancer cell lines analyzed
The following breast cancer cell lines were analyzed in this study: AU565, BT-20, BT474, BT-483, BT-549, CAL-120, CAL-148, CAL-51, CAL-85-1, CAMA-1, DU4475, EFM-19, EFM192A, HCC1143, HCC1187, HCC1395, HCC1419, HCC1428, HCC1500, HCC1569, HCC1599,
HCC1806, HCC1937, HCC1954, HCC202, HCC2157, HCC2218, HCC38, HCC70, HDQ-P1,
HMC-1-8, HMEL, Hs 274.T, Hs 281.T, Hs 343.T, Hs 578.T, Hs 606.T, Hs 739.T, Hs 742.T, JIMT1, KPL-1, MCF-7, MDA-MB-134-VI, MDA-MB-157, MDA-MB-175-VII, MDA-MB-231, MDA-MB361, MDA-MB-415, MDA-MB-436, MDA-MB-453, MDA-MB-468, SK-BR-3, T-47D, UACC-812,
UACC-893, ZR-75-1 and ZR-75-30.
Statistical analyses
Shapiro-Wilk tests were conducted to determine if the expression of the genes under
study were approximately normally distributed. Significant evidence of departures from
approximate normality was observed; therefore, non-parametric statistical techniques were
employed for subsequent analyses. Spearman’s correlation was used to evaluate the RNA
expression levels between gene pairs (i.e. ESR1 and NAT1, ESR1 and NAT2, NAT1 and NAT2).
Differences in the mRNA expression levels of NAT1 and NAT2 in each dataset, and differences in
RNA expression between primary breast tumor samples and normal breast tissue samples, were
evaluated using the Wilcoxon Rank-Sum test; median values were compared to determine folddifferences.
RNA expression data for each gene were stratified by ER status (+ or -) as defined in the
literature129-131 for the CCLE data, or as determined by immunohistochemistry during sample
collection and cataloging for TCGA data. Differences in gene expression following stratification
were evaluated using Wilcoxon Rank-Sum tests for each gene; median values were compared to
determine fold-differences. A total of 10 of the breast cancer cell lines had either conflicting or
unknown ER status in the literature.
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Wakefield et al published the NAT1 PABA N-acetylation activities of seven (ZR-75-1,
T47D, MCF-7, MDA-MB-453, MDA-MB-436, MDA-MB-231 and CAL-51) of the 57 breast cancer
cell lines included in the present study88. The association between previously reported NAT1
activity and NAT1 RNA expression data for the same cell lines in the CCLE repository was
evaluated. All statistical analyses were performed in R: A Language and Environment for
Statistical Computing, version 3.4.2132.
Results
Association between NAT1 & ESR1, NAT2 & ESR1, and NAT1 & NAT2
NAT1 RNA and ESR1 RNA were significantly correlated (P<0.0001 for all) at moderately
high magnitudes in breast cancer cell lines (Spearman rho r=0.59; Figure 2.1A and B), human
primary breast tumors (r=0.59; Figure 2.1C and D) and normal breast tissue (r=0.57; Figure 2.1E
and F). A significant (p<0.005 for all) association between ESR1 and NAT2 expression was
observed, although the magnitude of the association was low and varied across datasets. The
primary breast tumor dataset exhibited the weakest association (r=0.16; Figure 2.1C and D),
whereas the normal breast tissue (r=0.38; Figure 2.1E and F) and breast cancer cell line (r=0.39;
Figure 2.1A and B) datasets exhibited similar, albeit low, association. Strong evidence of an
association (p<0.0001 for all) between NAT1 RNA and NAT2 RNA levels was observed in all
three datasets, with moderately high magnitude in the breast cancer cell lines (r=0.64; Figure
2.1A and B). The primary breast tumor and normal breast tissue datasets exhibited
interdependence similar to each other (r=0.43 and 0.46, respectively; Figures 2.1C-F); however,
the association was lower than that observed in the breast cancer cell lines.
Comparison of NAT1 & NAT2 expression
NAT1 RNA expression in breast cancer cell lines, primary breast tumors, and normal
breast tissue was significantly higher compared with NAT2 expression by 33-, 222- and 52-fold,
respectively (p<0.0001 for all; Figure 2.2A-C). NAT1 expression was higher than NAT2
expression in all 57 breast cancer cell lines tested, with the exception of the UACC-893 cell line,
which expressed the highest NAT2 RNA of any of the breast cancer cell lines analyzed. A total of
15 of the 57 breast cancer cell lines (MDA-MB-134-IV, CAL-120, DU4475, MCF-7, JIMT-1, Hs
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Figure 2.1
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Figure 2.1: Scatterplot and correlation matrices for NAT1, NAT2, and ESR1.
Associations between NAT1, NAT2, and ESR1 RNA expression were analyzed in breast cancer cell lines, primary breast tumor tissue, and normal
breast tissue using the Spearman method. In the scatterplot matrices, each open circle represents a single sample and is color-coded according to
ER status; pink circles, ER− samples; blue circles, ER+ samples; black circles, samples with unknown ER status. In the association matrices,
boxes are labeled with the Spearman correlation coefficient (ρ) for each comparison and color reflects strength of association; dark blue
represents high association, light blue represents low association, and white represents no association. (A) Scatterplot matrix of the association
between NAT1, NAT2 and ESR1 RNA expression in breast cancer cell lines (n=57). (B) Correlation matrix between NAT1, NAT2 and ESR1 RNA
expression in breast cancer cell lines (n=57). (C) Scatterplot matrix of the association between NAT1, NAT2 and ESR1 RNA expression in primary
breast tumor samples (n=1,043 for NAT1 vs. ESR1, n=984 for NAT1 vs. NAT2 and NAT2 vs. ESR1). (D) Correlation matrix between NAT1, NAT2,
and ESR1 RNA expression in primary breast tumor samples (n=1,043 for NAT1 vs. ESR1, n=984 for NAT1 vs. NAT2 and NAT2 vs. ESR1). (E)
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Scatterplot matrix of the association between NAT1, NAT2 and ESR1 RNA expression in normal breast tissue samples (n=99 for NAT1 vs. ESR1,
n=92 for NAT1 vs. NAT2 and NAT2 vs. ESR1). (F) Correlation matrix between NAT1, NAT2 and ESR1 RNA expression in normal breast tissue
samples (n=99 for NAT1 vs. ESR1, n=92 for NAT1 vs. NAT2 and NAT2 vs. ESR1). ER, estrogen receptor; ESR1, estrogen receptor 1; NAT1,
arylamine N-acetyltransferase 1; NAT2, arylamine N-acetyltransferase 2.

Figure 2.2
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Figure 2.2: NAT1 and NAT2 RNA expression in breast cancer cell lines, primary breast tumor samples, and normal breast tissue
samples.
Differences in gene expression between NAT1 and NAT2 in breast cancer cell lines, primary breast tumor tissue and normal breast tissue were
statistically evaluated by Wilcoxon rank-sum test; ***p<0.001. Each dot represents a single sample and is color-coded according to ER status; pink
dots, ER− samples; blue dots, ER+ samples; black dots, samples with unknown ER status. In the boxplots, the solid black line represents the
median, the upper hinge represents the 75th quartile and the lower hinge represents the 25th quartile. The upper whisker represents the largest
observation less than or equal to the upper hinge + 1.5 x IQR, the lower whisker represents the smallest observation greater than or equal to the
lower hinge - 1.5 x IQR. (A) NAT1 RNA expression was significantly higher than NAT2 RNA expression in the breast cancer cell lines. (B) NAT1
RNA expression was significantly higher than NAT2 RNA expression in the primary breast tumor samples. (C) NAT1 RNA expression was
significantly higher than NAT2 RNA expression in the normal breast tissue samples. ER, estrogen receptor; IQR, interquartile range; NAT1,
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arylamine N-acetyltransferase 1; NAT2, arylamine N-acetyltransferase 2; RPKM, reads per kilobase of transcript per million mapped reads;
RSEM, RNA-Seq by Expectation-Maximization.

281.T, KPL-1, Hs 606.T, HCC70, EFM-19, CAL-148, HCC1569, HMC-1-8, HCC1599 and
HCC1395) had no reported NAT2 RNA expression, whereas all 57 reported NAT1 RNA
expression. The KPL-1 breast cancer cell line has been reported to be contaminated/misidentified
and to be an MCF-7 derivative133.
In TCGA dataset, normal breast tissue samples were collected from patients in which
primary breast tumor samples were also collected (but only for 99 individuals), allowing
comparison of gene expression between normal breast tissue and primary tumor breast tissue
within single individuals. In the primary breast tumor samples, only nine of the 984 samples had
higher NAT2 RNA expression than NAT1; of those nine samples, two were ER+ and seven were
ER–, and only one sample had a corresponding normal breast tissue sample. Notably, in that
individual’s normal breast tissue sample, NAT2 RNA expression was not higher than NAT1 RNA
expression. In the normal breast tissue samples, only one of the 92 samples had higher NAT2
RNA expression than NAT1; the corresponding primary breast tumor sample from the same
patient had lower NAT2 than NAT1.
Comparison of gene expression between ER+ and ER- samples
ESR1 and NAT1 gene expression were significantly increased, 86- and 2.6-fold,
respectively, in ER+ breast cancer cell lines (p<0.0001 for both; Figure 2.3A), whereas NAT2
gene expression did not significantly vary between ER+ and ER- breast cancer cell lines (p>0.05;
Figure 2.3A). Of the breast cancer cell lines with ER status defined in the literature129-131, a
connection between ESR1 RNA expression and the reported ER status was observed. In the
dataset, it was observed that samples with ESR1 RNA expression <1.7 RPKM were defined as
ER- in the literature, whereas samples with ESR1 expression >2.3 RPKM were defined as ER+ in
the literature. The expression levels of all three genes were significantly higher in ER+ primary
breast tumor samples (p<0.0001 for all; Figure 2.3B); however. the fold-change between NAT2
expression in ER+ and ER- samples was smaller (1.8-fold difference) than for NAT1 and ESR1.
In comparison, ESR1 and NAT1 were ~108- and 27-fold higher, respectively. The expression
levels of genes were not significantly different between ER+ and ER- normal breast tissue
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Figure 2.3: ESR1, NAT1 and NAT2 RNA expression in breast cancer cell lines, primary
breast tumor samples, and normal breast tissue stratified by ER status.
Differences in the expression levels of ESR1, NAT1 and NAT2 genes in breast cancer cell lines,
primary breast tumor tissue, and normal breast tissue stratified by ER status were evaluated by
Wilcoxon rank-sum test; ***p<0.001; NS, not significant. Boxplots are color-coded according to ER
status; pink boxplots, ER− samples; blue boxplots, ER+ samples. In the boxplots, the solid black
line represents the median, the upper hinge represents the 75th quartile and the lower hinge
represents the 25th quartile. The upper whisker represents the largest observation less than or
equal to the upper hinge + 1.5 x IQR, the lower whisker represents the smallest observation
greater than or equal to the lower hinge - 1.5 x IQR. (A) ESR1 and NAT1 RNA expression were
significantly higher in ER+ breast cancer cell lines compared with ER− breast cancer cell lines.
NAT2 RNA expression was not significantly different in ER+ breast cancer cell lines compared
with ER− breast cancer cell lines. A total of 10 cell lines had either conflicting reports or no
available data for ER status in the literature and were excluded from the analysis. (B) ESR1,
NAT1 and NAT2 RNA expression were significantly higher in ER+ samples compared with ER−
samples in the primary breast tumor dataset. (C) ESR1, NAT1 and NAT2 RNA expression levels
were not significantly different in ER+ samples compared with ER− samples in the normal breast
tissue dataset. ER, estrogen receptor; IQR, interquartile range; ESR1, estrogen receptor 1;
NAT1, arylamine N-acetyltransferase 1; NAT2, arylamine N-acetyltransferase 2; RPKM, reads
per kilobase of transcript per million mapped reads; RSEM, RNA-Seq by ExpectationMaximization.
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samples (p>0.05 for all; Figure 2.3C). Most of the breast cancer cell lines were ER-, whereas
most of the primary breast tumor and normal breast tissue samples were ER+.
Comparison of NAT1, NAT2, and ESR1 gene expression between normal breast tissue
and primary breast tumors
Differences in gene expression between normal breast tissue and primary breast tumor tissue
were evaluated for each gene, ESR1, NAT1, and NAT2. More spread was observed in the
primary breast tumor samples compared with the normal breast tissue samples for each gene.
ESR1 and NAT1 gene expression were significantly elevated 2.5- and 5.9-fold, respectively, in
primary breast tumor samples compared with normal breast tissue samples (p<0.0001 for both;
Figure 2.4). NAT2 expression was also significantly higher in primary breast tumor samples
compared with normal breast tissue samples, but at a lower significance and fold-change (1.4fold) than ESR1 and NAT1 (p<0.05; Figure 2.4)
Relationship between previously reported NAT1 N-acetylation activity and NAT1 RNA expression.
NAT1 N-acetylation activity previously reported in the literature and NAT1 RNA
expression in seven of the 57 breast cancer cell lines were significantly associated (p<0.05) with
a high magnitude (r=0.89; Figure 2.5).
Co-expression of NAT1 and NAT2 RNA expression in established breast cancer cell lines
Co-expression profiles of NAT1 and NAT2 RNA for each established breast cancer cell
line included in this study are presented in Figure 2.6. Of all the cell lines included in the present
study, the UACC-893 cell line expressed the highest level of NAT2 RNA, whereas the HCC1500
cell line expressed the highest level of NAT1 RNA. The ZR-75-1 cell line expressed high levels of
both NAT1 and NAT2 RNA, whereas the HCC1395 cell line expressed low levels of both.
Discussion
The present study analyzed established breast cancer cell lines and samples from
patients with breast cancer to evaluate the extent to which breast cancer cell lines serve as
appropriate models for NAT1, NAT2 and ESR1 expression in breast tumors. Overall, the present
findings demonstrated a strong association between NAT1 and ESR1 expression, which is in
agreement with previous reports that NAT1 and ESR1 are positively associated85-91, and this
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Figure 2.4

Figure 2.4: Comparison of ESR1, NAT1 and NAT2 RNA expression in normal breast tissue
and primary breast tumor samples.
Differences in gene expression of ESR1, NAT1 and NAT2 in normal breast tissue and primary
breast tumor tissue were evaluated by Wilcoxon rank-sum test; ***p<0.001; *p<0.05. Boxplots are
color-coded according to tissue type; green boxplots, normal breast tissue samples; blue
boxplots, primary breast tumor samples. In the boxplots, the solid black line represents the
median, the upper hinge represents the 75th quartile and the lower hinge represents the 25th
quartile. The upper whisker represents the largest observation less than or equal to the upper
hinge + 1.5 x IQR, the lower whisker represents the smallest observation greater than or equal to
the lower hinge - 1.5 * IQR. For all genes, more spread was observed in data from the primary
breast tumor samples compared with the normal breast tissue samples. ESR1 and NAT1 gene
expression were significantly elevated in primary tumor tissue compared with normal breast
tissue. NAT2 expression was also significantly higher in primary tumor tissue compared with
normal breast tissue, but at a lower significance than ESR1 and NAT1. IQR, interquartile range;
ESR1, estrogen receptor 1; NAT1, arylamine N-acetyltransferase 1; NAT2, arylamine Nacetyltransferase 2; RSEM, RNA-Seq by Expectation-Maximization.
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Figure 2.5

Figure 2.5 Association between NAT1 RNA expression and previously reported NAT1 Nacetylation activity in seven established breast cancer cell lines.
NAT1 RNA expression from Cancer Cell Line Encyclopedia and previously reported NAT1 Nacetylation activity88 in seven breast cancer cell lines were significantly associated (p<0.05;
ρ=0.89). Dots represent a single cell line and are color-coded according to ER status: Pink dots,
ER− samples; blue dots, ER+ samples. ER, estrogen receptor; NAT1, arylamine Nacetyltransferase 1; NAT2, arylamine N-acetyltransferase 2; PABA, p-aminobenzoic acid; RPKM,
reads per kilobase of transcript per million mapped reads.
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Figure 2.6: NAT1 and NAT2 association in breast cancer cell lines.
Association between NAT1 and NAT2 RNA expression was analyzed in breast cancer cell lines (each labeled in this figure). Each dot represents a
single breast cancer cell line and is color-coded according to ER status; pink dots, ER− samples; blue dots, ER+ samples; black dots, samples
with unknown or conflicting ER status in the literature. NAT1 and NAT2 RNA expression was significantly associated in breast cancer cell lines
(p<0.0001, ρ= 0.64).
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association was observed in all three sample types at approximately the same magnitude. These
findings suggested that breast cancer cell lines may accurately reflect this relationship and
provide a useful model for further research into the relationship. It is well known that ESR1
expression is frequently altered in breast cancer; therefore, the decrease in association between
NAT2 and ESR1 in primary breast tumors compared with in normal breast tissue samples and
established breast cancer cell lines may be due to more dysregulation of ESR1 than NAT2 in
primary breast tumors. The results of an analysis between NAT2 and ESR1 expression
suggested that, while NAT2 and ESR1 are associated, the magnitude is low.
Interdependence between NAT1 and NAT2 expression was moderately high in the breast
cancer cell line dataset, but substantially lower in the primary breast tumor and normal breast
tissue datasets. Additionally, the strength of the association between NAT1 and NAT2 in the
breast cancer cell line dataset was similar to the strength of the association observed between
NAT1 and ESR1 in that dataset; however, in the primary breast tumor and normal breast tissue
datasets, the association between NAT1 and NAT2 was lower. These findings suggested that
breast cancer cell lines may over-represent the interdependence between NAT1 and NAT2, and
not fully replicate the relationship observed in primary breast tumors or normal breast tissue.
In the breast cancer cell line data there appears to be a cut-off (between 1.7 and 2.3 RPKM)
linking ESR1 RNA expression and the reported ER status of the breast cancer cell lines. This
may provide a method to predict the ER status of breast cancer cell lines that currently have
conflicting or unknown ER status in the literature. Using that method, it may be predicted that the
HCC1500 and HCC1419 cell lines are ER+, whereas the HMC-1-8, Hs 742.T, Hs 343.T, Hs
739.T, HMEL, Hs 274.T, Hs 281.T and Hs 606.T cell lines are ER-. Notably, although 67-82% of
breast cancers are ER+134 and most of the primary breast tumor samples were ER+, the majority
of established breast cancer cell lines are ER-.
NAT1 and NAT2 RNA expression were reported in almost all samples included in the
present study, which concurs with published results that have detected NAT1 and NAT2 mRNA
by RT-PCR in human mammary tissue in smaller cohorts13,14,96. NAT1 RNA expression was
significantly higher than NAT2 RNA expression in the breast cancer cell lines, primary breast
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tumor samples and normal breast tissue. In addition, with only a few exceptions, NAT1 RNA
expression was always higher than NAT2 RNA expression in matched samples from the breast
cancer cell line, primary breast tumor sample and normal breast tissue sample datasets, thus
supporting previous findings that indicated NAT1 transcripts were 2- to 3-fold higher than NAT2
transcripts in human mammary tissues135. The UACC-893 cell line, the only breast cancer cell
line observed in this study to express higher NAT2 RNA than NAT1 RNA, is an ER- and
progesterone receptor-negative cell line that has a ~20-fold amplification of the human epidermal
growth factor receptor 2/neu oncogene sequence. Further study of this cell line may aid in the
identification of additional regulatory mechanisms of NAT1 and/or NAT2, since it expresses a
unique profile of NAT1 and NAT2 compared with the other breast cancer cell lines.
While NAT1 expression was reported in all 57 breast cancer cell lines in the present
study, 15 of those breast cancer cell lines had no reported NAT2 RNA expression (Figure 2.6).
The cell lines with no detected NAT2 RNA are plotted at ~-6.6 log2 RPKM NAT2. One of those 15
cell lines, MCF-7, has been reported to express NAT2 RNA96,136 albeit at very low levels. One
reason for the difference in observation between this study and the previous studies may be that
the detection threshold for NAT2 was higher when measured by RNA-Seq for the CCLE dataset
than in the previous studies. Additionally, in the previous studies that detected NAT2 RNA in the
MCF-7 breast cancer cell line, NAT1 RNA was not measured at the same time; therefore, direct
comparisons of the NAT isozymes was not possible. To the best of our knowledge, NAT2 RNA
expression has not been investigated in any of the other 56 breast cancer cell lines until this
study. The results of this study indicated that NAT2 may be expressed in breast tissues and
expression should be considered when studying NAT1, due to their overlapping substrate
specificities and the high degree of structural similarity.
In normal breast tissue samples no significant difference in gene expression for ESR1,
NAT1 and NAT2 was observed when data were stratified by ER status. However, in the primary
breast tumor samples and in the breast cancer cell lines, ESR1 and NAT1 exhibited increased
expression in the ER+ samples compared with in the ER- samples. NAT2 RNA expression did
not significantly vary in breast cancer cell lines when comparing ER+ and ER- samples, but was
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significantly increased in ER+ primary breast tumor samples compared with ER- primary breast
tumor samples, although the difference was small. This finding suggested that the dysregulation
of NAT1 and ESR1 during tumorigenesis may share similar mechanisms; however, NAT2 does
not.
ESR1, NAT1 and NAT2 RNA expression were each increased in primary breast tumor
samples compared with normal breast tissue samples although the significance and fold-change
of NAT2 were smaller than that of ESR1 and NAT1. Additionally, for all genes, more widely
spread expression was observed in the primary breast tumor samples compared with normal
breast tissue. These data suggested that expression of all three genes may become modified
during breast cancer tumorigenesis; however, the expression of NAT1 and ESR1 appear to be
dysregulated to a greater extent. As recently reviewed95, the role of NAT2 in breast cancer
etiology is considered to be due to its effects on carcinogen metabolism. The present study
suggested that the role of NAT2 in breast cancer is less likely a product of cell transformation, as
the expression levels of NAT2 between normal and tumor tissues exhibited smaller variance than
the expression levels of NAT1 and ESR1.
NAT1 N-acetylation activity has been reported in normal breast tissue and breast tumor
tissue13,14,96-99, whereas NAT2 N-acetylation activity has not been observed as consistently; when
NAT2 activity is observed, the activity is much lower than that of NAT1 activity13,97,98. Wakefield et
al profiled NAT1 expression and activity in seven breast cancer cell lines (MCF-7, T47D, ZR-75-1,
Cal51, MDA-MB-231, MDA-MB-437 and MDA-MB-453); NAT1 mRNA and activity was observed
in all seven cell lines88; however, NAT2 mRNA and activity were not co-investigated. The high
degree of association between the previously reported NAT1 N-acetylation activity and the NAT1
RNA expression of the same seven breast cancer cell lines suggested that NAT1 RNA
expression is highly reflective of NAT1 N-acetylation activity. mRNA expression is not always
predictive of enzyme activity, due to the numerous regulatory mechanisms that can occur
between RNA expression and protein function; however, these results suggested that RNA
expression of NAT1 may serve as an appropriate predictor of NAT1 N-acetylation activity. Further
studies with an increased number of breast cancer cell lines in which NAT1 N-acetylation activity
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has been measured are required to confirm this hypothesis. Additionally, further studies are
required to determine the association between NAT2 RNA expression and NAT2 N-acetylation
activity.
Summary and Conclusions
The CCLE and TCGA repositories offer a wealth of publicly available data. The present
study utilized this data to analyze and annotate the previously undefined relationships between
NAT1, NAT2 and ESR1 in breast cancer cell lines, primary breast tumors and normal breast
tissue. The results demonstrated that NAT1 and NAT2 RNA were expressed in normal breast
tissue and primary breast tumor tissue; however, NAT1 RNA expression was much higher than
NAT2. The expression of NAT1 and NAT2 were found to be associated; however, the magnitude
was lower than that observed between NAT1 and ESR1 in the primary breast tumors and normal
breast tissue. Additionally, although the association between NAT1 and NAT2 was slightly
exaggerated in the breast cancer cell line dataset, the cell lines generally reflected the NAT1 and
NAT2 expression profiles of the primary breast tumors investigated. The present study
demonstrated that while NAT1 and ESR1 expression were moderately associated in all datasets
included in this study, NAT2 and ESR1 expression were associated at a lower magnitude,
particularly in the primary breast tumor samples.
NAT1 and ESR1 expression were increased in primary breast tumor samples compared
with normal breast tissue samples and were increased in ER+ primary breast tumors compared
with ER- primary breast tumors. NAT2 expression was slightly increased in primary breast tumor
samples compared with normal breast tissue samples and in ER+ primary breast tumors
compared with ER- primary breast tumors. Although NAT1 and NAT2 are both implicated in
breast cancer, the majority of previous breast cancer studies have investigated each isozyme
individually. The present study suggested that both isozymes should be considered in each study,
since both are expressed in breast tissues. Defining the association between NAT1, NAT2 and
ESR1 is of great importance, as modification of NAT1 is currently being studied for breast cancer
prevention81,82,137,138.
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CHAPTER 3

BIOENERGETICS

Background
Defects in mitochondrial metabolism have been linked to cancer (reviewed in 139) and are
increasingly recognized as contributors, not only to the deregulation of cellular energetics, but
also as contributors to tumorigenesis. Bioenergetics evaluation provides a method to investigate
mitochondrial function in living cells140. By utilizing real-time profiling of the oxygen consumption
rate (OCR) and extracellular acidification rate (ECAR) as well as sequential injection of
compounds that inhibit specific portions of the electron transport chain, mitochondrial evaluation
can be conducted141. Oxygen consumption rate is a proxy measurement for cellular respiration
while extracellular acidification rate is a proxy measurement for glycolysis allowing us to probe
mitochondrial energetics. One can measure and quantify multiple mitochondrial parameters such
as basal OCR, ATP-linked OCR, proton leak, maximum mitochondrial capacity, and reserve
capacity142. Although it is known that NAT1 can catalyze the hydrolysis of acetyl-CoA using folate
as a cofactor, the implications of this NAT1-catalyzed reaction in cellular energetics remains to be
investigated. Measuring bioenergetics in the MDA-MB-231 cell lines we have constructed to vary
only in NAT1 activity allows evaluation of how varying levels of NAT1 impact mitochondrial
function.
Materials and methods
The Seahorse XF24 Analyzer (Agilent Technologies, Santa Clara, CA) was utilized to
interrogate differences in mitochondrial cellular metabolism via oxygen consumption rate (OCR)
and extracellular acidification rate (ECAR) measurements of live cells. All cell lines were cultured
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in high-glucose Dulbecco's Modified Eagle Medium (DMEM), with 10% fetal bovine serum, 5%
glutamine, and 5% penicillin/streptomycin added.
Twenty-four hours prior to each bioenergetics experiment, 100 μL of cell suspension from
each cell line was plated in quadruplicate in a 24-well Seahorse XF24 cell culture microplate at a
density of 40,000 cells per well, thus giving four biological replicates for each cell line.
Additionally, four wells contained medium only for background correction purposes. To minimize
the edge effects of plating and to ensure a monolayer of cells was formed on the bottom of the
well, microplates were left in the cell culture hood at room temperature for one hour before being
placed in a 37°C, 5% CO2 incubator. After cells had adhered to the plate (three hours after
placing in the incubator), 150 μL of medium was added to each well and cells were allowed to
grow overnight. One hour prior to the experiment, medium was aspirated from each well and
replaced with 675 μL Seahorse running medium. Seahorse running medium consisted of 8.3
grams/liter of Dulbecco’s Modified Eagle’s Medium (DMEM) base without glucose, L-glutamine,
phenol red, sodium pyruvate and sodium bicarbonate (Sigma, St. Louis, MO), and 1.85 g NaCl
per liter, glucose added to a final concentration of 25 mM, sodium pyruvate added to a final
concentration of 1 mM, and 10 mL/liter of 100 x Glutamax-1 added, all at pH 7.4. Microplates
were then incubated for one hour in a non-CO2 37 °C incubator. The XF24 sensor cartridge was
hydrated overnight in XF calibrant solution in a non- CO2 37 °C incubator.
Before each experiment, solutions of compounds to be loaded in the ports of the sensor
cartridge were freshly made from stock solutions. Selected compounds inhibit specific portions of
the mitochondrial electron transport chain to allow the elucidation of several different
measurements of mitochondrial function141. Seventy-five microliters of 15 μM Oligomycin (ATP
synthase inhibitor) was loaded into port A of the sensor cartridge, eighty-three microliters of 5 μM
carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP; mitochondrial inner membrane
uncoupler) was loaded into port B of the sensor cartridge, and ninety-two microliters of 10 μM
Antimycin A (complex III inhibitor) and 2 μM Rotenone (complex I inhibitor) was loaded into port C
of the sensor cartridge. For background correction wells seahorse running media was loaded into
each port in place of the compound solutions. The sensor cartridge was then loaded into the
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Seahorse XF24 analyzer and calibrated. Once calibration of the sensor cartridge was complete,
the microplate was loaded into the machine and the experiment was started. Timed sequential
injections of Oligomycin, FCCP, and Antimycin A/Rotenone occurred at 35, 50, and 64 minutes,
respectively.
Six independent experiments were conducted (Figure 3.1). Each experiment consisted of
four biological replicates for each of the cell lines. Baseline OCR, Baseline ECAR, Baseline
OCR/ECAR, ATP-Linked OCR, Reserve Capacity, Coupling Efficiency, Proton Leak, Glycolytic
Reserve, Maximum Mitochondrial Capacity, and Non-Mitochondrial Respiration were calculated
as described in Table 3.1 following each experiment141,143. Results from each independent
experiment were summarized as mean ± SEM from four biological replicates on the microplate.
Results from all six independent experiments were then compiled with final results represented as
mean ± SEM. One-way ANOVA was conducted for each measurement to test for overall
differences, followed by multiplicity adjusted post hoc tests on only those measurements that
were found to be significant.
MTT Cell Growth Assays
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assays were
conducted in triplicate to determine if there were differences in cell viability between the cell lines
given that the cells were allowed to grow in the plate for 24 hours prior to bioenergetics
measurements. Cells were plated in the Seahorse XF24 plates following the same procedure that
was used when plating cells for bioenergetics experiments. Instead of measuring the
bioenergetics of the cells 24 hours after plating, media was removed from each well and cells
were incubated with 250 μL of 5 mg/mL MTT dissolved in growth medium in a 37°C, 5% CO2
incubator. After one hour, the media was aspirated and 250 μL of dimethyl sulfoxide (DMSO) was
added to each well to solubilize the MTT. The microplate was gently rocked for 10 minutes and
then the resulting solution in each well was transferred to a 96-well plate. Absorbance was
measured at 570 nm using the Gen5 microplate reader (BioTek Instruments Inc., Winooski, VT).
All absorbance values were within the linear range of MTT. Absorbance measurements were
median-scaled by plate to minimize between-day variance. Scaled absorbance values were
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Figure 3.1
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Figure 3.1: Bioenergetics Experimental Approach.
Mitochondrial bioenergetics of five genetically modified MDA-MB-231 cell lines stably transformed
to differ only in human arylamine N-acetyltransferase 1 (NAT1) were measured. The Parent and
Scrambled cell lines express parental NAT1 activity, the Up cell line expresses increased NAT1
activity, and the CRISPR 2-19 and CRISPR 5-50 cell lines express no detectable NAT1 activity
(knockout). Bioenergetics were measured in six independent experiments with four biological
replicates of each cell line in each experiment.
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Table 3.1
Definition of Measurement Calculations and ANOVA p-value Summary Statistics
Measurement
Calculation
ANOVA p-value
Baseline OCR*
ATP-Linked OCR
Reserve Capacity
Proton Leak
Non-Mitochondrial Respiration
Maximum Mitochondrial Capacity
Coupling Efficiency
Baseline ECAR‡
Glycolytic Reserve Capacity
Baseline OCR/ECAR

OCR after equilibration but before
the injection of any compounds
(mean of two measurements)
(Minimum OCR after Oligomycin
injection) – (Baseline OCR)
(Maximum Mitochondria Capacity)
– (Baseline OCR).
(Minimum OCR after Oligomycin
injection) – (Non-Mitochondrial
Respiration)
Minimum OCR after
Rotenone/Antimycin A injection
(Maximum OCR measurement
after FCCP† injection) – (NonMitochondrial Respiration)
ATP-linked OCR/baseline OCR
ECAR after equilibration but
before the injection of any
compounds (mean of two
measurements)
(Minimum ECAR after Oligomycin
injection) – (Baseline ECAR)
(Baseline OCR)/(Baseline ECAR)

*OCR = oxygen consumption rate
†FCCP = carbonyl cyanide-p-trifluoromethoxyphenylhydrazone
‡ECAR= extracellular acidification rate
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0.055
0.052
<0.0001
0.021
0.229
<0.0001
0.368
<0.0001
<0.0001
0.011

tested for equivalence between cell lines. Equivalence was assessed using a two-one sided t-test
(TOST) procedure that evaluated equivalence given a 20% margin.
Results
Although NAT1 is overexpressed in breast tumors91,144-147 and catalyzes the hydrolysis of
acetyl-CoA, the impact of NAT1 inactivation or overexpression on cellular bioenergetics has yet
to be reported. We examined glucose oxidation and mitochondrial bioenergetics in MDA-MB-231
triple negative breast cancer (TNBC) cells constructed to knockout or overexpress NAT1 and
compared OCR and ECAR in these cells to the parental MDA-MB-231 cells by extracellular flux
analysis. A summary of ANOVA p-values for each measurement are presented in Table 3.1. We
did not observe an effect of modulation of NAT1 activity in MDA-MB-231 cells on basal OCR,
ATP-linked OCR, or non-mitochondrial respiration (p>0.05 for all; Table 3.1).
Knockout of NAT1 activity increased reserve capacity and maximum mitochondrial
capacity when compared to the cell lines with parental (Parent, Scrambled) and increased (Up)
NAT1 activity (p<0.05 for all; Figure 3.2). In the Parent, Scrambled, and Up cell lines the maximal
respiration was lower than the basal OCR measurements resulting in a negative value for the
reserve capacity calculation; since reserve capacity cannot be negative biologically, we termed
the reserve capacity measurements in these groups as 0. Reserve capacity was increased 91and 50-fold in the CRISPR 2-19 and CRISPR 5-50 cell lines, respectively. The 1.8-fold increase
in reserve capacity of the CRISPR 2-19 cell line compared to the CRISPR 5-50 cell line was also
statistically significant. Maximum mitochondrial capacity of the CRISPR 2-19 cell line was
significantly increased 3.2-fold, 6.0-fold, and 5.4-fold, with respect to the Parent, Scrambled and
Up cell lines. Maximum mitochondrial capacity of the CRISPR 5-50 cell line was also significantly
increased 2.5-fold, 4.7-fold, and 4.2-fold, with respect to the Parent, Scrambled and Up cell lines.
Proton leak was increased 1.8-fold in one of the NAT1 knockout (CRISPR 2-19) cell lines
but only when compared to the cell line with increased (Up) NAT1 activity (Figure 3.2). We cannot
conclude that this effect is due to NAT1 knockout since we did not observe the same result in the
other NAT1 knockout cell line (CRISPR 5-50).
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Figure 3.2
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Figure 3.2: OCR measurements in each cell line.
Evidence of a difference in baseline oxygen consumption rate (OCR), ATP-linked OCR, and non-mitochondrial respiration across cell lines was
not observed. Reserve capacity was significantly increased in the CRISPR 2-19 and CRISPR 5-50 cell lines when compared to the Parent,
Scrambled, and Up cell lines. Reported reserve capacity measurements for Parent, Scrambled, and Up cell lines were truncated at 0 since reserve
capacity cannot be negative. Proton leak was significantly increased in the CRISPR 2-19 cell line but not the CRISPR 5-50 cell line when
compared to the Up cell line. Maximum mitochondrial capacity was significantly increased in the CRISPR 2-19 and CRISPR 5-50 cell lines when
compared to the Parent, Scrambled, and Up cell lines. Order of bars are preserved throughout figure (Parent, Scrambled, Up, CRISPR 2-19,
CRISPR 5-50) and represent mean ± SEM. N=6. *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. The Parent and Scrambled cell lines express
parental NAT1 activity, the Up cell line expresses increased NAT1 activity, and the CRISPR 2-19 and CRISPR 5-50 cell lines express no NAT1
activity (knockout).
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Baseline ECAR was increased in the two NAT1 knockout cell lines compared to the cell
line with parental (Parent) NAT1 activity (Figure 3.3). Baseline ECAR in the CRISPR 2-19 cell line
was increased 2.1-fold, 1.8-fold, 1.6-fold, and 1.4-fold with respect to the Parent, Scrambled, Up,
and CRISPR 5-50 cell lines. Baseline ECAR in the CRISPR 5-50 cell line was also increased 1.5fold compared to the Parent cell line (p<0.05 for all).
In the NAT1 knockout cell lines glycolytic reserve was increased compared to the cell
lines with parental (Parent, Scrambled) and increased (Up) NAT1 activity (Figure 3.3). Glycolytic
reserve of the CRISPR 2-19 cell line was increased 3.8-fold, 9.0-fold, and 45-fold with respect to
the Parent, Scrambled and Up cell lines. Similarly, glycolytic reserve of the CRISPR 5-50 cell line
was increased 3.8-fold, 9.2-fold, and 46-fold with respect to the Parent, Scrambled and Up cell
lines (p<0.05 for all).
Transfection of the Parent cell line with the scrambled control showed no effect on
baseline OCR/ECAR results. However, the cell line with increased NAT1 activity as well as one of
the NAT1 knockout cell lines had decreased baseline OCR/ECAR relative to the Parent cell line
(Figure 3.3). Both the Up and CRISPR 2-19 cell lines were decreased 1.7-fold with respect to the
Parent cell line (p<0.05). We did not observe an effect of modulation of NAT1 activity on coupling
efficiency, also called coupling ratio, which is defined as (oligomycin-sensitive OCR)/(basal OCR)
(Figure 3.4). This result agrees with the data in Figure 3.3 showing that altering NAT1 activity had
no effect on basal OCR or ATP-linked OCR in these cell lines.
Overall, it is important to note that the two cell lines with parental NAT1 activity (Parent,
Scrambled) showed comparable results. The knockout of NAT1 in MDA-MB-231 cells led to
differences in multiple bioenergetics measurements while the overexpression of NAT1 led to no
significant (p>0.05) differences when compared to the cell lines expressing parental (Parent,
Scrambled) NAT1 activity.
To rule out differences in cell growth rate between cell lines over the course of our
experiments, an MTT assay was conducted and the equivalence of MTT absorbance values were
evaluated. With the exception of the Parent to Scrambled comparison, there was sufficient
evidence to assert equivalence (p<0.05) in each of the pairwise equivalence tests. The Parent to

50

Figure 3.3
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Figure 3.3: ECAR measurements in each cell line.
Baseline extracellular acidification rate (ECAR) was significantly increased in the CRISPR 2-19
cell line when compared to the Parent, Scrambled, Up, and CRISPR 5-50 cell lines. The CRISPR
5-50 cell line was also significantly increased compared to the Parent cell line. Glycolytic reserve
capacity was significantly increased in the CRISPR 2-19 and CRISPR 5-50 cell lines compared to
the Parent, Scrambled, and Up cell lines. Baseline OCR/ECAR was significantly decreased in the
Up and CRISPR 2-19 cell lines when compared to the Scrambled cell line. Order of bars are
preserved throughout figure (Parent, Scrambled, Up, CRISPR 2-19, CRISPR 5-50) and represent
mean ± SEM. N=6. *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. The Parent and Scrambled
cell lines express parental NAT1 activity, the Up cell line expresses increased NAT1 activity, and
the CRISPR 2-19 and CRISPR 5-50 cell lines express no NAT1 activity (knockout).
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Figure 3.4
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Figure 3.4: Coupling Efficiency measurements in each cell line.
Coupling efficiency did not significantly differ between cell lines. Bars represent mean ± SEM.
N=6. The Parent and Scrambled cell lines express parental NAT1 activity, the Up cell line
expresses increased NAT1 activity, and the CRISPR 2-19 and CRISPR 5-50 cell lines express no
NAT1 activity (knockout).
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Scrambled equivalence test was marginally significant (p = 0.065; Figure 3.5). This data suggests
that modulation of NAT1 activity does not affect MDA-MB-231 cell viability over the course of
these experiments.
Discussion
It has been previously reported that TNBC cell lines, including MDA-MB-231 cells, have
profound metabolic changes characterized by decreased mitochondrial respiration and increased
glycolysis when compared to breast cancer cell lines that are ER positive, PR positive, and/or
HER2 positive148. Since the purpose of this study was to evaluate how increased and knockout
levels of human NAT1 affected the cellular bioenergetics of MDA-MB-231 breast cancer cells, the
Parent MDA-MB-231 (no genetic alterations or transfections) was used as a baseline
comparison. The Scrambled cell line (the Parent MDA-MB-231 cell line with a FRT site added into
the genome and a scrambled shRNA transfected into that FRT site) was included as a
transfection control84. We did not observe a significant effect of the scrambled shRNA on cellular
bioenergetics in MDA-MB-231 cells. The Up cell line (the Parent MDA-MB-231 cell line with a
FRT site added into the genome and a plasmid overexpressing human NAT1 stably transfected
into that FRT site) yields overexpression of NAT184. Finally, two complete NAT1 knockout cell
lines (CRISPR 2-19 and CRISPR 5-50) constructed using CRISPR/Cas9 technology (as
described in the Methods section), were evaluated to verify that observed effects were due to
differences in NAT1 as opposed to off-target effects caused by a specific guide-RNA. Therefore,
we have concluded a result was due to the knockout of NAT1 only when the same trend was
observed in both CRISPR/Cas9 constructed cell lines.
Knockout of NAT1 in MDA-MB-231 cells significantly altered the bioenergetics profile of
the cells while increased NAT1 expression did not significantly alter the bioenergetics profile
when compared to the Parent MDA-MB-231 cell line. Significant increases in reserve capacity,
maximum mitochondrial capacity, and glycolytic reserve were observed in both NAT1 knockout
cell lines compared to cell lines expressing parental and increased NAT1 activity. While basal
OCR was unaffected by altered NAT1 activity, baseline ECAR was significantly increased in
NAT1 knockout cells, suggesting an increase in glycolysis.
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Figure 3.5
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Figure 3.5: MTT Equivalence Test Results.
Equivalence between MTT absorbance values in each cell line was tested to access if there were
differences in growth of the cell lines during bioenergetics experiments. There was sufficient
evidence to assert equivalence in each of the pairwise equivalent tests.
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Baseline OCR is an indicator of baseline mitochondrial respiration. ATP-linked OCR is
the difference between OCR before and after ATP synthase is inhibited with oligomycin. This
allows estimation of the OCR that is used to drive mitochondrial ATP synthesis and is largely set
by the ATP demand of the cells149. Modulation of NAT1 expression did not alter baseline or ATPlinked OCR in MDA-MB-231 cells. This result suggests NAT1 does not play a role in the ATP
demand responses in the cells. Coupling efficiency is calculated as the fraction of baseline OCR
used for ATP synthesis (ATP-linked OCR/baseline OCR)140. Coupling efficiency was also
unaffected by modulation of NAT1 in MDA-MB-231 cells providing further evidence to support the
conclusion that that NAT1 does not play a role in ATP demand responses in these cells.
Reserve capacity is the difference between the basal and maximal respiration of the
mitochondria and is broadly an evaluation of a cell’s ability to respond to increased energy
demands such as those found in rapidly dividing cancer cells149. Increases in reserve capacity, as
observed in the NAT1 knockout cell lines, could reflect enhanced oxidative capacity,
mitochondrial biogenesis, or increased substrate provision149. Reserve capacity does not
explicitly implicate or identify molecular mechanisms of action since it is dependent upon multiple
parameters. The significant increase in reserve capacity measured in the two NAT1 knockout cell
lines appears to be driven by the increase in maximal respiration in those cell lines. Maximal
respiration rate is primarily determined by substrate supply and oxidation149. This includes
substrate transport across the mitochondrial membrane as well as rate controlling metabolic
enzymes. Taken together, these results indicate NAT1 may have a role, either directly or through
its influence on acetyl-CoA levels, in regulation of mitochondrial substrate transport or
metabolism. One could speculate that knockdown of NAT1 increases acetyl-CoA thereby
increasing substrate(s) for the TCA cycle which could increase mitochondrial reserve capacity.
This hypothesis should be investigated in future studies.
Glycolytic reserve is the difference between oligomycin-induced ECAR and baseline
ECAR and is a measure of the maximum rate of conversion of glucose to pyruvate or lactate that
can be achieved acutely by a cell150. This measurement is an important parameter to evaluate in
cancer cells because there is such an increased demand for energy precursors. Increases in
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glycolytic reserve, as we observed in the two NAT1 knockout cell lines, also indicate that these
cells can respond better to these increased energy demands. Here we report that NAT1
knockout, using two guide RNAs, increased the glycolytic reserve in MDA-MB-231 cells. There
have been many studies49,81,137,151 investigating the inhibition of NAT1 with small molecule
inhibitors as a possible way to decrease the cancerous and metastatic properties of malignant
cells; however, this data suggest knockout of NAT1 may allow cells to increase glycolysis and
use mitochondrial reserve.
Mitochondria facilitate cellular stress responses, including the response to hypoxia and
the activation of programmed cell death via the release of pro-apoptotic molecules152. Differences
in mitochondrial function between cells that express varying levels of NAT1 may play a role in
cancer initiation or tumorigenesis by modulating these responses. It appears knockout of NAT1
allows cells to express more plasticity in terms of response to energy demand. Our data suggest
that NAT1 may play a role in an unknown response mechanism that keeps cancer cells from
hijacking the mitochondrial machinery to produce increased amounts of ATP that would be
needed by cancer cells.
Summary and conclusions
In conclusion, differences in NAT1 activity, particularly the knockout of NAT1, significantly
altered the bioenergetics profile of MDA-MB-231 triple negative breast cancer cells. Reserve
capacity, maximal respiration, and glycolytic reserve capacity were increased in the NAT1
knockout cell lines. Increases in these measurements suggest that NAT1 knockout cells may be
better able to respond to stress. These findings provide evidence that NAT1 modifies cellular
acetyl-CoA levels and mitochondrial bioenergetics. Further investigation into the specific role
NAT1 is playing in regulating cellular metabolism and bioenergetics is needed, ongoing, and will
best be investigated via a multidisciplinary approach.
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CHAPTER 4

METABOLOMICS

Background
Metabolomics is particularly well-suited for studying global metabolism as metabolites are
the end-products of metabolism. In addition, performing an untargeted metabolomics study allows
the collection of abundance data on many metabolites at once, from a single sample, giving a
global snapshot of metabolism. While we acknowledge that untargeted metabolomics is still
unable to detect and/or quantify ALL metabolites found in humans, it is the best way to get a
global view of metabolism. The Human Metabolome Database (HMDB) approximates there are
22,000 endogenous metabolites that have been detected153 however less than a thousand can be
reliably measured. Many metabolomics studies have been conducted to better understand breast
cancer and resulting alterations in metabolism154-164 and the use of metabolomics for systems
biology approaches has recently been reviewed165. Additionally, there has been increased
interest recently in “oncometabolites”—metabolites that when dysregulated can contribute to the
progression of cancer166-170. Notably, it has been suggested that oncometabolites can affect
mitochondrial dynamics166.
Materials and Methods
A global, untargeted metabolomics approach was utilized to interrogate differences in
metabolic profile across six biological replicates of previously constructed and characterized
MDA-MB-231 breast cancer cell lines expressing parental (Scrambled), increased (Up),
decreased (Down, CRISPR 2-12), or knockout (CRISPR 2-19, CRISPR 5-50) levels of human
arylamine N-acetyltransferase 1 (NAT1). All cell lines were cultured in high-glucose Dulbecco's
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Modified Eagle Medium (DMEM), with 10% fetal bovine serum, 5% glutamine, and 5%
penicillin/streptomycin.
Cells were plated in triplicate per biological replicate at a density of 500,000 cells per 150
x 25 mm cell plate, resulting in 18 plates total. Three plates were combined to form a single
biological sample so that enough biological mass would be collected for future analysis. Cells
were allowed to grow for three days in an incubator at 37 °C containing 5% CO2. Prior to
collecting the cells, 200 μL of media from each plate was reserved. Media from the 3 plates that
were combined as a single biological replicate were collected in the same vial. Vials containing
media were centrifuged to pellet out any cells that may have been present and the resulting
supernatants were placed into separate cryovials. Cryovials containing media samples were then
flash frozen in liquid nitrogen for 1 minute and then stored in -80 °C freezer for possible future
metabolomic analysis.
Cells were then harvested on ice by adding 5 mL 0.25% trypsin and scraping the cells
from the plate. Three plates of cells were combined to form one sample (biological replicate) to
ensure there was enough cells for analysis. After harvesting the cells were washed 3 times with
ice-cold 1 x PBS. Supernatant was removed and 100 μL of cell pellet from 3 samples of each cell
line was reserved for transcriptomic analysis (presented in Chapter 5). The cryovials containing
cell pellets were then flash frozen in liquid nitrogen for 1 minute followed by immediate storage at
-80 °C. Samples were then shipped on dry ice to Metabolon Inc. (Durham, NC) for sample
preparation and analysis, as described below.
Sample Accessioning
Following receipt, samples were inventoried and immediately stored at -80 oC by
Metabolon. The Metabolon Laboratory Information Management System (LIMS) system was
utilized for sample management. Samples were assigned a unique identifier by the LIMS that was
associated with the original source identifier only. This identifier was used to track all sample
handling, tasks, results, etc. The samples (and all derived aliquots) were tracked by the LIMS
system. All portions of any sample were automatically assigned their own unique identifiers by the
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LIMS when a new task was created; the relationship of these samples was also tracked. All
samples were maintained at -80 oC until processed.
Sample Preparation
Metabolon sample preparation has been described in great detail elsewhere171 but is
presented briefly here. Samples were prepared using the automated MicroLab STAR® system
(Hamilton Company, Reno, NV). Several recovery standards (described in great detail
elsewhere171) were added prior to the first step in the extraction process for quality control (QC)
purposes. To remove protein, dissociate small molecules bound to protein or trapped in the
precipitated protein matrix, and to recover chemically diverse metabolites, proteins were
precipitated with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000)
followed by centrifugation. The resulting extract was divided into five fractions: two for analysis by
two separate reverse phase ultrahigh performance tandem mass spectroscopy (RP/UPLCMS/MS) methods with positive ion mode electrospray ionization (ESI), one for analysis by
RP/UPLC-MS/MS with negative ion mode ESI, one for analysis by hydrophilic interaction liquid
chromatography (HILIC)/UPLC-MS/MS with negative ion mode ESI, and one sample was
reserved for backup. Samples were placed briefly on a TurboVap® (Zymark) to remove the
organic solvent. The sample extracts were stored overnight under nitrogen before preparation for
analysis.
Quality Assessment/Quality Control (QA/QC)
Several types of controls were analyzed in concert with the experimental samples: a
pooled matrix sample generated by taking a small volume of each experimental sample served as
a technical replicate throughout the data set; extracted water samples served as blanks; and a
cocktail of QC standards that were carefully chosen not to interfere with the measurement of
endogenous compounds were spiked into every analyzed sample, allowed instrument
performance monitoring and aided chromatographic alignment. Instrument variability was
determined by calculating the median relative standard deviation (RSD) for the standards that
were added to each sample prior to injection into the mass spectrometers. Overall process
variability was determined by calculating the median RSD for all endogenous metabolites (i.e.,
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non-instrument standards) present in 100% of the pooled matrix samples. Experimental samples
were randomized across the platform run with QC samples spaced evenly among the injections.
Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLCMS/MS)
All methods utilized a Waters ACQUITY ultra-performance liquid chromatography (UPLC)
and a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a
heated electrospray ionization (HESI-II) source and an Orbitrap mass analyzer operated at
35,000 mass resolution. The sample extract was dried, then reconstituted in solvents compatible
to each of the four methods. Each reconstitution solvent contained a series of standards at fixed
concentrations to ensure injection and chromatographic consistency. One aliquot was analyzed
using acidic positive ion conditions, chromatographically optimized for more hydrophilic
compounds. In this method, the extract was gradient eluted from a C18 column (Waters UPLC
ethylene bridged hybrid (BEH) C18-2.1x100 mm, 1.7 µm) using water and methanol, containing
0.05% perfluoropentanoic acid (PFPA) and 0.1% formic acid (FA). Another aliquot was also
analyzed using acidic positive ion conditions, however it was chromatographically optimized for
more hydrophobic compounds. In this method, the extract was gradient eluted from the same
aforementioned C18 column using methanol, acetonitrile, water, 0.05% PFPA and 0.01% FA and
was operated at an overall higher organic content. Another aliquot was analyzed using basic
negative ion optimized conditions using a separate dedicated C18 column. The basic extracts
were gradient eluted from the column using methanol and water, however with 6.5 mM
ammonium bicarbonate at pH 8.0. The fourth aliquot was analyzed via negative ionization
following elution from a HILIC column (Waters UPLC BEH Amide 2.1x150 mm, 1.7 µm) using a
gradient consisting of water and acetonitrile with 10 mM ammonium formate, pH 10.8. The MS
analysis alternated between MS and data-dependent MSn scans using dynamic exclusion. The
scan range varied slightly between methods but covered 70-1000 m/z. Raw data files were
archived and extracted as described below.
Data Extraction and Compound Identification
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Raw data were extracted, peak-identified and QC processed by Metabolon utilizing
proprietary methods. Compounds were identified by comparison to library entries of purified
standards or recurrent unknown entities. Metabolon maintains a library based on authenticated
standards that contains the retention time/index (RI), mass to charge ratio (m/z), and
chromatographic data (including MS/MS spectral data) on all molecules present in the library.
Furthermore, biochemical identifications are based on three criteria: retention index within a
narrow RI window of the proposed identification, accurate mass match to the library +/- 10 ppm,
and the MS/MS forward and reverse scores between the experimental data and authentic
standards. The MS/MS scores are based on a comparison of the ions present in the experimental
spectrum to the ions present in the library spectrum. While there may be similarities between
these molecules based on one of these factors, the use of all three data points can be utilized to
distinguish and differentiate biochemicals. More than 3300 commercially available purified
standard compounds have been acquired and registered into LIMS for analysis on all platforms
for determination of their analytical characteristics. Additional mass spectral entries have been
created for structurally unnamed biochemicals, which have been identified by virtue of their
recurrent nature (both chromatographic and mass spectral). These compounds have the potential
to be identified by future acquisition of a matching purified standard or by classical structural
analysis.
Curation
A variety of curation procedures were carried out by Metabolon to ensure that a high
quality data set was made available for statistical analysis and data interpretation. The QC and
curation processes were designed to ensure accurate and consistent identification of true
chemical entities, and to remove those representing system artifacts, mis-assignments, and
background noise. Metabolon data analysts use proprietary visualization and interpretation
software to confirm the consistency of peak identification among the various samples. Library
matches for each compound were checked for each sample and corrected if necessary.
Metabolite Quantification and Data Normalization
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Peaks were quantified using area-under-the-curve. For studies spanning multiple days, a
data normalization step was performed to correct variation resulting from instrument inter-day
tuning differences. Essentially, each compound was corrected by registering the medians equal
to one (1.00) and normalizing each data point proportionately. For studies that did not require
more than one day of analysis, no normalization is necessary, other than for purposes of data
visualization. Biochemical data was also normalized to total protein as determined by Bradford
assay to account for differences in metabolite levels due to differences in the amount of material
present in each sample.
Statistical Analyses
Figure 4.1 illustrates experimental approach and data analyses methods. Normality of
data was accessed via the Shapiro–Wilk test; normality of non-log and log transformed data was
visualized (Figure 4.2). All statistical analyses were performed on log transformed data using R: A
Language and Environment for Statistical Computing version 3.3.1132. One-way ANOVA was
performed to test for significant differences between groups for each metabolite at an alpha level
of 0.05. Q-values were then calculated using the false discovery rate method to correct for
multiple hypothesis testing172. Dunnett’s post-tests were utilized to compare all groups (Up,
Down, CRISPR 2-12, CRISPR 2-19, CRISPR 5-50) to the Scrambled group for those metabolites
with one-way ANOVA q£0.05. Q-values were then calculated using the false discovery rate (FDR)
method for Dunnett’s post-test p-values.
Fold-change was calculated using equation 1 (shown below). Briefly, the mean
abundance for each metabolite was calculated for each group. We then divided the mean of the
comparison group (Up, Down, CRISPR 2-12, CRISPR 2-19, CRISPR 5-50) by the mean of the
Scrambled group to give us fold-change relative to the Scrambled group.
+
*
,

%&'() + %

!" = 2

Equation 1

In the equation, FC = fold-change, -̅ = average metabolite abundance in the reference group, /0=
average metabolite abundance in the comparison group. A negative sign was added to
the fold-change when metabolite abundance was lower in the comparison group compared to the
reference group.
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Figure 4.1: Metabolomics Experimental Approach Diagram.
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single biological replicate to have enough sample for analysis). Samples were then analyzed by
UPLC-MS/MS at Metabolon using 4 methods optimized for the greatest coverage across the
metabolome. Following metabolite identification, abundance data was protein normalized, median
scaled, minimum values imputed, and log-transformed. Metabolite abundances were then
analyzed for differential abundance, correlation with NAT1 N-acetylation activity, unbiased
multivariate analysis/clustering, and pathway enrichment.
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Figure 4.2
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Figure 4.2: Accessing Normality of Metabolomics Data.
Normality of raw metabolite intensities before (A) and after log transformation was assessed (B).
Normality of non-protein normalized metabolite abundances before (C) and after log
transformation was assessed (D). Normality of protein normalized metabolite abundances before
(E) and after log transformation was assessed (F). For all, log transformation led to approximate
normality.
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Data were plotted as volcano plots to simultaneously visualize the between group differences in
abundance of all detected metabolites and significance. Additionally, data were plotted as boxplots to better visualize the abundance distribution of each metabolite between all groups.
Pearson correlation was calculated between NAT1 activity and relative metabolite abundance for
all metabolites to generate hypotheses about novel NAT1 substrates or products. Additionally,
Pearson correlation was calculated between carnosine and metabolites whose abundance was
concordantly altered in the two NAT1 KO cell lines. Data were also plotted as a heatmap and
hierarchal clustering was conducted using the Weighted Pair Group Method with Arithmetic Mean
(WPGMA) method. Principal component analysis was conducted by singular value decomposition
of the centered data matrix. The loadings of the first (x-axis) and second (y-axis) principal
component were plotted. Weighted gene co-expression network analysis (WGCNA) was
conducted on metabolite abundance data. Enrichment analysis was conducted for each group
compared to Scrambled. The normalized enrichment score was utilized to determine the relative
degree of enrichment.
Results
Univariate Analyses
A large proportion (515/567; 90.8%) of the detected metabolites were found to
significantly differ (q £ 0.05) between the six cell lines (Table 4.1). Following Dunnett’s post tests
it was observed that more metabolites differed in the cell lines constructed via CRISPR/Cas9 than
the cell lines constructed via siRNA when compared to the Scrambled cell line. Thirty-four point
four percent, 28.4%, 61.7%, 64.4%, and 53.8% of total detected metabolites were differentially
expressed in the Down, Up, CRISPR 2-12, CRISPR 2-19, and CRISPR 5-50 groups,
respectively. Metabolites were further characterized by direction of fold-change compared to
Scrambled (Table 4.1; Figures 4.3 – 4.7); more metabolites were decreased than increased in all
group comparisons to Scrambled except the CRISPR 2-19 cell line. The CRISPR/Cas-9
generated cell lines had not only more total metabolites differentially expressed compared to the
siRNA generated cell lines, but also more metabolites whose fold-changes were greater than 4.
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Table 4.1
Metabolomics Summary Statistics
Statistical Comparison

One-way
ANOVA

All Groups

Total
Metabolites
p ≤ 0.05

519

Total
Metabolites
q ≤ 0.05

515

Dunnett’s
t-test
Post Test

Statistical Comparison
Down
Scrambled

Up
Scrambled

CRISPR 2-12
Scrambled

CRISPR 2-19
Scrambled

CRISPR 5-50
Scrambled

Total
Metabolites
p ≤ 0.05

220

199

380

384

326

Metabolites
(↑↓)

68|152

155|44

190|190

179|205

173|153

Total
Metabolites
q ≤ 0.05

198

161

352

365

305

Metabolites
(↑↓)

60|138

30|131

175|177

173|192

163|142

One-way ANOVA was conducted for each metabolite abundance between all groups. q-values
were calculated from resulting one-way ANOVA p-values to account for the multiple hypothesis
testing. Dunnett’s t-test post tests were conducted for each group compared to Scrambled on
metabolites found to significantly vary between all groups. Significant metabolites were further
characterized by direction of fold-change; metabolites with increased abundance are shown in
green while metabolites with decreased abundances are shown in red. q-values were calculated
from resulting Dunnett’s t-test p-values.
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Figure 4.3
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Figure 4.3: Down vs Scrambled Volcano Plot.
Each dot represents a single metabolite and is color coded according to q-value. The black dots
represent metabolites that had a Dunnett’s post test q-value greater than 0.05, blue dots
represent metabolites that had a q-value less than or equal to 0.05 but greater than 0.01, and red
dots represent metabolites that had a q-value less than or equal to 0.01. Negative fold changes
represent a decrease in that metabolite compared to the Scrambled group while positive fold
changes represent an increase in that metabolite compared to the Scrambled group.
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Figure 4.4
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Figure 4.4: Up vs Scrambled Volcano Plot.
Each dot represents a single metabolite and is color coded according to q-value. The black dots
represent metabolites that had a Dunnett’s post test q-value greater than 0.05, blue dots
represent metabolites that had a q-value less than or equal to 0.05 but greater than 0.01, and red
dots represent metabolites that had a q-value less than or equal to 0.01. Negative fold changes
represent a decrease in that metabolite compared to the Scrambled group while positive fold
changes represent an increase in that metabolite compared to the Scrambled group.
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Figure 4.5
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Figure 4.5: CRISPR 2-12 vs Scrambled Volcano Plot.
Each dot represents a single metabolite and is color coded according to q-value. The black dots
represent metabolites that had a Dunnett’s post test q-value greater than 0.05, blue dots
represent metabolites that had a q-value less than or equal to 0.05 but greater than 0.01, and red
dots represent metabolites that had a q-value less than or equal to 0.01. Negative fold changes
represent a decrease in that metabolite compared to the Scrambled group while positive fold
changes represent an increase in that metabolite compared to the Scrambled group.
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Figure 4.6
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Figure 4.6: CRISPR 2-19 vs Scrambled Volcano Plot.
Each dot represents a single metabolite and is color coded according to q-value. The black dots
represent metabolites that had a Dunnett’s post test q-value greater than 0.05, blue dots
represent metabolites that had a q-value less than or equal to 0.05 but greater than 0.01, and red
dots represent metabolites that had a q-value less than or equal to 0.01. Negative fold changes
represent a decrease in that metabolite compared to the Scrambled group while positive fold
changes represent an increase in that metabolite compared to the Scrambled group.
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Figure 4.7
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Figure 4.7: CRISPR 5-50 vs Scrambled Volcano Plot.
Each dot represents a single metabolite and is color coded according to q-value. The black dots
represent metabolites that had a Dunnett’s post test q-value greater than 0.05, blue dots
represent metabolites that had a q-value less than or equal to 0.05 but greater than 0.01, and red
dots represent metabolites that had a q-value less than or equal to 0.01. Negative fold changes
represent a decrease in that metabolite compared to the Scrambled group while positive fold
changes represent an increase in that metabolite compared to the Scrambled group.
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The overlap in significant metabolites with a fold-change greater than or equal to 2 was
compared between the two NAT1 KO cell lines and the Scrambled group (Figure 4.8). Eighteen
metabolites were increased concordantly in the two NAT1 KO cell lines compared to Scrambled
with 102 and 32 metabolites uniquely increased in the CRISPR 2-19 and CRISPR 5-50 cell lines,
respectively. Twenty-five metabolites were decreased concordantly in the two NAT1 KO cell lines
compared to Scrambled with 58 and 38 metabolites uniquely decreased in the CRISPR 2-19 and
CRISPR 5-50 cell lines, respectively. Table 4.2 lists metabolites whose abundances were
concordantly changed in the NAT1 KO cell lines. More metabolites had conflicting differential
abundance between the two CRISPR NAT1 KO cell lines compared to Scrambled than those that
agreed. Notably, many of the metabolites decreased concordantly in the CRISPR NAT1 KO cell
lines were carnitine conjugates. Assessing correlation between carnitine and all metabolites
concordantly changed in the CRISPR NAT1 KO cell lines revealed the abundance of most
metabolites were associated with carnitine (Table 4.2). This suggests dysregulation of carnitine is
driving the differential abundances observed in this subset of metabolites.
Eight metabolites, N-acetylasparagine, N-acetylputrescine, saccharopine, cytidine, 1palmitoyl-2-alpha linolenoyl-GPC (16:0/18:3n3), isovalerylcarnitine (C5), cysteine sulfinic acid,
and serotonin, were significantly associated with NAT1 PABA N-acetylation activity (Table 4.3).
The last five of the eight metabolites listed had a high degree of variation in the within-group
measurement of metabolite abundance therefore the association is not as well defined as the
others. The top two metabolites correlated with PABA N-acetylation, N-acetylasparagine (Figure
4.9; Table 4.4) and N-acetylputrescine (Figure 4.10; Table 4.5), had a correlation coefficient (r)
value greater than 0.9 and are N-acetylated compounds, suggesting they may be products of Nacetylation by NAT1. Two of the metabolites significantly correlated with PABA N-acetylation,
saccharopine (Figure 4.11; Table 4.6) and isovalerylcarnitine (C5), had an inverse relationship
suggesting a role in a NAT1 catalyzed reaction as the substrate or possibly down-stream of a
NAT1 catalyzed reaction. Additionally, differential acetyl-CoA levels due to NAT1’s ability to
hydrolyze acetyl-CoA could be driving these observations.
Multivariate/Multivariable Analyses
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Figure 4.8

Figure 4.8: Concordance of Metabolite Abundance Differences in CRISPR NAT1 Knockout
Cell Lines.
Significant metabolites with a fold-change greater than or equal to 2 were compared between
CRISPR/Cas9 generated NAT1 knockout cell lines. Eighteen metabolites were increased
concordantly in the two NAT1 KO cell lines compared to Scrambled with 102 and 32 metabolites
uniquely increased in the CRISPR 2-19 and CRISPR 5-50 cell lines, respectively. Twenty-five
metabolites were decreased concordantly in the two NAT1 KO cell lines compared to Scrambled
with 58 and 38 metabolites uniquely decreased in the CRISPR 2-19 and CRISPR 5-50 cell lines,
respectively. Green: metabolites increased compared to Scrambled; red: metabolites decreased
compared to Scrambled.
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Table 4.2
Metabolites Concordantly Differentially Abundant in CRISPR 2-19 and CRISPR 5-50 Cell Lines
CORRELATION
FOLD-CHANGE
WITH
ANOVA
CARNITINE
M#
BIOCHEMICAL
q-value
CRISPR CRISPR
2-19/S
5-50/S
1-(1-enyl-palmitoyl)-2-linoleoyl-GPE
M6
<0.0001
4.1
2.2
-0.60
(P-16:0/18:2)*
M26
13-HODE + 9-HODE
0<0.002
2.5
2.0
-0.68
M33

1-linoleoyl-GPE (18:2)*

<0.0001

5.4

3.6

-0.68

M116

3-hydroxydecanoate

<0.0001

2.7

3.3

-0.91

M119

3-hydroxylaurate

<0.0001

2.2

2.3

-0.77

M120

3-hydroxyoctanoate

<0.0001

2.8

3.3

-0.62

<0.0001

5.5

4.5

-0.77

<0.0001

26.4

19.1

-0.82

M339

dihydroxyacetone phosphate
(DHAP)
lactose

M387

N-acetyl-beta-alanine

<0.0001

13.3

4.1

-0.72

M417

nicotinamide ribonucleotide (NMN)

<0.0001

25.9

2.9

-0.41

M437

oleoylcholine

<0.0001

8.3

2.6

-0.66

M445

palmitoleoyl ethanolamide*

<0.0001

3.0

2.3

-0.70

M447

palmitoloelycholine

<0.0001

8.4

2.4

-0.57

M452

palmitoylcholine

<0.0001

9.7

2.1

-0.53

M456

penicillin G

<0.0001

18.2

5.7

-0.70

M481

pyridoxine (Vitamin B6)

<0.0001

4.5

3.8

-0.83

M526

stearoyl ethanolamide

<0.0001

2.6

2.2

-0.82

M555

urate

<0.0001

2.0

3.5

-0.87

M102

2'-O-methylcytidine

<0.002

0.4

0.4

0.88

M110

3-aminoisobutyrate

<0.0001

0.3

0.5

0.79

M132

4-hydroxyglutamate

<0.0001

0.2

0.2

0.93

M161

adrenoylcarnitine (C22:4)*

<0.0001

0.1

0.1

0.92

M176

arachidonoylcarnitine (C20:4)

<0.0001

0.2

0.2

0.91

M190

beta-guanidinopropanoate

<0.0001

0.3

0.4

0.84

M210

cis-4-decenoylcarnitine (C10:1)

<0.0001

0.2

0.4

0.69

M218

cystathionine

<0.0001

0.2

0.1

0.92

M226

cytidine diphosphate

<0.0001

0.3

0.4

0.85

<0.0001

0.1

0.2

0.86

<0.0001

0.1

0.4

0.88

M233

M231
M232

dihomo-linolenoylcarnitine
(20:3n3 or 6)*
dihomo-linoleoylcarnitine (C20:2)*

*Continued on Next Page
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M242

docosatrienoylcarnitine (C22:3)*

<0.0001

0.1

0.2

0.88

M344

laurylcarnitine (C12)

<0.0001

0.2

0.5

0.85

M352

linolenoylcarnitine (C18:3)*

<0.0001

0.1

0.2

0.83

M353

linoleoylcarnitine (C18:2)*

<0.0001

0.0

0.3

0.77

M371

myristoleoylcarnitine (C14:1)*

<0.0001

0.1

0.4

0.75

M376

N2,N2-dimethylguanosine

<0.006

0.5

0.4

0.70

M384

N-acetylasparagine

<0.0001

0.1

0.1

0.28

M412

N-carbamoylaspartate

<0.0001

0.1

0.1

0.89

M441

orotate
palmitoyl dihydrosphingomyelin
(d18:0/16:0)*

<0.0001

0.1

0.1

0.95

<0.0001

0.4

0.4

0.95

pantetheine
sphingomyelin
(d18:0/18:0, d19:0/17:0)*

<0.0001

0.5

0.3

0.78

<0.0001

0.4

0.5

0.63

M544

tryptamine

<0.0001

0.5

0.5

0.93

M559

uridine 5'-triphosphate (UTP)

<0.0001

0.04

0.1

0.95

M448
M453
M508

Metabolites concordantly differentially abundant in CRISPR 2-19 and CRISPR 5-50 cell lines
were identified. Eighteen metabolites were concordantly increased while 25 metabolites were
concordantly decreased. Pearson correlation between identified concordant metabolites and
carnitine was conducted. M# represents an arbitraily assigned identifier for analysis purposes,
biochemical is the metabolite identity, ANOVA q-value is the one-way ANOVA q-value, and
correlation is the Pearson correlation coefficient between that metabolite and carnitine. Foldchanges were color coded according to direction of fold-change with green for metabolites
increased compared to Scrambled and red for metabolites decreased compared to Scrambled.
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Table 4.3
Metabolites Significantly Correlated with NAT1 N-acetylation Activity
CORRELATION
COEFFICIENT
0.986

M#
M384

BIOCHEMICAL
N-acetylasparagine

p-value
0.00030

M404

N-acetylputrescine

0.0046

0.944

M491

saccharopine

0.022

-0.876

M224

cytidine

0.029

0.856

M49

1-palmitoyl-2-alpha-linolenoyl-GPC (16:0/18:3n3)*

0.043

0.825

M336

isovalerylcarnitine (C5)

0.046

-0.820

M220

cysteine sulfinic acid

0.047

0.816

M498

serotonin

0.050

0.811

Pearson correlation between NAT1 N-acetylation activity in constructed cell lines and all 567
detected metabolites was conducted. Eight metabolites were significantly correlated with NAT1
N-acetylation activity. M# represents an arbitrability assigned identifier for analysis purposes,
biochemical is the metabolite identity, p-value is the Pearson correlation p-value, and correlation
is the Pearson correlation coefficient. Correlation coefficients were color coded according to
direction of correlation, with green for positive correlation and red for inverse (negative)
correlation.
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Table 4.4
N-acetylasparagine
Statistical Comparison

One-way
ANOVA

All Groups

q-value

<0.00001

Statistical Comparison
Dunnett’s
t-test
Post Test

Down
Scrambled

Up
Scrambled

CRISPR 2-12
Scrambled

CRISPR 2-19
Scrambled

CRISPR 5-50
Scrambled

q-value

<0.001

<0.00001

<0.0001

<0.00001

<0.00001

FoldChange

-2.3

3.0

-2.5

-11.6

-17.9

One-way ANOVA was conducted for N-acetylasparagine abundance between all groups. qvalues were calculated from resulting one-way ANOVA p-values to account for the multiple
hypothesis testing. Dunnett’s t-test post tests were conducted for each group compared to
Scrambled. N-acetylasparagine abundance was further characterized by direction of fold-change;
metabolites with increased abundance are shown in green while metabolites with decreased
abundances are shown in red. q-values were calculated from resulting Dunnett’s t-test p-values.
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Table 4.5
N-acetylputrescine
Statistical Comparison

One-way
ANOVA

All Groups

q-value

<0.0001

Statistical Comparison
Dunnett’s
t-test
Post Test

Down
Scrambled

Up
Scrambled

CRISPR 2-12
Scrambled

CRISPR 2-19
Scrambled

CRISPR 5-50
Scrambled

q-value

0.03

<0.00001

0.95

<0.00001

0.003

FoldChange

-1.2

1.7

1

-1.9

-1.3

One-way ANOVA was conducted for N-acetylputrescine abundance between all groups. q-values
were calculated from resulting one-way ANOVA p-values to account for the multiple hypothesis
testing. Dunnett’s t-test post tests were conducted for each group compared to Scrambled. Nacetylputrescine abundance was further characterized by direction of fold-change; metabolites
with increased abundance are shown in green while metabolites with decreased abundances are
shown in red. q-values were calculated from resulting Dunnett’s t-test p-values
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Table 4.6
Saccharopine
Statistical Comparison

One-way
ANOVA

All Groups

q-value

<0.00001

Statistical Comparison
Dunnett’s
t-test
Post Test

Down
Scrambled

Up
Scrambled

CRISPR 2-12
Scrambled

CRISPR 2-19
Scrambled

CRISPR 5-50
Scrambled

q-value

<0.001

<0.00001

0.57

<0.00001

<0.00001

FoldChange

-1.4

-2.9

1

1.8

1.7

One-way ANOVA was conducted for saccharopine abundance between all groups. q-values were
calculated from resulting one-way ANOVA p-values to account for the multiple hypothesis testing.
Dunnett’s t-test post tests were conducted for each group compared to Scrambled. Saccharopine
abundance was further characterized by direction of fold-change; metabolites with increased
abundance are shown in green while metabolites with decreased abundances are shown in red.
q-values were calculated from resulting Dunnett’s t-test p-values.
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Figure 4.9
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Figure 4.9: N-acetylasparagine Abundance Distribution and Correlation with NAT1 Nacetylation Activity.
(A) Boxplots of abundance distribution of N-acetylasparagine in each cell line. In the boxplots, the
solid black line represents the median, the upper hinge represents the 75th quartile and the lower
hinge represents the 25th quartile. The upper whisker represents the largest observation less
than or equal to the upper hinge + 1.5 x IQR, the lower whisker represents the smallest
observation greater than or equal to the lower hinge - 1.5 * IQR. (B) Correlation plot between Nacetylasparagine abundance and NAT1 N-acetylation activity in each cell line. Error bars
represent standard deviation. Pearson correlation coefficient = 0.986, p-value < 0.001
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Figure 4.10

N−acetylputrescine

Median Scaled Relative Abundance

A
2.0

1.5

1.0

0.5
Scrambled
(Parental)

Median Scaled Relative
Abundance of
N−acetylputrescine

B

Down
(Decreased)

Up
(Increased)

CRISPR 2−12 CRISPR 2−19 CRISPR 5−50
(Decreased)
(Knockout)
(Knockout)

2.0
1.5
Cell Line
Scrambled

1.0

Down
Up

0.5

CRISPR 2−12
CRISPR 2−19
CRISPR 5−50

0.0
0

10
20
30
40
50
60
PABA Activity (nmoles acetylated
PABA/min/mg protein)

82

Figure 4.10: N-acetylputrescine Abundance Distribution and Correlation with NAT1 Nacetylation Activity.
(A) Boxplots of abundance distribution of N-acetylputrescine in each cell line. In the boxplots, the
solid black line represents the median, the upper hinge represents the 75th quartile and the lower
hinge represents the 25th quartile. The upper whisker represents the largest observation less
than or equal to the upper hinge + 1.5 x IQR, the lower whisker represents the smallest
observation greater than or equal to the lower hinge - 1.5 * IQR. (B) Correlation plot between Nacetylputrescine abundance and NAT1 N-acetylation activity in each cell line. Error bars
represent standard deviation. Pearson correlation coefficient = 0.944, p-value < 0.01

83

Figure 4.11
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Figure 4.11: Saccharopine Abundance Distribution and Correlation with NAT1 Nacetylation Activity.
(A) Boxplots of abundance distribution of Saccharopine in each cell line. In the boxplots, the solid
black line represents the median, the upper hinge represents the 75th quartile and the lower
hinge represents the 25th quartile. The upper whisker represents the largest observation less
than or equal to the upper hinge + 1.5 x IQR, the lower whisker represents the smallest
observation greater than or equal to the lower hinge - 1.5 * IQR. (B) Correlation plot between
Saccharopine abundance and NAT1 N-acetylation activity in each cell line. Error bars represent
standard deviation. Pearson correlation coefficient = -0.876, p-value <0.05
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Unsupervised hierarchical clustering of each sample revealed the global metabolomic
profile of each cell line is distinct (Figure 4.12). The individual sample replicates clustered
accurately by group except for sample 10 of the Down group that clustered with the Scrambled
group. The first split in the dendrogram of the hierarchical clustering is between the two
CRISPR/Cas9 cell lines constructed using guide RNA 2 and the other four cell lines; this provides
evidence that those two cell lines have global metabolic profiles that are more similar to each
other than to the respective cell lines that express the same level of NAT1 N-acetylation activity.
The heatmap visualization of the data shows distinct clusters of metabolites whose relative
abundance is much more similar between the two cell lines constructed using CRISPR/Cas9
guide RNA 2 but have different levels of NAT1 activity than the two CRISPR/Cas9 cell lines that
were constructed using two different guide RNAs but both had no detectable NAT1 activity.
Similarly, principal component analysis showed that the CRISPR/Cas9 generated cell
lines had global metabolomic profiles that were distinct from the siRNA generated cell lines as
well as each other. In our dataset, principal component 1 explains 53% of the variance in the data
while principal component 2 explains 14% of the variance (Figure 4.13). There are two types of
variance within the data set; within group and between group variance. For our experimental
question, we are most interested in the between group variance. The CRISPR 2-12 and CRISPR
2-19 groups are separated from the other four groups by principal component 1. This reveals that
these two groups have global metabolomics profiles that are similar to each other but very
different from the other four groups given that PC1 represents 53% of the variance in our dataset.
The CRISPR 5-50 group is separated from the other five groups along principal component 2.
From the loadings of each principal component we can infer which metabolites, together,
contribute the most to the separation between the groups and thus the variance between the
groups (Figure 4.14). Most metabolites in the dataset are not contributing to the variance
observed. There are groups of approximately 5-15 metabolites that are contributing the greatest
to each principle component (in each direction). Adenosine and carnosine related metabolites are
negatively correlated with principal component 1 while phosphate related metabolites are
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Figure 4.12
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Figure 4.12: Metabolomics Heatmap and Hierarchical Clustering.
Metabolites colored red on the heatmap had a median scaled relative abundance less than 1, metabolites colored white had a median scaled
relative abundance of 1, and metabolites colored blue had a median scaled relative abundance greater than 1. Each column represents a single
metabolite and each row represents a single metabolomics sample. Samples are color coded according to cell line identity. Unbiased hierarchical
clustering reveals the two CRISPR/Cas9 cell lines constructed using guide RNA 2 are more similar than the two NAT1 complete knockout cell
lines, as would be expected.
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Figure 4.13: Principal Component Analysis Scores Plot.
Each symbol represents an individual metabolomics sample, is numbered by sample number,
and color coded by cell line. Principal component one (PC1) represents 53% of the total variance
in our dataset and separates the CRISPR 2-12 and CRISPR 2-19 cell lines from all other cell
lines. Principal component 2 (PC2) represents 14% of the total variance in our dataset and
separates the CRISPR 5-50 cell line from all other cell lines.

89

30

Figure 4.14

0.2

Positively Correlated
With PC1 & PC2

N−acetylasparagine

Positively Correlated

uridine 5'−triphosphate (UTP)

cystathionine
AICA ribonucleotide
6−phosphogluconate
serotonin With PC2
orotate
gluconate
5−phosphoribosyl diphosphate (PRPP)
phosphoenolpyruvate (PEP)
adrenoylcarnitine (C22:4)*
glucose 6−phosphate
arachidonoylcarnitine (C20:4) glycosyl−N−(2−hydroxynervonoyl)−sphingosine (d18:1/24:1(2OH))*
3−phosphoglycerate
acetylphosphate

90

PC2 Loadings

0.1

Negatively Correlated
With PC1
linoleoylcarnitine (C18:2)*

2−phosphoglycerate

glutathione, reduced (GSH)

0.0

2'−deoxyadenosine 2'−O−methyladenosine
Minimal
adenosine
glutathione, oxidized (GSSG) myristoleoylcarnitine (C14:1)*

Influence

ophthalmate

arachidonate (20:4n6)

phosphoethanolamine
nicotinamide riboside adenosine 2'−monophosphate (2'−AMP)
eicosapentaenoate (EPA; 20:5n3) 1−arachidonoyl−GPI (20:4)*

dihomo−linolenate (20:3n3 or n6)

Positively Correlated
With PC1
nicotinamide ribonucleotide (NMN)

−0.1

adenylosuccinate

Negatively Correlated
With PC1 & PC2

N−acetyl−beta−alanine
imidazole lactate

Positively Correlated
With PC1 &
lactose Negatively Corelated
with PC2

phenyllactate (PLA)

Negatively Correlated
With PC2 indolelactate

−0.2
−0.2

−0.1

0.0
PC1 Loadings

0.1

0.2

Figure 4.14: Principal Component Loadings Plot.
Loadings from principal component 1 and principal component 2 are plotted showing which metabolites have the greatest contribution to each
principal component. Each point represents a single metabolite and is color-coded by contribution to principal component.

positively correlated. Lactate related metabolites are negatively correlated with principal
component 2 while phosphate and carnitine related metabolites are positively correlated.
Pathway Analysis
Pathway enrichment analysis was conducted on each on each group compared to the
Scrambled group (Figure 4.15). A normalized enrichment score of 1.2 in at least one of the
groups was selected as the cut-off value for significance. The Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways were used173,174. Disease associated pathways were removed from
the analysis results. Amino acid, lipid, and fatty acid metabolism pathways were found to be
significantly enriched. Some enriched pathways did not include all group comparisons suggesting
differential impacts on metabolism.
Discussion
Given that (theoretically) only a single gene, NAT1, was genetically altered in each cell
line, we expected only a small proportion of metabolite abundances to be significantly different,
given the vast homeostasis mechanisms present175-177. However, we observed a very large
proportion (~90%) of all metabolites detected to be significantly altered. Additionally, very few, if
any, differences in metabolite abundances were expected between the two NAT1 knockout cell
lines since each cell line should have the exact same genome. Yet one of the most striking
observations of this study is the differences in relative metabolite abundance between the two
complete NAT1 knockout cell lines. The hierarchical clustering, principal components analysis,
and pathway enrichment analysis show there were significant differences between the two cell
lines constructed using CRISPR/Cas9 guide RNA 2 and the cell line constructed using
CRISPR/Cas9 guide RNA 5. Even though, in terms of NAT1 activity, the CRISPR 2-19 and
CRISPR 5-50 cell lines are identical, their metabolic profiles are extremely different. This result
suggests there are additional genetic differences between the two cell lines (discussed in greater
detail in Chapter 7). However, we have not identified what genes the additional differences are in
as whole genome sequencing of the cell lines would be required. The large number of
differentially abundant metabolites between each knockout cell line compared to the Scrambled
cell line and compared to each other could be because the cell lines have undergone additional
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unique mutations during passaging or because each CRISPR guide RNA used caused unique
off-target effects in addition to targeting NAT1. To focus on metabolome differences associated
with varying levels of NAT1 in breast cancer, we have focused our interpretation of this study to
metabolites that agreed between the two CRISPR NAT1 knockout cell lines.
Ten of 25 metabolites decreased concordantly between the two CRISPR NAT1 KO cell
lines were metabolites containing carnitine, more specifically fatty acyl-coA carnitine conjugates
(Table 4.2). To further clarify whether this observation was due to dysregulation of fatty acyl-coA’s
or carnitine in NAT1 KO cell lines, association between carnitine and metabolites decreased and
increased concordantly in both NAT1 KO cell lines was determined. Nearly every metabolite
concordantly differentially abundant showed strong correlation with carnitine suggesting the
observation is due to dysregulation of carnitine. Carnitine is biosynthesized from lysine and
methionine178 with important biological roles in the transport of activated long-chain fatty acids
from the cytosol to the mitochondrial matrix for beta-oxidation179,180, modulation of the acylCoA/CoA ratio180,181, and storage of energy as acetylcarnitine181,182. Further studies are required
to discern whether these observations are due to NAT1 directly or indirectly due to NAT1’s effect
on acetyl-CoA levels or other possible indirect effects.
Notably, NAT1 has been shown to have redundancy with methylthioribose-1-phosphate
isomerase (MRI-1) in the methionine salvage pathway, but this role was not observed in MDAMB-231 cells since they do not have a functional methionine salvage pathway due to a lack of
methylthioadenosine phosphorylase (MTAP) activity107. However, this observation by other NAT
researchers adds interest to deciphering the relationship between NAT1 and carnitine since
carnitine is closely connected biochemically to methionine. It will be important for future studies to
focus on these relationships and pathways to gain a better understanding of the role of NAT1 in
breast cancer cell metabolism.
The strong positive association between the abundance of N-acetylasparagine and NAT1
activity in the 6 MDA-MB-231 cell lines is consistent with N-acetylasparagine being a product of
NAT1 N-acetylation (Figure 4.16). There is currently no known mechanism or enzyme
responsible for the acetylation of free amino acids. It is hypothesized that acetylated free amino
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vs Scrambled.
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Figure 4.15: Metabolomics Pathway Enrichment Analysis.

Pathway enrichment analysis was conducted for each group compared to Scrambled and is
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Figure 4.16: Possible Association Between NAT1 and N-acetylasparagine.
The positive relationship between NAT1 N-acetylation activity and the abundance of Nacetylasparagine suggests either L-asparagine is a NAT1 substrate or acetyl-CoA levels affect
the activity of an enzyme for which L-asparagine is a substrate.
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acids originate from the breakdown of N-terminal acetylated proteins however L-asparagine
residues in proteins are not known to be acetylated by N-terminal acetyltransferases (different
family of N-acetyltransferases from NAT1 and NAT2)183. Additionally, the biosynthesis of Nacetylasparagine is not defined in the literature. Recombinant murine and human aminoacylase 2
(ASPA) have been reported to catabolize N-acetylasparagine, albeit at a much lower level than
the prototypic ASPA substrate N-acetylaspartate184. Additionally, aminoacylase 1 deficiency
(ACY1), a rare inborn error of metabolism disease, is diagnosed by increased N-acetylated amino
acids in the urine, including N-acetylasparagine185 suggesting ACY1 can also metabolize Nacetylasparagine. Given the abundance distribution of N-acetylasparagine in our constructed cell
lines, we hypothesize L-asparagine is the substrate being N-acetylated by NAT1 to form Nacetylasparagine however the substrate could be a different biochemical.
Similarly, the strong positive association between the abundance of N-acetylputrescine
and NAT1 N-acetylation activity in the 6 MDA-MB-231 cell lines is consistent with Nacetylputrescine being a product of NAT1 N-acetylation (Figure 4.17). Putrescine is known to be
N-acetylated by Spermidine/Spermine N1-Acetyltransferase 1 (SAT1) and Spermidine/Spermine
N1-Acetyltransferase 2 (SAT2) but with much lower affinity than for other SAT substrates such as
spermidine186. Redundancy in non-homologous metabolic enzymes has been shown to
occur187,188 and we postulate NAT1 and the SATs may both be able to N-acetylate putrescine.
Both L-asparagine and putrescine have been implicated in the promotion of cell
growth189-194. The data indicate cell lines with higher levels of NAT1 activity have increased
amounts of N-acetylated asparagine and putrescine while cell lines with decreased and knockedout NAT1 activity have decreased amounts of N-acetylated asparagine and putrescine. It is
predicted this leads to decreased asparagine and putrescine in cell lines with high NAT1 and
increased asparagine and putrescine in cell lines with decreased and knocked-out levels of NAT1
relative to cell lines with basal NAT1 activity. It has been shown that intracellular asparagine
exchanges with extracellular amino acids to promote mTORC1 activation, protein and nucleotide
synthesis and cell proliferation under normal growth (non-starvation) conditions190. Additionally, it
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Figure 4.17

Figure 4.17: Possible Association Between NAT1 and N-acetylputrescine.
The positive relationship between NAT1 N-acetylation activity and the abundance of Nacetylputrescine suggests either putrescine is a NAT1 substrate or acetyl-CoA levels affect the
activity of an enzyme for which putrescine is a substrate.
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has been reported that the invasiveness of a mouse breast cancer model could be modulated
either by altering asparagine biosynthetic capacity or by modifying extracellular asparagine pools
with decreases in asparagine leading to decreased metastatic burden189. Polyamines, such as
putrescine, are known to facilitate the interactions of transcription factors, such as estrogen
receptors with their specific response element and are involved in the proliferation of ER negative
breast cancer tumor cells (reviewed in 195). Additionally, rises in intracellular polyamine
concentrations has been associated with increased cell proliferation and has been linked to
tumorigenesis196-200. This data, interpreted through the finding of previous studies, suggests cell
lines with knocked-out NAT1 may have increased cell growth capabilities due to higher levels of
asparagine and putrescine.
The strong negative association between the abundance of saccharopine and NAT1
activity in the 6 MDA-MB-231 cell lines suggests saccharopine is a NAT1 substrate or located
upstream of a NAT1 catalyzed reaction (Figure 4.18). Saccharopine is an intermediate in the
main pathway responsible for the catabolism of lysine201,202. This observation may be connected
to lysine’s role in carnitine biosynthesis178.
Pathway analysis indicated pathways that directly involve acetyl-coA such as the lysine
degradation (Figure 4.19) and tryptophan metabolism pathways were enriched for differences.
Additionally, pathways that feed into the TCA cycle were also significantly enriched suggesting
varying levels of NAT1 impact energy metabolism.
Summary and Conclusions
These results support the hypothesis that NAT1 is not just a xenobiotic metabolizing
enzyme and may have a role in endogenous cellular metabolism whether that is directly or
indirectly through the ability of NAT1 to metabolize acetyl-CoA remains unclear. The
metabolomics data have shown NAT1 expression differentially affects cellular metabolism
dependent on the level of expression. Additionally, potential novel substrates and products of Nacetylation by NAT1 have been identified but further validation is required. These metabolites
have recently been implicated in enhanced cell growth and metastatic potential in breast cancer
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Figure 4.18

Figure 4.18: Possible Association Between NAT1 and Saccharopine.
The inverse relationship between NAT1 N-acetylation activity and the abundance of saccharopine
suggests either saccharopine is a NAT1 substrate, acetyl-CoA levels affect the activity of an
enzyme for which saccharopine is a substrate, lysine, the substrate that is degraded to form
saccharopine, is a NAT1 substrate or acetyl-CoA levels affect the activity of an enzyme for which
lysine is a substrate.
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Figure 4.19
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Figure 4.19: Lysine Degradation Pathway.
NAT1 knockout cell lines, CRISPR 2-19 and CRISPR 5-50, metabolite abundance data compared to Scrambled cell line projected onto the KEGG
lysine degradation pathway. Metabolites abundances in yellow are decreased in the NAT1 knockout cell lines, metabolites in gray are unchanged,
and metabolites in blue are increased in the NAT1 knockout cell lines.
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models suggesting they may be the key to understanding how varying levels of NAT1 affect
breast cancer risk and progression. Additionally, many of the pathways significantly enriched in
pathway analysis are pathways where acetyl-CoA plays a role, adding further evidence for the
connection between NAT1 and acetyl-CoA in metabolism.
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CHAPTER 5

TRANSCRIPTOMICS

Background
Transcriptomics allows measurement of global changes in gene abundance between
samples and gives a snapshot of mRNA expression. Resulting information can be utilized to
determine genes that may be interacting. While not all mRNAs will be translated into proteins and
there are additional regulatory mechanisms that occur prior to protein expression, mRNA
abundances can still provide a lot of information about a system. Additionally, numerous studies
have utilized transcriptomics to better understand breast cancer203-207.
Materials and Methods
Collection of Samples
Figure 5.1 illustrates the experimental approach and workflow of sample collection
described below. Cells were plated in triplicate per biological replicate at a concentration of
500,000 cells per 150 x 25 mm cell plate for both transcriptomics and metabolomics analysis. All
cell lines were cultured in high-glucose Dulbecco's Modified Eagle Medium (DMEM), with 10%
fetal bovine serum, 5% glutamine, and 5% penicillin/streptomycin added. Cells were allowed to
grow for three days at 37°C and 5% CO2 in an incubator.
Cells were then harvested on ice by adding 5 mL 0.25% trypsin and scraping the cells
from the plate. Three plates were combined to form one sample (biological replicate). Three
biological replicates for each cell line were collected for transcriptomics analysis. After harvesting
the cells, cells were washed 3 times with ice-cold 1 x PBS. All supernatant was removed and 100
µL of cell pellet was reserved for transcriptomics analysis. The remaining cell pellet was reserved
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Figure 5.1: Transcriptomics Experimental and data analysis approach.
Three biological replicates from each cell line were collected. RNA was extracted and RNA-seq
libraries prepared. Samples were then sequenced on the Illumina NextSeq 500 instrument.
Following preprocessing of resulting data by the TopHat pipeline, genes were analyzed for
differential abundance, unbiased multivariate analysis/clustering, and pathway enrichment.
Notably, transcriptomics samples were the same samples collected for metabolomics analysis
(discussed in Chapter 4).
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for metabolomic analysis (presented in Chapter 4). Samples were then flash frozen by placing in
a pool of liquid nitrogen for 1 minute and stored in an -80 °C freezer.
Transcriptomics
RNA Isolation
Total RNA was isolated from MDA-MB-231 breast cancer cells expressing parental
(Scrambled), increased (Up), decreased (Down, CRISPR 2-12), and knockout (CRISPR 2-19,
CRISPR 5-50) levels of NAT1 using the RNeasy® Mini Kit (Qiagen Sciences, Germantown,
Maryland) according to manufacturer’s instructions. RNA purity was evaluated, and
concentrations were measured in each sample using a NanoDrop Bioanalyzer (Life Technologies
Sciences).
Library Preparation
Libraries were prepared in collaboration with the University of Louisville Genomics Core
(who kindly allowed me to be a part of the process) using the TruSeq Stranded mRNA LT Sample
Prep Kit- Set A (Illumina, San Diego, California; Cat# RS-122-2101) with poly-A enrichment per
manufacturer’s instructions. One µg of total RNA (in a volume of 50 µL) from each sample was
used in library preparation. Briefly, the total RNA was fragmented to improve sequence coverage
over the transcriptome. Next, the first strand of cDNA was synthesized from the cleaved RNA
fragments that were primed with random hexamers using reverse transcriptase and random
primers. Then the second strand of cDNA was synthesized, thus providing double stranded blunt
end cDNA. Next, a single ‘A’ nucleotide was added to the 3’ ends of the blunt fragments to
prevent them from ligating to one another during the adapter ligation reaction. A corresponding
single ‘T’ nucleotide on the 3’ end of the adapter provides a complementary overhang for ligating
the adapter to the fragment. Then, multiple indexing adapters were ligated to the ends of the
double stranded cDNA, preparing them for hybridization onto a flow cell. Next the DNA fragments
were enriched using polymerase chain reaction (PCR) to selectively enrich those DNA fragments
that have adapter molecules on both ends and to amplify the amount of DNA in the library. The
PCR was performed with a PCR Primer Cocktail (included in the TruSeq Stranded mRNA LT
Sample Prep Kit- Set A) that anneals to the ends of the adapters. Finally, 30 µl of eluted library

104

was collected and stored at -20 oC. To avoid skewing the representation of the library, the
number of PCR cycles were minimized. This kit includes steps to validate and normalize
constructed libraries and methods to check quality control.
Library Validation
Quality: Size, purity and semi quantitation were performed on an Agilent Bioanalyzer
using the Agilent DNA 1000 Kit (Santa Clara, CA). The final fragment size for all the samples was
approximately 300 basepairs as expected according to the protocol.
Quantity: Sequencing library quantitation was performed by quantitative polymerase
chain reaction (qPCR) using the KAPA Library Quantitation Kit (Roche, Basel, Switzerland) for
Illumina Platforms. A standard curve method was generated for quantitation using 1-5 DNA
standards provided with the kit.
Normalize and Pool Libraries
Ten µl of sample was transferred from the wells to a new MIDI plate. The concentration of
the libraries were then normalized to 10 nM using Tris-HCl 10 mM, pH 8.5 with 0.1% Tween 20.
Five µl of each sample was then transferred to be pooled into a new LowBind 1.5 ml micro
centrifuge tube for a total volume of 60 µl pooled 10 nM library. Then 4 nM dilution was made
from the 10 nM pooled library by diluting with Tris-HCl 10 mM, pH 8.5 with 0.1% Tween 20.
Denaturing and diluting Libraries for the Nextseq 500
A total volume of 1.3 mL of 1.8 pM denatured library was needed for sequencing using
the NextSeq 500/550 75 cycle High Output Kit v2 (FC-404-2005; Illumina, San Diego, CA) kit.
Pooled 4 nM library was denatured by mixing with diluted NaOH and incubated at room
temperature for 5 minutes. Tris HCl, 200 mM, pH 7.0 was then added. The reaction mixture was
diluted to 20 pM using a pre-chilled Hybridization Buffer (included in the NextSeq 500/550 75
cycle High Output Kit v2). The 20 pM denatured library was further diluted to 1.8 pM using the
same Hybridization Buffer. Before loading onto the reagent cartridge, 1.3 µl of denatured 20 pM
Phix control (Illumina, San Diego, CA; FC-110-3001) was added to the 1299 µl of denatured 1.8
pM library to a total volume of 1.3 mL for the first sequencing run (for the 2nd sequencing run 1.9
pM library was used).
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Sequencing
Sequencing was performed on the University of Louisville Center for Genetics and
Molecular Medicine’s (CGeMM) Illumina NextSeq 500 using the NextSeq 500/550 75 cycle High
Output Kit v2 (FC-404-2005). A second run was performed to increase the number of reads. For
each run, 72 single-end raw sequencing files (.fastq)208 representing six conditions with three
biological replicates and four lanes per replicate were downloaded from Illumina’s BaseSpace209
(https://basespace.illumina.com/) onto the Kentucky Biomedical Research Infrastructure Network
(KBRIN) server for analysis using pre-written scripts.
RNA-Seq Analysis
Resulting data were preprocessed and analyzed using the tuxedo suite210,211 pipeline
which includes TopHat, Cufflinks, Cuffmerge, and Cuffdiff. Cuffdiff was utilized to calculate
differential gene expression for all groups (Up, Down, CRISPR 2-12, CRISPR 2-19, CRISPR 550) compared to the Scrambled group211. Quality control (QC) of the raw sequence data was
performed using FastQC (version 0.10.1)212. Although the FastQC results indicate the last base of
all samples has a lower quality value, we chose not to trim in this case. Concatenated sequences
were directly aligned to the Homo sapiens hg38 reference genome assembly (hg38.fa) using
TopHat2 (version 2.0.13)213, generating alignment files in bam format. Table 5.1 indicates the
number of raw reads successfully aligned for each of the samples.
Further analysis and visualization of the resulting data were performed using R: A
Language and Environment for Statistical Computing version 3.3.1132. Fold-change and
significance of differential gene expression between groups was visualized using volcano plots.
The Pearson correlation coefficient was calculated between NAT1 and NAT2 transcript
abundance and transcript abundance of all other genes to generate hypotheses about genes that
may be interacting with NAT1 and NAT2, respectively. Data also were plotted as a heatmap and
hierarchal clustering was conducted using the WPGMA method. Principal component analysis
was conducted by singular value decomposition of the centered data matrix. The loadings of the
first (x-axis) and second (y-axis) principal components were plotted. Weighted gene coexpression network analysis (WGCNA) was conducted on metabolite abundance data to identify
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Table 5.1
Transcriptomics Sample Alignment

Scrambled 1

INPUT
READS
37,984,684

ALIGNED
READS
36,841,298

PERCENT
ALIGNED
97.0%

Scrambled 2

35,361,628

34,368,699

97.2%

Scrambled 3

38,238,715

36,597,025

95.7%

Down 1

41,290,001

40,114,301

97.2%

Down 2

41,339,117

40,184,597

97.2%

Down 3

44,859,187

43,503,707

97.0%

Up 1

38,199,308

37,143,906

97.0%

Up 2

37,337,039

36,125,963

96.8%

Up 3

39,022,651

37,890,392

97.1%

CRISPR 2-12 1

33,319,727

32,384,934

97.2%

CRISPR 2-12 2

38,610,686

37,399,482

96.9%

CRISPR 2-12 3

38,275,581

37,201,657

97.2%

CRISPR 2-19 1

38,870,999

37,718,655

97.0%

CRISPR 2-19 2

34,811,726

33,815,087

97.1%

CRISPR 2-19 3

34,097,370

33,138,856

97.2%

CRISPR 5-50 1

35,429,756

34,386,174

97.1%

CRISPR 5-50 2

42,535,551

41,226,671

96.9%

CRISPR 5-50 3

37,749,977

36,718,233

97.3%

SAMPLE

The number of raw reads successfully aligned to the homo sapiens reference genome assembly
hg.38 for each sample using TopHat2. Percent aligned was calculated by dividing aligned reads
by input reads for each sample.

107

modules of related metabolites given the topology of the weighted network. Pathway enrichment
analysis was conducted for each group compared to Scrambled. The normalized enrichment
score was utilized to determine the relative degree of enrichment.
Quantitative Measurement of NAT1 and NAT2 mRNA
Reverse transcription- quantitative polymerase chain reaction (RT-qPCR) was conducted
for NAT1 and NAT2 mRNAs in all 6 constructed cell lines as previously described40,96,214. Briefly,
total RNA was isolated from each cell line using the RNeasy Mini Kit (Qiagen, Germantown, MD).
Isolated RNA was used to transcribe cDNA using the High Capacity Reverse Transcriptase kit
(Life Technologies, Carlsbad, CA). Resulting cDNA was utilized for quantitative measurement of
NAT1 and NAT2 mRNAs via RT-qPCR. TaqMan analysis was performed using the ABI 7700
sequence detection system (Applied Biosystems, Foster City, CA). Utilized gene probes were
designed previously to discriminate between NAT1 and NAT2.
NAT2 N-Acetylation Activity Assays
In vitro NAT2 N-acetylation activity was determined in each constructed cell line as
previously described12,215. Briefly, cell lysate from each cell line was incubated with 1 mM acetylcoenzyme A and 300 µM sulfamethazine (SMZ) at 37°C for 10 minutes. Reactions were
terminated with the addition of 1/10 reaction volume 1 M acetic acid. Reaction products were
collected and analyzed using an Agilent Technologies 1260 Infinity high performance liquid
chromatography (HPLC) using a LiChrospher ® 100 RP-18 (5 µm) column to determine the
amount of acetylated product.
Results
Expression of many genes was found to significantly differ (q £ 0.05, |FC|>2) between the
six cell lines (Table 5.2). More genes were differentially expressed in the cell lines with decreased
or knockout NAT1 (Down, CRISPR 2-12, CRISPR 2-19, CRISPR 5-50) than the cell line with
increased NAT1 activity (Up) when compared to the Scrambled cell line. Two thousand sixty-five,
544, 1911, 2383, and 1937 genes were differentially expressed in the Down, Up, CRISPR 2-12,
CRISPR 2-19, and CRISPR 5-50 groups, respectively (Table 5.2). Genes were further
characterized by direction of fold-change compared to Scrambled (Figures 5.2 - 5.6). MSR1 gene
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Table 5.2
Transcriptomics Summary Statistics
Statistical Comparison
Student’s
t-test
Post Test

Down
Scrambled

Up
Scrambled

CRISPR 2-12
Scrambled

CRISPR 2-19
Scrambled

CRISPR 5-50
Scrambled

Total
DEGs
q ≤ 0.05;
FC ≥ 2

2065

544

1911

2383

1937

DEGs
(↑↓)

680|1385

310|234

1169|742

1472|911

1112|825

DEGs = differentially expressed genes
Cuffdiff was utilized to calculate differential gene expression for all groups (Up, Down, CRISPR 212, CRISPR 2-19, CRISPR 5-50) compared to the Scrambled group211. Significantly differentially
expressed genes were further characterized by direction of fold-change; genes with increased
abundance are shown in green while genes with decreased abundances are shown in red.
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Figure 5.2
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Figure 5.2: Up vs Scrambled Volcano Plot.
Each dot represents a single gene and is color coded according to q-value. The black dots represent genes that had a Dunnett’s post test q-value
greater than 0.05, blue dots represent genes that had a q-value less than or equal to 0.05 but greater than 0.01, and red dots represent genes that
had a q-value less than or equal to 0.01. Negative fold changes represent a decrease in that gene compared to the Scrambled group while
positive fold changes represent an increase in that gene compared to the Scrambled group. NAT1 is shown by a purple dot while NAT2 is shown
by a green dot.
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Figure 5.3: Down vs Scrambled Volcano Plot.
Each dot represents a single gene and is color coded according to q-value. The black dots represent genes that had a Dunnett’s post test q-value
greater than 0.05, blue dots represent genes that had a q-value less than or equal to 0.05 but greater than 0.01, and red dots represent genes that
had a q-value less than or equal to 0.01. Negative fold changes represent a decrease in that gene compared to the Scrambled group while
positive fold changes represent an increase in that gene compared to the Scrambled group. NAT1 is shown by a purple dot while NAT2 is shown
by a green dot.
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Figure 5.4: CRISPR 2-12 vs Scrambled Volcano Plot.
Each dot represents a single gene and is color coded according to q-value. The black dots represent genes that had a Dunnett’s post test q-value
greater than 0.05, blue dots represent genes that had a q-value less than or equal to 0.05 but greater than 0.01, and red dots represent genes that
had a q-value less than or equal to 0.01. Negative fold changes represent a decrease in that gene compared to the Scrambled group while
positive fold changes represent an increase in that gene compared to the Scrambled group. NAT1 is shown by a purple dot while NAT2 is shown
by a green dot.
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Figure 5.5: CRISPR 2-19 vs Scrambled Volcano Plot.
Each dot represents a single gene and is color coded according to q-value. The black dots represent genes that had a Dunnett’s post test q-value
greater than 0.05, blue dots represent genes that had a q-value less than or equal to 0.05 but greater than 0.01, and red dots represent genes that
had a q-value less than or equal to 0.01. Negative fold changes represent a decrease in that gene compared to the Scrambled group while
positive fold changes represent an increase in that gene compared to the Scrambled group. NAT1 is shown by a purple dot while NAT2 is shown
by a green dot.

Figure 5.6
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Figure 5.6: CRISPR 5-50 vs Scrambled Volcano Plot.
Each dot represents a single gene and is color coded according to q-value. The black dots represent genes that had a Dunnett’s post test q-value
greater than 0.05, blue dots represent genes that had a q-value less than or equal to 0.05 but greater than 0.01, and red dots represent genes that
had a q-value less than or equal to 0.01. Negative fold changes represent a decrease in that gene compared to the Scrambled group while
positive fold changes represent an increase in that gene compared to the Scrambled group. NAT1 is shown by a purple dot while NAT2 is shown
by a green dot.

expression was compared between the cell lines since it has previously been reported that NAT1
has redundancy with the MSR1 enzyme (Table 5.3). However MSR1 was differentially expressed
only between the CRISPR 2-12 cell line and the Scrambled cell line.
The overlap in genes that were differentially expressed with a fold-change greater than or
equal to 2 was compared between the two NAT1 KO cell lines and the Scrambled group (Figure
5.7). Five hundred ninety-nine genes were increased concordantly in the two NAT1 KO cell lines
compared to Scrambled with 873 and 512 genes uniquely increased in the CRISPR 2-19 and
CRISPR 5-50 cell lines, respectively. Three hundred nineteen genes were decreased
concordantly in the two NAT1 KO cell lines compared to Scrambled with 592 and 506 genes
uniquely decreased in the CRISPR 2-19 and CRISPR 5-50 cell lines, respectively. More genes
had conflicting differential expression between the two CRISPR NAT1 KO cell lines compared to
Scrambled that those that agreed.
Transcript expression of NAT1 and its isozyme, NAT2, were compared in all cell lines.
Notably, in the two complete NAT1 knockout cell lines (CRISPR 2-19 & CRISPR 5-50), NAT2
transcripts were significantly increased 6.7- and 2.8-fold, respectively, compared to the
Scrambled cell line (Figure 5.8; Table 5.4), however NAT2 transcript expression was not
increased in any of the other cell lines (p>0.05; Up, Down, CRISPR 2-12). Individual NAT2
transcript mapping in the RNA-seq data in the Scrambled and NAT1 knockout cell lines, CRISPR
2-19 and CRISPR 5-50, was visualized using Integrated Genomics Viewer (IGV; Figure 5.9). This
observation was verified with RT-qPCR analysis for NAT1 and NAT2 in all six cell lines (Figure
5.10). Although, not significant for all cell lines, there was a trend of decreased NAT1 transcripts
and increased NAT2 transcripts in the RT-qPCR data. NAT2 activity assays were conducted for
all 6 constructed cell lines using the NAT2 specific substrate sulfamethazine (SMZ) however no
NAT2 activity was detected in any cell line. Currently, the functionality of the NAT2 transcripts
produced in the NAT1 knockout cell lines is unknown.
Many more genes correlated with NAT2 transcript abundance than NAT1 transcript
abundance (r|≥0.9|). Twenty-two genes correlated with NAT1 (Table 5.5) while 342 genes were
correlated with NAT2 (Table 5.6--abbreviated to show top 50 positively correlated and all
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Table 5.3
Differential Expression of the Methylthioribose-1-Phosphate Isomerase (MRI1) Gene
Log2 FC
COMPARISON
q-value
Comparison/Scrambled
Up vs Scrambled

0.39

0.93

Down vs Scrambled

-0.03

0.98

CRISPR 2-12 vs Scrambled

1.52

0.01

CRISPR 2-19 vs Scrambled

1

0.16

CRISPR 5-50 vs Scrambled

0.86

0.17

Methylthioribose-1-phosphate isomerase (MRI1) transcript fold-changes between each cell line
compared to the Scrambled cell line. Fold-change and q-value were calculated using cuffdiff.
Significant differential gene expression is color-coded by direction of fold-change with increases
shown in green while decreases are shown in red.
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Figure 5.7
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Figure 5.7: Gene Concordance Between CRISPR 2-19 and CRISPR 5-50 Cell Lines Compared to Scrambled.
Genes significantly differentially expressed with a fold-change greater than or equal to 2 were compared between CRISPR/Cas9 generated NAT1
knockout cell lines. Five hundred ninety-nine genes were increased concordantly in the two NAT1 KO cell lines compared to Scrambled with 873
and 512 genes uniquely increased in the CRISPR 2-19 and CRISPR 5-50 cell lines, respectively. Three hundred nineteen genes were decreased
concordantly in the two NAT1 KO cell lines compared to Scrambled with 592 and 506 genes uniquely decreased in the CRISPR 2-19 and CRISPR
5-50 cell lines, respectively. Green: genes up-regulated compared to Scrambled; red: genes down-regulated compared to Scrambled.

Figure 5.8

Figure 5.8: NAT1 and NAT2 Gene Expression in Each Cell Line Compared to Scrambled
and Up.
Fold change of NAT1 and NAT2 between each cell line (Down, Up, CRISPR 2-12, CRISPR 2-19,
and CRISPR 5-50) compared to Scrambled was assessed. We additionally compared NAT1 and
NAT2 gene expression in all cell lines to the Up cell line. In the heatmap, red represents a
decrease in gene expression, black represents no change, and green represents an increase in
gene expression.
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Table 5.4
Differential Expression of the N-acetyltransferase (NAT) Genes
Log2 FC
COMPARISON
GENE
Comparison/Scrambled
NAT1
3.3
Up vs Scrambled
NAT2
0.1
Down vs Scrambled
CRISPR 2-12 vs Scrambled
CRISPR 2-19 vs Scrambled
CRISPR 5-50 vs Scrambled

q-value
0.003
1

NAT1

-0.7

0.08

NAT2

-0.9

1

NAT1

-1.0

0.009

NAT2

-1.6

1

NAT1

-1.1

0.02

NAT2

6.7

0.0005

NAT1

-1.9

0.0005

NAT2

2.8

0.006
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NAT transcript fold-changes between each cell line compared to the Scrambled cell line. Fold-change and q-value were calculated using cuffdiff.
Genes with q≥0.05 were considered significantly differentially expressed. Significant differential gene expression is color-coded by direction of
fold-change with increases shown in green while decreases are shown in red.

Figure 5.9
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Figure 5.9: Integrated Genomics Viewer (IGV) NAT2 Transcript Mapping
Raw transcript reads mapping to NAT2 were visualized with IGV. Each gray bar represents a single transcript read. Colored lines in the transcripts
represent the presence of a SNP in comparison to the homo sapiens hg.38 reference genome.
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log2 mRNA Relative to Parent Cell Line

Figure 5.10
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Figure 5.10: NAT1 and NAT2 mRNA Expression.
NAT1 and NAT2 were quantitated via RT-qPCR in the six constructed cell lines as well as the parental MDA-MB-231 cell line.
Results represent are from 3 independent experiments with 3 replicates in each experiment and are reported relative to the Parent cell line. Bars
represent log2 mean ± SEM. N=3. *=p<0.05, **=p<0.01, ***=p<0.001.
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Table 5.5
Genes Correlated with NAT1 Transcript Abundance
ENSEMBLE
GENE
q-value
CORRELATION
GENE ID
ENSG00000171428
NAT1
N/A
1.00
ENSG00000202310

Y_RNA

<0.00001

0.98

ENSG00000253377

AC068672.2

<0.00001

0.98

ENSG00000258168

AC025569.1

<0.00001

0.96

ENSG00000176571

CNBD1

<0.00001

0.96

ENSG00000174125

TLR1

<0.00001

0.95

ENSG00000167355

AC087380.1

<0.00001

0.94

ENSG00000165078

CPA6

<0.0001

0.93

ENSG00000187189

TSPYL4

<0.0001

0.92

ENSG00000173157

ADAMTS20

<0.0001

0.92

ENSG00000106034

CPED1

<0.0001

0.92

ENSG00000081148

IMPG2

<0.0001

0.92

ENSG00000165424

ZCCHC24

<0.0001

0.92

ENSG00000170915

PAQR8

<0.0001

0.92

ENSG00000162139

NEU3

0.0001

0.91

ENSG00000173930

SLCO4C1

0.0001

0.91

ENSG00000141219

C17orf80

0.0001

0.91

ENSG00000270157

NA

0.0001

0.91

ENSG00000179331

RAB39A

0.0002

0.91

ENSG00000196449

YRDC

<0.0001

-0.92

ENSG00000054116

TRAPPC3

0.0001

-0.91

ENSG00000116288

PARK7

0.0002

-0.90

Pearson correlation between NAT1 gene abundance in constructed cell lines and all genes in the
transcriptomics dataset was conducted. Twenty-two genes were significantly correlated (r > 0.90)
with NAT1 transcript abundance. q-value is the Pearson correlation q-value, and correlation is the
Pearson correlation coefficient. Correlation coefficients were color coded according to direction of
correlation with green for positive correlation and red for inverse (negative) correlation.
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Table 5.6
Genes Correlated with NAT2 Transcript Abundance (Abbreviated to top 50 genes)
ENSEMBLE
GENE
p-value
CORRELATION
GENE ID
COEFFICIENT
ENSG00000156006 NAT2
NA
1.00
ENSG00000186479

RGS7BP

<0.00001

1.00

ENSG00000158270

COLEC12

<0.00001

1.00

ENSG00000021645

NRXN3

<0.00001

1.00

ENSG00000188086

PRSS45

<0.00001

1.00

ENSG00000179097

HTR1F

<0.00001

1.00

ENSG00000197506

SLC28A3

<0.00001

1.00

ENSG00000134247

PTGFRN

<0.00001

1.00

ENSG00000267313

KC6

<0.00001

1.00

ENSG00000112902

SEMA5A

<0.00001

1.00

ENSG00000243486

AC068985.1

<0.00001

1.00

ENSG00000129514

FOXA1

<0.00001

1.00

ENSG00000261122

LINC02167

<0.00001

1.00

ENSG00000233403

AC121342.1

<0.00001

1.00

ENSG00000078596

ITM2A

<0.00001

0.99

ENSG00000095777

MYO3A

<0.00001

0.99

ENSG00000105383

CD33

<0.00001

0.99

ENSG00000105851

PIK3CG

<0.00001

0.99

ENSG00000110002

VWA5A

<0.00001

0.99

ENSG00000115165

CYTIP

<0.00001

0.99

ENSG00000124429

POF1B

<0.00001

0.99

ENSG00000125848

FLRT3

<0.00001

0.99

ENSG00000130224

LRCH2

<0.00001

0.99

ENSG00000137745

MMP13

<0.00001

0.99

ENSG00000140379

BCL2A1

<0.00001

0.99

ENSG00000140563

MCTP2

<0.00001

0.99

ENSG00000143061

IGSF3

<0.00001

0.99

ENSG00000145649

GZMA

<0.00001

0.99

ENSG00000147246

HTR2C

<0.00001

0.99

ENSG00000149573

MPZL2

<0.00001

0.99

ENSG00000152217

SETBP1

<0.00001

0.99

<0.00001

0.99

ENSG00000155622 XAGE2
*continued on next page
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ENSG00000165061

ZMAT4

<0.00001

0.99

ENSG00000165449

SLC16A9

<0.00001

0.99

ENSG00000165795

MIR6717

<0.00001

0.99

ENSG00000165868

HSPA12A

<0.00001

0.99

ENSG00000166669

ATF7IP2

<0.00001

0.99

ENSG00000170927

PKHD1

<0.00001

0.99

ENSG00000171004

HS6ST2

<0.00001

0.99

ENSG00000178235

SLITRK1

<0.00001

0.99

ENSG00000180287

PLD5

<0.00001

0.99

ENSG00000183230

CTNNA3

<0.00001

0.99

ENSG00000184564

SLITRK6

<0.00001

0.99

ENSG00000189398

OR7E12P

<0.00001

0.99

ENSG00000205628

LINC01446

<0.00001

0.99

ENSG00000223756

TSSC2

<0.00001

0.99

ENSG00000224960

PPP4R3CP

<0.00001

0.99

ENSG00000226372

DCAF8L1

<0.00001

0.99

ENSG00000255501

CARD18

<0.00001

0.99

ENSG00000261780

LOC100505817

<0.00001

0.99

ENSG00000238755

NA

<0.00001

0.99

ENSG00000253651

NA

<0.00001

0.99

ENSG00000228065

NA

<0.00001

0.99

ENSG00000151208

DLG5

<0.00001

-0.91

Pearson correlation between NAT2 gene abundance in constructed cell lines and all genes in the
transcriptomics dataset was conducted. Three hundred forty-two genes were significantly
correlated (r > 0.90) with NAT1 transcript abundance. q-value is the Pearson correlation q-value,
and correlation is the Pearson correlation coefficient. Correlation coefficients were color coded
according to direction of correlation with green for positive correlation and red for inverse
(negative) correlation.
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negatively correlated). This observation may be because of the low abundance of NAT2 in most
of our cell lines. Notably, multiple genes associated with NAT1 transcript abundance are located
on chromosome 8, the same chromosome on which NAT1 is located. There was no overlap in
genes correlated with NAT1 and NAT2 transcript expression, suggesting different regulation
mechanisms.
Correlation Concordance
To determine if the genes strongly correlated with NAT1 and NAT2 transcript expression,
respectively, show the same relationship in other independent datasets correlation was compared
in publicly available data repositories. Gene expression data for top 20 genes in the lists as well
as NAT1 and NAT2 were downloaded from the cancer cell line encyclopedia (CCLE) and the
cancer genome atlas (TCGA). Breast cancer datasets were utilized since our original samples
were from the breast cancer cell line MDA-MB-231. However, there are data for many different
cancers in the repositories. Correlation between NAT1 and NAT2 and the genes they correlated
with in the transcriptomics dataset was assessed in the two independent datasets using the
Pearson method.
Unsupervised hierarchical clustering of each sample revealed the global transcriptomic
profile of each cell line is distinct (Figure 5.11). The individual sample replicates clustered
accurately by group. The first split in the dendrogram of the hierarchical clustering is between the
two CRISPR/Cas9 cell lines constructed using guide RNA 2 and the other four cell lines; this
provides evidence that those two cell lines have global transcriptomic profiles that are more
similar to each other than to the respective cell lines that express the same level of NAT1 Nacetylation activity. The heatmap visualization of the data shows distinct clusters of gene
transcripts whose expression is much more similar between the two cell lines constructed using
CRISPR/Cas9 guide RNA 2 but have different levels of NAT1 activity than the two CRISPR/Cas9
cell lines that were constructed using two different guide RNAs but both had no detectable NAT1
activity. Differential gene expression between each cell line compared to Scrambled was also
visualized as a heatmap with hierarchical clustering (Figure 5.12).
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Figure 5.11
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Figure 5.11: Hierarchical Clustering and Heatmap of Each Cell Lines Global Transcriptomics Signature.
Genes colored red on the heatmap had a median scaled relative abundance less than 1, genes colored white had a median scaled relative
abundance of 1, and genes colored blue had a median scaled relative abundance greater than 1. Each column represents a single gene and each
row represents a single transcriptomics sample; rows are labeled with sample number. Samples are color coded according to cell line identity.
Unbiased hierarchical clustering reveals the two CRISPR/Cas9 cell lines constructed using guide RNA 2 are more similar than the two NAT1
complete knockout cell lines as would be expected.
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Figure 5.12
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Figure 5.12: Hierarchical Clustering and Heatmap of Differential Gene Expression Compared to Scrambled.
Each column represents a single gene and each row represents the average gene expression for the specific comparison labeled across the three
biological replicates. Red represents genes that were decreased compared to Scrambled, black represents no change, and green represents
genes increased compared to Scrambled. U vs S: Up vs Scrambled; D vs S: Down vs Scrambled; C 212 vs S: CRISPR 2-12 vs Scrambled; C 219
vs S: CRISPR 2-19 vs Scrambled; C 550 vs S: CRISPR 5-50 vs Scrambled.
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Similarly, principal component analysis showed that the CRISPR/Cas9 generated cell
lines had global transcriptomic profiles that were distinct from the siRNA generated cell lines as
well as each other. In our dataset, principal component 1 explains 43% of the variance in the data
while principal component 2 explains 17% of the variance (Figure 5.13). There are two types of
variance within the data set; within group and between group variance. For our experimental
question, we are most interested in the between group variance. The CRISPR 2-12, CRISPR 219, and CRISPR 5-50 groups are separated from the other three groups by principal component
1 (PC1). This reveals that the Scrambled, Up, and Down groups have global transcriptomic
profiles that are similar to each other but very different from the other three groups given that PC1
represents 43% of the variance in our dataset. The CRISPR 5-50 group is separated from the
other five groups along principal component 2.
WGCNA Analysis
Weighted gene correlation network analysis was conducted to analyze networks of genes
whose expression suggested interaction and/or involvement in the same pathways. First, all
transcriptomics data were analyzed with the WGCNA algorithm to create modules of genes
(Figure 5.14). Next Pearson correlation was conducted on resulting modules to identify modules
correlated with NAT1 N-acetylation activity (Figure 5.15). We used this analysis to identify genes
whose network topology suggested interaction with NAT2 as a strategy to identify genes that may
have a role in the transcription of NAT2 (Figure 5.16).
Pathway Analysis
Pathway enrichment analysis was conducted on each group compared to the Scrambled
group (Figure 5.17). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways173,174 that
had a normalized enrichment score of ≥ 1.60 were focused on. Disease associated pathways
were removed from the analysis results because samples are known to be malignant thus
confounding any possible conclusions about other diseases. Many pathways were significantly
enriched for differences; amino acid, lipid, and nucleotide metabolism pathways were significantly
enriched. Some enriched pathways did not include all group comparisons suggesting differential
impacts on metabolism.
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Figure 5.13
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Figure 5.13: Transcriptomics Principal Components Analysis.
Each symbol represents an individual transcriptomics sample and is color coded by cell line.
Principal component one represents 43% of the total variance in the dataset and separates the
CRISPR 2-12 and CRISPR 2-19 cell lines from all other cell lines. Principal component 2
represents 17% of the total variance in our dataset and separates the CRISPR 5-50 cell line from
all other cell lines.
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Figure 5.14
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Figure 5.14: WGCNA Transcript Module Branches by Color
The Weighted Gene Correlation Network Analysis (WGCNA) algorithm was used to create modules of correlated genes based on topological
overlap. Each module assignment is designated by a color. The clustering for each module of genes is shown. Modules of genes were utilized in
further analysis.

Figure 5.15
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NAT1 Activity (log scale)
Figure 5.15: Correlation Between WGCNA Transcript Modules and NAT1 N-acetylation Activity.
To identify gene modules related to varying levels of NAT1 correlation analysis between the module score of each sample and NAT1 N-acetylation
activity was conducted. Four modules, white, yellow3, thistle, and tan, were associated with NAT1 activity. Each point represents a single
metabolomics sample and is color coded according to cell line.

Figure 5.16

NAT2

Figure 5.16: Heatmap of genes in WGCNA white module.
Heatmap showing relative gene expression for each gene in the white module. NAT2 is contained
in this module. Clustering of genes in the white module is shown. Genes colored red on the
heatmap had a median scaled relative abundance less than 1, genes colored white had a median
scaled relative abundance of 1, and genes colored blue had a median scaled relative abundance
greater than 1. Clustering indicates degree of topological overlap in gene expression.
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Figure 5.17: Transcriptomics Enrichment Analysis.
Pathway enrichment analysis was conducted for each group compared to Scrambled and is color-coded by comparison. We utilized the
normalized enrichment score to determine the relative degree of enrichment. U vs S: Up vs Scrambled; D vs S: Down vs Scrambled; C212 vs S:
CRISPR 2-12 vs Scrambled; C219 vs S: CRISPR 2-19 vs Scrambled; C550 vs S: CRISPR 5-50 vs Scrambled.
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Discussion
Given that (theoretically) only a single gene, NAT1, was genetically altered in each cell
line, it was expected that only a small proportion of genes would be differentially expressed, given
the vast homeostasis mechanisms present175-177. However, a very large proportion (~90%) of all
genes were observed to be significantly differentially expressed. Additionally, very few, if any,
differences in gene expression were expected between the two NAT1 knockout cell lines because
each cell line should otherwise have the exact same genome. Yet one of the most striking
observations of this study is the differences in gene expression between the two complete NAT1
knockout cell lines. The hierarchical clustering, principal components analysis, and pathway
enrichment analysis show there were significant differences between the two cell lines
constructed using CRISPR/Cas9 guide RNA 2 and the cell line constructed using CRISPR/Cas9
guide RNA 5. Even though, in terms of NAT1 activity the CRISPR 2-19 and CRISPR 5-50, cell
lines are identical, their transcriptomic profiles are extremely different. This result suggests there
are additional genetic differences between the two cell lines. The large number of differentially
expressed genes between each knockout cell line compared to the Scrambled cell line and
compared to each other could be because the cell lines have undergone additional unique
mutations and/or because each CRISPR guide RNA used caused unique off-target effects in
addition to targeting NAT1. To focus on transcriptome differences associated with varying levels
of NAT1 in breast cancer, interpretation of this study has been focused on differentially expressed
genes that agreed between the two CRISPR NAT1 knockout cell lines.
The observation that the complete knockout, but not knockdown, of NAT1 lead to NAT2
transcript production leads to the postulation that there may be a compensation mechanism that
occurs when NAT1 N-acetylation is lost, suggesting NAT1 has an essential role. There have been
reports of genetic compensation in a zebrafish model in which a gene was knocked out by a
deleterious mutation but not in a zebrafish model where the same gene was knocked down by
siRNA216. There have been cases reported of humans that have no detectable NAT1 Nacetylation activity but NAT2 expression and/or activity was not investigated. Notably, a
retrospective analysis of publicly available NAT1 and NAT2 gene expression data in established
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breast cancer cell lines, primary breast tumor tissues, and normal breast tissues showed a small
positive correlation between the two genes217. One reason that study did not observe an inverse
relationship between NAT1 and NAT2 gene expression may be because complete knockout of
NAT1 may be necessary before the compensation mechanism occurs since NAT2 transcripts
were only observed in the complete NAT1 KO cell lines but not the cell lines with decreased
NAT1.
NAT1 has been shown to have redundancy with methylthioribose-1-phosphate isomerase
(MRI1) in the methionine salvage pathway107. However, MRI1 was only differentially expressed
(increased) in one cell line, CRISPR 2-12, compared to Scrambled. As the MDA-MB-231 cell line
does not have a functional methionine salvage pathway this result is not surprising. This example
highlights the importance of studying the effects of varying NAT1 in multiple cell lines as each has
unique mutations that may confound results.
Summary and Conclusions
This is the first study to measure the global transcriptome profile of breast cancer cells
with varying levels of NAT1 N-acetylation activity. Most notably, NAT1 knockout and knockdown
had a much greater impact on differential gene expression than the overexpression of NAT1.
Additionally, NAT2 transcript production was observed in the two complete NAT1 knockout cell
lines, CRISPR 2-19 and CRISPR 5-50, but not any of the other cell lines. This observation
suggests NAT2 transcripts are produced as a compensation mechanism for the complete loss of
NAT1. However, the mechanism by which the cell senses the loss of NAT1 and transcribes NAT2
has not been identified and requires further investigation. Although NAT2 transcripts were
detected in the NAT1 knockout cell lines, NAT2 N-acetylation activity was not thus the
functionality of the NAT2 transcripts requires further investigation. Since this is the first study to
measure the global transcriptome profile of breast cancer cells with varying levels of NAT1 Nacetylation activity I envision this transcriptomics dataset being mined for years to come as new
discoveries are made about NAT1. An important use of this data will be comparisons and joint
analysis between the transcriptomics data presented in this chapter and the metabolomics data
presented in Chapter 4; this comparison is discussed in Chapter 6.
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CHAPTER 6

COMBINING DATASETS

Background
The ability to combine multiple omics datasets for joint analysis is important for achieving
a systems biology view of metabolism as there are many layers of regulation at each step,
including transcriptional, translational, and post-translational regulation. Additionally, comparing
results from multiple omics datasets can provide confidence that observations are not due to
chance when multiple, independently measured datasets support a specific conclusion. Multiomics integration is a relatively new area of research and as such methodologies are still being
developed and improved (reviewed in 218). There are many tools currently available, including
MetaCore™, MetaboAnalyst219, InCroMAP220, PaintOmics221,222, Pathview223, MixOmics224, and
3Omics225. However, the “best” methodology for multi-omics integration is a fiercely debated topic
in the omics field. It is the author’s opinion that there is considerable room for improvement and
development of tools in the field of multi-omics analyses. Currently, most tools for combining
omics datasets perform a pathway enrichment analysis using data from the multiple datasets.
However, pathway enrichment analysis is highly biased by what is currently known about
metabolism and what can be measured/detected by the omics methods. Bioinformatics skills as
well as broad knowledge of metabolism are indispensable when utilizing the above mentioned
omics integration tools to obtain and interpret the results in a meaningful way.
Methods and Results
Bioenergetics and Transcriptomics
To combine the bioenergetics and transcriptomics datasets expression of nuclearencoded mitochondrial genes from the transcriptomics data was compared between constructed
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cell lines. First, a list of ENTREZ gene IDs was created containing all mitochondrial complex
genes from the HUGO gene nomenclature committee website226; the list contained 96 genes.
Although the hg.38 reference assembly, which includes the human mitochondrial genome, was
utilized for transcript mapping, mitochondrial DNA (mtDNA) encoded genes were not detected in
the transcriptomics dataset. It is hypothesized that this is because of the relatively low abundance
of mitochondrial DNA compared to nuclear DNA. Nuclear-encoded mitochondrial gene
expression in all cell lines was visualized utilizing a heatmap (Figure 6.1). Fold change and
significance of differential expression of those mitochondrial genes was visualized using volcano
plots (Figure 6.2). Tables 6.1 – 6.4 lists fold-change and significance of all differentially expressed
mitochondrial genes by cell line comparison. Notably, no mitochondrial genes were significantly
differentially expressed between the Up and Scrambled cell lines. Additionally, most
mitochondrial genes in the cell lines with decreased or knockout NAT1 N-acetylation activity
(Down, CRISPR 2-12, CRISPR 2-19, and CRISPR 5-50) were downregulated compared to the
cell line with parental NAT1 N-acetylation activity (Scrambled). Table 6.5 lists mitochondrial
genes that were concordantly differentially expressed (q ≤ 0.05) in the two NAT1 knockout cell
lines, CRISPR 2-19 and CRISPR 5-50.
Metabolomics and Transcriptomics
To combine the metabolomics and transcriptomics datasets a combined pathway
enrichment analysis was performed and both metabolite abundance (from metabolomics dataset)
and gene expression (from transcriptomics dataset) were mapped onto KEGG pathway maps for
visualization utilizing Pathview223, an R/Bioconductor package for pathway-based data integration
and visualization. For the combined enrichment analysis, the normalized enrichment score for
each pathway from both datasets was averaged. Many KEGG pathways showed significant
enrichment in the combined analysis (Figure 6.3), including 1. lysine degradation (Figure 6.4), 2.
alanine, aspartate, and glutamate metabolism, 3. amino sugar and nucleotide sugar metabolism,
4. AMPK signaling, 5. biosynthesis of unsaturated fatty acids, 6. fructose and
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Figure 6.1
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Figure 6.1: Heatmap of Mitochondrial Gene Expression.
Mitochondrial gene expression from the transcriptomics dataset was compared between constructed cell lines. A list of 96 ENTREZ gene IDs was
created for all mitochondrial complex genes from the HUGO gene nomenclature committee website226. Transcript abundance was plotted as a
heatmap. Cyan represents genes not expressed, yellow represents genes lowly expressed, and orange and red represent genes with high
expression. Each row represents average transcript expression for 3 biological replicates from each cell line and columns represent a single
mitochondrial gene.
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Figure 6.2
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Figure 6.2: Mitochondrial Gene Expression
Mitochondrial gene expression was compared in the constructed cell lines. Genes were selected
by creating a list of ENTREZ gene IDs for all mitochondrial complex genes from the HUGO gene
nomenclature committee website226. Each point represents a single mitochondrial gene and is
color coded by cell line compared to Scrambled. US: Up vs Scrambled; DS: Down vs Scrambled;
C212S: CRISPR 2-12 vs Scrambled; C219S: CRISPR 2-19 vs Scrambled; C550 S: CRISPR 5-50
vs Scrambled. (A) All data was visualized as a volcano plot. (B) Only genes significantly
differentially expressed were plotted.
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Table 6.1
Differentially Abundant Nuclear-encoded Mitochondrial Genes in Down Cell Line Compared to
Scrambled
log2
COMPARISON
ENSEMBL GENE
ENTREZ ID
GENE SYMBOL
Foldq-value
Change
ENSG00000099624 513
ATP5D
-2.80
0.0005

Down vs
Scrambled

ENSG00000124172

514

ATP5E

-0.68

0.0042

ENSG00000135390

517

ATP5G2

-0.86

0.0005

ENSG00000131143

1327

COX4I1

-1.21

0.0005

ENSG00000135940

1329

COX5B

-0.69

0.0005

ENSG00000126267

1340

COX6B1

-0.79

0.0005

ENSG00000131174

1349

COX7B

0.55

0.0129

ENSG00000127184

1350

COX7C

-0.40

0.0257

ENSG00000176340

1351

COX8A

-1.34

0.0005

ENSG00000179091

1537

CYC1

-1.10

0.0005

ENSG00000170906

4696

NDUFA3

-1.62

0.0387

ENSG00000099795

4713

NDUFB7

-3.06

0.0005

ENSG00000167792

4723

NDUFV1

-0.94

0.0005

ENSG00000164258

4724

NDUFS4

-0.38

0.0431

ENSG00000145494

4726

NDUFS6

-0.80

0.0045

ENSG00000110717

4728

NDUFS8

-1.47

0.0005

ENSG00000010256

7384

UQCRC1

-1.02

0.0005

ENSG00000127540

10975

UQCR11

-1.20

0.0005

ENSG00000184076

29796

UQCR10

-1.14

0.0005

ENSG00000186010

51079

NDUFA13

-2.13

0.0005

ENSG00000147123

54539

NDUFB11

-0.60

0.0260

ENSG00000174886

126328

NDUFA11

-2.22

0.0005

ENSG00000115286

374291

NDUFS7

-2.07

0.0005

Nuclear-encoded Mitochondrial Genes Differentially Abundant in the Down Cell Line Compared to
Scrambled are listed.
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Table 6.2
Differentially Abundant Nuclear-encoded Mitochondrial Genes in CRISPR 2-12 Cell Line
Compared to Scrambled
log2
COMPARISON
ENSEMBL GENE
ENTREZ ID GENE SYMBOL
Foldq-value
Change
ENSG00000110955
506
ATP5B
-0.53
0.0038

CRISPR 2-12
vs Scrambled

ENSG00000124172

514

ATP5E

-0.73

0.0087

ENSG00000135390

517

ATP5G2

-0.58

0.0009

ENSG00000127184

1350

COX7C

-0.43

0.0178

ENSG00000128609

4698

NDUFA5

-1.11

0.0005

ENSG00000184983

4700

NDUFA6

-0.49

0.0326

ENSG00000139180

4704

NDUFA9

-0.58

0.0280

ENSG00000004779

4706

NDUFAB1

-0.75

0.0005

ENSG00000183648

4707

NDUFB1

-0.55

0.0059

ENSG00000090266

4708

NDUFB2

-0.95

0.0024

ENSG00000164258

4724

NDUFS4

-0.64

0.0005

ENSG00000160194

4731

NDUFV3

0.78

0.0005

ENSG00000156467

7381

UQCRB

-0.73

0.0005

ENSG00000169021

7386

UQCRFS1

-0.59

0.0005

ENSG00000178741

9377

COX5A

-0.64

0.0005

ENSG00000241468

9551

ATP5J2

-0.83

0.0393

ENSG00000167863

10476

ATP5H|

-0.64

0.0034

ENSG00000127540

10975

UQCR11

-0.83

0.0097

ENSG00000164405

27089

UQCRQ

-0.50

0.0313

ENSG00000184076

29796

UQCR10

-0.66

0.0005

ENSG00000174886

126328

NDUFA11

-0.62

0.0230

Nuclear-encoded Mitochondrial Genes Differentially Abundant in the CRISPR 2-12 Cell Line
Compared to Scrambled are listed.
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Table 6.3
Differentially Abundant Nuclear-encoded Mitochondrial Genes in CRISPR 2-19 Cell Line
Compared to Scrambled
GENE
log2
COMPARISON ENSEMBL GENE
ENTREZ ID
q-value
SYMBOL
Fold-Change
ENSG00000165629 509
ATP5C1
-0.73
0.0013

CRISPR 2-19
vs Scrambled

ENSG00000099624

513

ATP5D

-1.36

0.0076

ENSG00000124172

514

ATP5E

-0.98

0.0013

ENSG00000135390

517

ATP5G2

-1.07

0.0005

ENSG00000131143

1327

COX4I1

-0.80

0.0094

ENSG00000126267

1340

COX6B1

-0.55

0.0312

ENSG00000127184

1350

COX7C

-1.06

0.0005

ENSG00000176340

1351

COX8A

-1.09

0.0016

ENSG00000131495

4695

NDUFA2

-1.47

0.0398

ENSG00000128609

4698

NDUFA5

-0.83

0.0005

ENSG00000184983

4700

NDUFA6

-0.59

0.0306

ENSG00000119421

4702

NDUFA8

-0.61

0.0039

ENSG00000139180

4704

NDUFA9

-0.59

0.0494

ENSG00000004779

4706

NDUFAB1

-0.60

0.0076

ENSG00000183648

4707

NDUFB1

-0.64

0.0057

ENSG00000090266

4708

NDUFB2

-0.85

0.0336

ENSG00000065518
ENSG00000099795

4710
4713

NDUFB4
NDUFB7

-0.61
-1.00

0.0272
0.0051

ENSG00000167792

4723

NDUFV1

-0.58

0.0231

ENSG00000164258

4724

NDUFS4

-0.80

0.0005

ENSG00000160194

4731

NDUFV3

0.86

0.0033

ENSG00000156467

7381

UQCRB

-0.58

0.0071

ENSG00000169021

7386

UQCRFS1

-0.62

0.0005

ENSG00000178741

9377

COX5A

-0.51

0.0156

ENSG00000241468

9551

ATP5J2

-0.93

0.0356

ENSG00000167863

10476

ATP5H

-0.68

0.0042

ENSG00000127540

10975

UQCR11

-0.99

0.0039

ENSG00000164405

27089

UQCRQ

-1.06

0.0005

ENSG00000184076

29796

UQCR10

-0.94

0.0005

ENSG00000160471

125965

COX6B2

2.04

0.0013

ENSG00000174886

126328

NDUFA11

-1.77

0.0005

ENSG00000115286

374291

NDUFS7

-2.25

0.0005
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Nuclear-encoded Mitochondrial Genes Differentially Abundant in the CRISPR 2-19 Cell Line
Compared to Scrambled are listed.
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Table 6.4
Differentially Abundant Nuclear-encoded Mitochondrial Genes in CRISPR 5-50 Cell Line
Compared to Scrambled
log2
COMPARISON
ENSEMBL GENE
ENTREZ ID
GENE SYMBOL
FoldChange
ENSG00000110955 506
ATP5B
-0.55

CRISPR 5-50 vs
Scrambled

q-value
0.0013

ENSG00000124172

514

ATP5E

-0.80

0.0005

ENSG00000154518

518

ATP5G3

-0.38

0.0383

ENSG00000169020

521

ATP5I

-0.75

0.0005

ENSG00000135940

1329

COX5B

-0.46

0.0160

ENSG00000127184

1350

COX7C

-0.90

0.0005

ENSG00000125356

4694

NDUFA1

0.57

0.0023

ENSG00000128609

4698

NDUFA5

-0.48

0.0217

ENSG00000184983

4700

NDUFA6

-0.85

0.0005

ENSG00000004779

4706

NDUFAB1

-1.81

0.0005

ENSG00000183648

4707

NDUFB1

-0.62

0.0013

ENSG00000065518

4710

NDUFB4

-0.49

0.0361

ENSG00000158864

4720

NDUFS2

0.55

0.0074

ENSG00000164258

4724

NDUFS4

-0.63

0.0005

ENSG00000145494

4726

NDUFS6

-0.53

0.0271

ENSG00000204370

6392

SDHD

-0.68

0.0294

ENSG00000156467

7381

UQCRB

-0.58

0.0013

ENSG00000169021

7386

UQCRFS1

-0.53

0.0009

ENSG00000178741

9377

COX5A

-0.52

0.0027

ENSG00000167863

10476

ATP5H

-0.53

0.0068

ENSG00000164405

27089

UQCRQ

-1.12

0.0005

ENSG00000160471

125965

COX6B2

2.05

0.0005

Nuclear-encoded Mitochondrial Genes Differentially Abundant in the CRISPR 5-50 Cell Line
Compared to Scrambled are listed.
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Table 6.5
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Nuclear-encoded Mitochondrial Genes Concordantly Differentially Abundant in CRISPR 2-19 and CRISPR 5-50 Cell Lines
log2FC.C.R
ENSEMBL GENE ID ENTREZ ID
GENE SYMBOL/DESCRIPTION
CRISPR 2-19/S CRISPR 5-50/S
ATP5E|ATP synthase, H+ transporting,
ENSG00000124172
514
-0.98
-0.80
mitochondrial F1 complex, epsilon subunit
ENSG00000127184
1350
COX7C|cytochrome c oxidase subunit VIIc
-1.06
-0.90
NDUFA5|NADH dehydrogenase
ENSG00000128609
4698
-0.83
-0.48
(ubiquinone) 1 alpha subcomplex, 5
NDUFA6|NADH dehydrogenase
ENSG00000184983
4700
(ubiquinone) 1 alpha subcomplex, 6,
-0.59
-0.85
14kDa
NDUFAB1|NADH dehydrogenase
ENSG00000004779
4706
(ubiquinone) 1, alpha/beta subcomplex, 1,
-0.60
-1.81
8kDa
NDUFB1|NADH dehydrogenase
ENSG00000183648
4707
-0.64
-0.62
(ubiquinone) 1 beta subcomplex, 1, 7kDa
NDUFB4|NADH dehydrogenase
ENSG00000065518
4710
-0.61
-0.49
(ubiquinone) 1 beta subcomplex, 4, 15kDa
NDUFS4|NADH dehydrogenase
ENSG00000164258
4724
(ubiquinone) Fe-S protein 4, 18kDa
-0.80
-0.63
(NADH-coenzyme Q reductase)
UQCRB|ubiquinol-cytochrome c reductase
ENSG00000156467
7381
-0.58
-0.58
binding protein
UQCRFS1|ubiquinol-cytochrome c
ENSG00000169021
7386
-0.62
-0.53
reductase, Rieske iron-sulfur polypeptide 1
ENSG00000178741
9377
COX5A|cytochrome c oxidase subunit Va
-0.51
-0.52
ATP5H|ATP synthase, H+ transporting,
ENSG00000167863
10476
-0.68
-0.53
mitochondrial Fo complex, subunit d
UQCRQ|ubiquinol-cytochrome c
ENSG00000164405
27089
-1.06
-1.12
reductase, complex III subunit VII, 9.5kDa
COX6B2|cytochrome c oxidase subunit
ENSG00000160471
125965
2.04
2.05
VIb polypeptide 2 (testis)
Nuclear-encoded Mitochondrial Genes Concordantly Differentially Abundant in CRISPR 2-19 and CRISPR 5-50 Cell Lines
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Figure 6.3: Combined Metabolomics and Transcriptomics Enrichment Analysis.
Pathway enrichment analysis was conducted for each group compared to Scrambled and is color-coded by comparison. The normalized
enrichment score was utilized to determine the relative degree of enrichment. U vs S: Up vs Scrambled; D vs S: Down vs Scrambled; C212 vs S:
CRISPR 2-12 vs Scrambled; C219 vs S: CRISPR 2-19 vs Scrambled; C550 vs S: CRISPR 5-50 vs Scrambled.
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Figure 6.4
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Figure 6.4: Metabolites and Genes Projected onto the KEGG Lysine Degradation Pathway.
NAT1 knockout cell lines, CRISPR 2-19 and CRISPR 5-50, metabolite abundance and gene expression data compared to Scrambled cell line
projected onto the KEGG lysine degradation pathway. Metabolite abundances in yellow are decreased in the NAT1 knockout cell lines,
metabolites in gray are unchanged, and metabolites in blue are increased in the NAT1 knockout cell lines. Gene abundances in red are decreased
in the NAT1 knockout cell lines, genes in gray are unchanged, and genes in green are increased in the NAT1 knockout cell lines. The CRISPR 219 cell line abundance and expression data are shown on the right of the circles and boxes, respectively, while the CRISPR 5-50 cell line
abundance and expression data are shown on the left of the circles and boxes, respectively.
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mannose metabolism, 7. glycerolipid metabolism, 8. glycerophospholipid metabolism, 9.
pyrmidine metabolism, 10. sphingolipid metabolism, and 11. sulfur metabolism. Notably, the Up
cell line compared to the Scrambled cell line was not significantly enriched in 5 of the pathways.
MixOmics224, an R package for omics feature selection and multiple data integration, was
additionally utilized to conduct sparse partial least squares-discriminant analysis (sPLS-DA)227
utilizing the metabolomics and transcriptomics datasets as blocks. The transcriptomics dataset
was first filtered to remove genes that had no detected expression in any sample, leaving 25,515
genes. A second filter was then applied to remove genes from the analysis for which 16 or more
of the 18 total samples had no expression recorded; this left 23,931 genes in the dataset after
both filters were applied. Additionally, because the chosen analysis relies on paired biological
samples, only data from metabolomics samples that had corresponding transcriptomics data
were utilized. This analysis had 18 samples total with 3 samples in each group.
Tuning of the algorithm parameters was required. First, a design matrix was created
where blocks (metabolomics and transcriptomics datasets) were correlated with a link of 0.1.
Utilizing four components was found to be optimal in minimizing the overall error rate. Therefore 4
components were utilized in the final model (Figure 6.5). The model was also tuned for the
optimal number of variables to be selected from each dataset. It is important to note that the
tuning function was set to favor relatively small numbers of variables to aide in interpretation of
the final model results. The discriminant ability of components 1 and 2 was then visualized for
each group in each block (metabolomics and transcriptomics; Figure 6.6). Component 1
separated the CRISPR 5-50 cell line from the other cell lines; the corresponding loadings plot of
component 1 visualized metabolites and genes that contribute the most to this discrimination
(Figure 6.7; Tables 6.6 and 6.7). Conversely, component 2 separated the CRISPR/Cas9
constructed cell lines from the siRNA constructed cell lines; however, the metabolites and genes
of component 2 have greater contribution to the separation of the cell lines constructed using
guide RNA 2 from all other cell lines. The corresponding loadings plot of component 2 visualized
metabolites and genes that contributed the most to this discrimination and are each color coded
by which group it is contributing to most (Figure 6.8; Tables 6.8 and 6.9). This result suggests that
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Figure 6.5

0.6
0.4
0.2

Classification error rate

0.8

1.0

Overall.BER
Overall.ER
max.dist
centroids.dist
mahalanobis.dist

1

2

3

4

5

Component

Figure 6.5 Optimization of Number of Components Included in sPLS-DA.
Solid lines represent the overall error rate. Blue line represents the max distance measure,
orange line represents the centroids distance measure, and gray line represents the mahalanobis
distance measure. Four components were chosen for the sPLS-DA model.
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Figure 6.6
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Figure 6.6: sPLS-DA Scores Plot.
Scores plot showing the discriminant ability of sPLS-DA components 1 (variate 1) and 2 (variate
2) for each group in each block (metab=metabolomics dataset and trans=transcriptomics
dataset). S: Scrambled; U: Up; D: Down; C12: CRISPR 2-12; C19: CRISPR 2-19; C50: CRISPR
5-50.
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Figure 6.7
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Figure 6.7: sPLS-DA Component 1 Loadings Plot.
Component 1 separates the CRISPR 5-50 cell line from the other cell lines; the corresponding
loadings plot of component 1 visualizes metabolites and genes that are contributing the most to
this discrimination S: Scrambled; U: Up; D: Down; C12: CRISPR 2-12; C19: CRISPR 2-19; C50:
CRISPR 5-50.
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Table 6.6
sPLS-DA Component 1 Metabolites
M#
BIOCHEMICAL
M327
indolelactate
M462
phenyllactate (PLA)
M259
galactosylglycerol*
M265
gamma-glutamyl-epsilon-lysine
M324
imidazole lactate
M189
beta-citrylglutamate
M180
argininosuccinate
M364
methionine sulfoxide
M530
sulfate*
Metabolites included in sPLS-DA component 1.
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Table 6.7
sPLS-DA Component 1 Genes
ENSEMBL GENE ID
ENTREZ GENE NAME
ENSG00000019186
cytochrome P450 family 24 subfamily A member 1 (CYP24A1)
ENSG00000030304
muscle associated receptor tyrosine kinase (MUSK)
ENSG00000100628
ankyrin repeat and SOCS box containing 2 (ASB2)
ENSG00000126752
SSX family member 1 (SSX1)
ENSG00000131370
SH3 domain binding protein 5 (SH3BP5)
ENSG00000138347
myopalladin (MYPN)
ENSG00000156395
sortilin related VPS10 domain containing receptor 3 (SORCS3)
ENSG00000162366
PDZK1 interacting protein 1 (PDZK1IP1)
ENSG00000162639
HEN1 methyltransferase homolog 1 (HENMT1)
ENSG00000170848
pregnancy specific beta-1-glycoprotein 6 (PSG6)
ENSG00000173432
serum amyloid A1 (SAA1)
ENSG00000183668
pregnancy specific beta-1-glycoprotein 9 (PSG9)
ENSG00000231924
pregnancy specific beta-1-glycoprotein 1 (PSG1)
ENSG00000248596
centrosomal protein 192kDa pseudogene (LOC643201)
ENSG00000249306
long intergenic non-protein coding RNA 1411 (LINC01411)
ENSG00000275896
protease, serine 2 (PRSS2)
ENSG00000248257
NA
ENSG00000248191
NA

Genes included in sPLS-DA component 1.
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Figure 6.8
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Figure 6.8: sPLS-DA Component 2 Loadings Plot.
Component 2 separates the CRISPR/Cas9 constructed cell lines from the siRNA constructed cell
lines; however, the metabolites and genes of component 2 have greater contribution to the
separation of the cell lines constructed using guide RNA 2 from all other cell lines. The
corresponding loadings plot of component 2 visualizes metabolites and genes that are
contributing the most to this discrimination and are each color coded by which group it is
contributing to most S: Scrambled; U: Up; D: Down; C12: CRISPR 2-12; C19: CRISPR 2-19; C50:
CRISPR 5-50.
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Table 6.8
sPLS-DA Component 2 Metabolites
M#
BIOCHEMICAL
M447
palmitoloelycholine
M437
oleoylcholine
M452
palmitoylcholine *
M31
1-lignoceroyl-GPC (24:0)
M78
1-stearoyl-GPC (18:0)

Metabolites included in sPLS-DA component 2.
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Table 6.9
sPLS-DA Component 2 Genes
ENSEMBL GENE ID
ENTREZ GENE NAME
ENSG00000084734
glucokinase regulator (GCKR)
transmembrane phosphatase with tensin homology pseudogene 1
ENSG00000100181
(TPTEP1)
ENSG00000115216
nuclear receptor binding protein 1 (NRBP1)
ENSG00000168032
ectonucleoside triphosphate diphosphohydrolase 3 (ENTPD3)
ENSG00000185860
coiled-coil domain containing 190 (CCDC190)
myeloid/lymphoid or mixed-lineage leukemia; translocated to, 11
ENSG00000213190
(MLLT11)
ENSG00000227372
TP73 antisense RNA 1 (TP73-AS1)
ENSG00000263753
long intergenic non-protein coding RNA 667 (LINC00667)
ENSG00000084734
glucokinase regulator (GCKR)

Genes included in sPLS-DA component 2.
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while choline metabolism is altered in the CRISPR/Cas9 constructed cell lines it is dysregulated
to a greater extent in the cell lines constructed using guide RNA 2.
We have additionally utilized a chord diagram (also known as circos plot) to visualize the
correlations between variables of different types (i.e. metabolites and genes; Figure 6.9). A
correlation cut-off of 0.9 was chosen; positive correlations are shown with green connectors while
negative correlations are shown with red connectors. A high degree of correlation between
variables was observed with most correlations being positive. The data are also presented as a
clustered heatmap specifically implemented to represent the multi-omics molecular signature
expression for each sample (Figure 6.10). Each cell line has a unique multi-omics signature with
distinct clusters of both metabolites and genes that appear to differentiate each cell line. This
result agrees with the hierarchical clustering and heatmaps generated for each dataset
independently, as each cell line had a unique global metabolomics and transcriptomics signature,
respectively.
Additionally, differential gene expression of SAT1 and SAT2 in the transcriptomics
dataset were evaluated because SAT1 and SAT2 are known to N-acetylate putrescine and Nacetylputrescine was positively correlated with NAT1 N-acetylation activity in the metabolomics
dataset. SAT1 expression was significantly increased in the Down, CRISPR 2-12, and CRISPR 219 cell lines compared to the Scrambled cell line (Table 6.10). This result suggests the Down,
CRISPR 2-12, and CRISPR 2-19 cell lines should have increased N-acetylputrescine abundance
compared to Scrambled. However, N-acetylputrescine abundances were observed to be
decreased in those cell lines in the metabolomics dataset compared to the Scrambled cell line.
These findings suggest the expression of SAT1 is not responsible for the N-acetylputrescine
abundance observations. SAT2 was not significantly differentially expressed in any cell lines
compared to the Scrambled cell line (Table 6.10).
Discussion
The presence of additional differences other than NAT1 (presented in Chapter 7)
complicates interpretation of the results. However, the combined results from all experiments
have been utilized to develop a working postulation of the role of NAT1 in breast cancer cell
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Table 6.10
Differential Expression of the Spermidine/Spermine N1-Acetyltransferase (SAT) Genes
Log2 FC
COMPARISON
GENE
q-value
Comparison/Scrambled
SAT1
0.17
0.85
Up vs Scrambled
SAT2
-0.61
0.84
Down vs Scrambled
CRISPR 2-12 vs Scrambled
CRISPR 2-19 vs Scrambled
CRISPR 5-50 vs Scrambled

SAT1

0.41

0.02

SAT2

-0.81

0.56

SAT1

0.93

<0.001

SAT2

-0.08

0.97

SAT1

1.50

<0.001

SAT2

-0.56

0.73

SAT1

0.24

0.24

SAT2

0.15

0.94

SAT transcript fold-changes between each cell line compared to the Scrambled cell line. Foldchange and q-value were calculated using cuffdiff. Genes with q≥0.05 were considered
significantly differentially expressed. Significant differential gene expression is color-coded by
direction of fold-change with increases shown in green.
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Figure 6.9: Circos Plot of Metabolites and Transcripts Included in sPLS-DA Model.
Metabolites are colored orange and genes are colored blue. A correlation cut-off of 0.9 was
chosen; positive correlations are shown with green connectors while negative correlations are
shown with red connectors. Relative abundances are shown with color coded lines on the outside
of the plot. S: Scrambled; U: Up; D: Down; C12: CRISPR 2-12; C19: CRISPR 2-19; C50: CRISPR
5-50.
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Figure 6.10: Combined Metabolomics and Transcriptomics Hierarchical Clustering and Heatmap.
Each row represents a single biological replicate and each column represents a single variable (gene or metabolite). Variables colored purple,
blue, or green on the heatmap had a median scaled relative abundance less than 1, genes colored yellow had a median scaled relative
abundance of 1, and genes colored orange or red had a median scaled relative abundance greater than 1. S: Scrambled; U: Up; D: Down; C12:
CRISPR 2-12; C19: CRISPR 2-19; C50: CRISPR 5-50. Green represents the Up cell line, yellow represents the Down cell line, light red
represents the Scrambled cell line, cyan represents the CRISPR 2-12 cell line, sky blue represents the CRISPR 2-19 cell line, and pink/purple
represents the CRISPR 5-50 cell line.
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metabolism (Figure 6.11). Although many pathways were significantly enriched in the combined
pathway analysis, the lysine degradation pathway has been focused on. Both carnitine and
saccharopine, significant metabolites from the metabolomics dataset, are included in the lysine
degradation pathway. Carnitine, an important metabolite in many pathways related to acetyl-CoA,
is biosynthesized from methionine and lysine178. Notably, NAT1 has a role in the methionine
salvage pathway107. Saccharopine is the first metabolite formed in the main lysine degradation
pathway in mammals201,202. Further experiments will be necessary to understand how NAT1 is
connected to the lysine degradation pathway.
More generally, it was observed in the experiments presented in this dissertation that
manipulation of NAT1 alters many metabolic pathways including amino acid, fatty acid, and
nucleotide metabolism however it has been harder to narrow in on NAT1’s role specifically due to
the presence of differences other than NAT1. While the exact mechanism by which NAT1 affects
breast cancer cell metabolism has not been identified, significant “pieces” have been added to the
“puzzle”. I predict, that as more experiments investigating the role of NAT1 in breast cancer are
conducted, the bioenergetics, metabolomics, transcriptomics and combined analyses results
presented here will not only have better context for interpretation but can also be utilized to add
supporting or refuting information to those studies.
Summary and Conclusions
Combined analysis of the bioenergetics & transcriptomics and metabolomics &
transcriptomics datasets was conducted utilizing currently available bioinformatics tools. The joint
analysis of the bioenergetics and transcriptomics analysis suggest differential mitochondrial gene
expression may help explain some of our bioenergetics observations however further
experiments investigating mitochondrial number and morphology are needed to gain a better
understanding of the relationship between NAT1 and mitochondria. Notably, mitochondrial
function has been linked to regulation of metabolism, cell-cycle control, and cell death in addition
to mitochondria’s well-known role as the energy producers of the cell228.
Although the combined metabolomics and transcriptomics pathway analysis indicated 11
KEGG biochemical pathways were significantly enriched, the lysine degradation pathway was
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Figure 6.11

Figure 6.11: Overall Dissertation Conclusion.
The overall dissertation conclusion is that NAT1 has a role in the lysine degradation pathway
however whether it is a direct role or a result of NAT1’s ability to hydrolyze acetyl-CoA remains
unknown. By utilizing a systems biology approach we were able to measure that fatty acyl-CoA
carnitine conjugates are decreased when NAT1 is knocked out. Fatty acyl-CoA conjugates are
necessary for transporting fatty acyl-CoAs to the mitochondria for beta-oxidation which in turn
produces acetyl-CoA. We observed differences in mitochondrial bioenergetics. Additionally,
carnitine is biosynthesized from methionine and lysine and lysine is degraded to saccharopine.
Saccharopine is increased when NAT1 is knocked out.
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focused on. Interpretation of the other pathways was complicated by the strong evidence of
differences in addition to NAT1 in the genetically modified cell lines. Additionally, the strongly
suggested presence of mutation of genes in addition to NAT1 lead to the sPLS-DA model not
yielding useful information about genes and transcripts, that together, vary based on NAT1 Nacetylation activity. As better methods to integrate omics datasets become available, the datasets
generated in this dissertation can be re-evaluated for novel insights. Currently available methods
either have a reliance on pathway databases (hindering detection of unknown biochemical
reactions) or have been developed to aide in the discovery of biomarkers or classification of
patient samples.

171

CHAPTER 7

EVIDENCE OF DIFFERENCES OTHER THAN IN NAT1 IN GENETICALLY MODIFIED CELL
LINES

Background
The constructed MDA-MB-231 cell lines utilized for the experiments presented in this
dissertation were designed to vary only in NAT1 and were expected to have otherwise identical
genomes. The guide RNAs utilized for construction were specifically designed to target only the
NAT1 genomic sequence, thus limiting the risk of off-target effects. However, in all three datasets,
bioenergetics (Chapter 3), metabolomics (Chapter 4), and transcriptomics (Chapter 5), evidence
of differences in addition to NAT1 were observed in the constructed MDA-MB-231 cell lines which
we discuss in detail in this chapter (Figure 7.1). Although evidence of differences in addition to
NAT1 were observed between the CRISPR/Cas9 NAT1 knockout cell lines, the additional genes
altered have not been identified. A whole genome sequencing (WGS) approach would be
necessary to determine what additional genes differ between the cell lines. I postulate that the
observed additional differences are likely due to both CRISPR/Cas9 off-target effects as well as
mutations in the cell lines that may have occurred during clonal isolation, passaging, and/or
propagation. STR-profiling authenticated all constructed cell lines as MDA-MB-231 but is limited
by the fact that only a few genomic locations are interrogated. Mutations could have occurred at
locations not probed by STR-profiling.
While I acknowledge that there is very strong evidence of differences in addition to NAT1
expression in the constructed cell lines, the elegant study design and sample selection utilized in
this dissertation allowed those differences to be filtered out and focus to be placed on results that
were due to the modulation of NAT1. For example, observations and results that were present
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Figure 7.1
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Figure 7.1: Evidence of Additional Differences Between Cell Lines Other Than NAT1.
There are many sources of evidence for the assertion that there are differences other than NAT1 in the constructed cell lines. Concordance
between both metabolites and genes was lower than disagreement between the two MDA-MB-231 cell lines with no detectable NAT1 Nacetylation activity but constructed using two different guide RNAs; metabolites and genes in green were increased while metabolites and genes in
red were decreased. Additionally, the first branch in hierarchical clustering, in both the metabolomics and transcriptomics datasets, separated the
two MDA-MB-231 cell lines constructed utilizing guide RNA 2 but with different levels of NAT1 N-acetylation activity. In the bioenergetics dataset,
both mitochondrial reserve capacity and baseline ECAR were significantly increased in the CRISPR 2-19 cell line compared to the CRISPR 5-50
cell line, even both have no detectable NAT1 activity. Principal component analysis in the metabolomics dataset revealed most of the variance in
the dataset was between the two MDA-MB-231 cell lines constructed utilizing guide RNA 2 but with different levels of NAT1 N-acetylation activity
and all other cell lines. Data is color coded by cell line; Scrambled:salmon, Up:green, Down:mustard, CRISPR 2-12:teal, CRISPR 2-19:sky blue,
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CRISPR 5-50:pinkish purple.

in both NAT1 knockout cell lines were focused on, given any off-target effects caused by the use
of a single guide RNA are likely not present in both cell lines. Additionally, mutations that
occurred during clonal isolation or passaging are not likely to have occurred in the same gene in
multiple cell lines thus allowing a focus on similarities rather than differences in the two NAT1
knockout cell lines.
Bioenergetics
Mitochondrial reserve capacity was increased in both NAT1 knockout cell lines (CRISPR
2-19 and CRISPR 5-50) compared to the Parent, Scrambled, and Up cell lines. However, it was
also significantly higher in the CRISPR 2-19 cell line compared to the CRISPR 5-50 cell line
suggesting differences other than NAT1 between the two cell lines. Baseline ECAR was also
significantly increased in the CRISPR 2-19 cell line compared to the CRISPR 5-50 cell line. In the
bioenergetics conclusions (Chapter 3), observations have been attributed to the modulation of
NAT1 only if the change was observed in the same direction in both NAT1 knockout cell lines,
CRISPR 2-19 and CRISPR 5-50. Unfortunately, the CRISPR 2-12 cell line was not utilized in the
Bioenergetics studies thus preventing comparison between the two cell lines constructed via
guide RNA 2.
Metabolomics
Multiple analyses of the metabolomics dataset suggested there are differences in
addition to NAT1 between the constructed cell lines. Comparing metabolites that were
concordantly differentially abundant in the two complete NAT1 knockout cell lines revealed many
more metabolites were uniquely differentially abundant than agreed between the two NAT1
knockout cell lines, with only 16% concordance between the CRISPR 2-19 and CRISPR 5-50 cell
lines. Additionally, hierarchical clustering analysis revealed the cell lines constructed using guide
RNA 2, CRISPR 2-12 and CRISPR 2-19, had more similar global metabolomics profiles than the
cell lines with comparable NAT1 N-acetylation activity, Down and CRISPR 5-50, respectively.
Furthermore, principal component analysis of the data revealed that nearly 53% of the total
variance in the metabolomics data was between the two cell lines generated using guide RNA 2
and all other cell lines while approximately 17% of the total variance in the data was between the
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CRISPR 5-50 cell line and all other cell lines. The first two principle components, together,
account for approximately 70% of the total variance in the dataset and separate the
CRISPR/Cas9 constructed cell lines from the siRNA constructed cell lines.
Transcriptomics
Similar to the metabolomics dataset, many more genes were uniquely differentially
expressed than were concordantly differentially expressed between the two NAT1 knockout cell
lines with only 27% concordance between the CRISPR 2-19 and CRISPR 5-50 cell lines.
Additionally, hierarchical clustering analysis revealed the cell lines constructed using guide RNA
2, CRISPR 2-12 and CRISPR 2-19, had more similar global transcriptomics profiles than the cell
lines with comparable NAT1 N-acetylation activity, Down and CRISPR 5-50, respectively.
Furthermore, principal component analysis supported this conclusion although the results were
not as striking as the metabolomics principal component analysis.
Combined Analysis
Analysis of the combined metabolomics and transcriptomics datasets also indicates there
are differences other than NAT1 in our constructed cell lines. Component 1 of the sPLS-DA
discriminates the CRISPR 5-50 cell line from all others; the metabolites found in component 1 are
characterized by lactate and sulfate moieties thus suggesting the CRISPR 5-50 has additional
mutations in pathways that contain these metabolites. Component 2 of the sPLS-DA
discriminates the CRISPR 2-12 and CRISPR 2-19 cell lines from all others; the metabolites found
in component 2 are characterized by choline moieties thus suggesting the CRISPR 2-12 and
CRISPR 2-19 cell lines have additional mutations in pathways that contain choline metabolites.
Discussion
Since February 2013, when it was first reported that the CRISPR/Cas9 system could be
used to edit eukaryotic genomes229, many researchers and labs around the world have taken
advantage of this system as a research tool to study the role of single genes in a variety of
diseases230-239. Although the CRISPR/Cas9 system has been shown to have high specificity, it is
still possible for the guide RNAs used to cause off-target effects240-242. Also, when using the clonal
isolation method to select single cells where the gene of interest has been knocked-out rather
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than a pool of cells, the chance of spontaneous, independent mutations occurring in each
generated cell line increases. These off-target effects and spontaneous mutations may lead to
incorrect conclusions about the role of the specific gene under investigation.
There are multiple online tools, including MIT CRISPR Design Tool243 and E-CRISP244,
that use algorithms to generate CRISPR gRNA sequences and predict off-target mutation sites of
those gRNAs based on “rules” about mismatch number and position. The E-CRISP web-based
“evaluation” algorithm has been utilized to predict off-target mutation sites based on the
sequences of the two guide RNAs utilized during construction (Table 7.1 & 7.2); MIT CRISPR
Design Tool does not allow posteriori evaluation of gRNA sequences. The transcriptomics
dataset was then utilized to compare gene expression of genes in which there was a predicted
off-target sites. The author acknowledges that RNA expression does not always correlate
perfectly with protein function and will not indicate definitely if a mutation causing knockout of the
gene has occurred. However, a decrease in NAT1 transcripts in the two NAT1 knockout cell lines
was observed and decreases in transcript abundance of off-target genes can serve as a proxy
measure for off-target effects. No differences were observed in any of the genes predicted by the
web-based algorithms to have off-target mutations.
Additionally, there are currently multiple methods available that have been developed
specifically to detect off-target activity of CRISPR-Cas9 guide RNAs such as integrase-defective
lentiviral vectors (IDLVs)245, Digenome-seq246, GUIDE-seq247, and qEva-CRISPR248, however
these need to be performed during construction. Additionally, some researchers use whole
genome sequencing (WGS) to evaluate the presence of possible off-target mutations. This is the
only method that can definitively identify additional mutations a posteriori construction. Notably,
however, not all researchers make use of these technologies to profile their cell lines. Moreover,
many studies utilizing CRISPR/Cas9 technology to construct knockout cell lines do not conduct
global, holistic profiling of the resulting cell lines but rather make small, very targeted, reductionist
measurements. Additionally, very few studies utilize two different guide RNAs to knockout the
gene of interest. The author hypothesizes other studies utilizing CRISPR/Cas9
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Table 7.1
Guide RNA 2 predicted targets
TARGET
START
CHROMOSOME
20
62393719
5
149360724
9
78994637
17
74041132
4
1816643
2
63708726
8
18222137
8
18400093

END
62393742
149360747
78994660
74041155
1816666
63708749
18222160
18400116

GENE TARGET
(ENSBL ID)
ENSG00000149679
ENSG00000145882
NA
NA
ENSG00000168924
ENSG00000143951
ENSG00000171428
ENSG00000156006

GENE
NAME
CABLES2
PCYOX1L
NA
NA
LETM1
WDPCP
NAT1
NAT2

SEQUENCE
TGAAGGGAACAACTCAGATCAAG
CAAAGGGAACAGCTCGGACAAAG
TAAAGAGAACAGCTGGGATCAAG
CTAAGGGGACAGCTGGGATCCAG
AGAAGGGCCCAGCTCGGATCCAG
AAATGGGAACAGCTCCGATCTAG
CAAAGGGAACAGCTCGGATCTGG
CAAAGGGAACAGCCCGGATCTGG

DIRECTION
fw
fw
fw
fw
fw
rc
rc
rc

E-CRISP web-based “evaluation” algorithm was utilized to predict off-target mutation sites based on the sequences of the guide RNA 2 utilized
during construction. fw = forward orientation, rc = reverse orientation
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Table 7.2
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Guide RNA 5 predicted targets
TARGET
START
CHROMOSOME
3
122941233
8
77188268
21
24269418
2
194868769
CHR_HSCHR6_
30001513
MHC_COX_CTG1
CHR_HSCHR6_
30004125
MHC_APD_CTG1
CHR_HSCHR6_
30001951
MHC_DBB_CTG1
8
91943377
2
208352693
3
104893231
5
117577755
6
123305929
18
39817888
5
91359933
7
22336060
8
18222075
8
18400031
1
90780522
11
37011189

122941256
77188291
24269441
194868792

GENE TARGETS
(ENSBL ID)
ENSG00000082684
NA
NA
NA

SEMA5B
NA
NA
NA

ACATTGGCTCTAAGAAGCCTAAG
TCATTGGCTAGAACAAGTCTTAG
GAATTGGCTATCAGAAGTCCTAG
AAAATGGCTACAAGAAGTCTTAG

fw
rc
fw
fw

30001536

ENSG00000229653

NCRNA00171

CTATTGGTTATAAGAAGTCACAG

fw

30004148

ENSG00000236598

NCRNA00171

CTATTGGTTATAAGAAGTCACAG

fw

30001974

ENSG00000225618

NCRNA00171

CTATTGGTTATAAGAAGTCACAG

fw

91943400
208352716
104893254
117577778
123305952
39817911
91359956
22336083
18222098
18400054
90780545
37011212

NA
ENSG00000115020
NA
NA
ENSG00000186439
NA
NA
ENSG00000136237
ENSG00000171428
ENSG00000156006
NA
NA

NA
PIKFYVE
NA
NA
TRDN
NA
NA
RAPGEF5
NAT1
NAT2
NA
NA

TTATTGGCTATAAGATGCCTCAG
GAATTGGTTATAAGAACTCTCAG
TCATTGGATATGAGAAGTCTCAG
TAATTGGCTAGAAGAAGTTTCAG
TCAGTGGCTATAACAAGTCTCAG
GGATTGGCTATAAGAAGTAAGAG
TGGTTGGCTATAAGAAGACTGGG
GCATTGGGAATAAGAAGTCTGGG
GAATTGGCTATAAGAAGTCTAGG
GAATTGGCTATAAGAACTCTAGG
GGATTGGCTATATGAAGTCAAGG
TTATTAGCTATAAGAAGGCTAGG

rc
fw
fw
rc
fw
fw
fw
rc
fw
fw
fw
rc

END

GENE NAME

SEQUENCE

DIRECTION

E-CRISP web-based “evaluation” algorithm was utilized to predict off-target mutation sites based on the sequences of the guide RNA 5 utilized
during construction. fw = forward orientation, rc = reverse orientation

generated cell lines most likely have additional differences in addition to their gene of interest but
do not make measurements that would allow detection of such differences. Convincing evidence
has been presented in this chapter that greater caution should be applied when interpreting
results from studies utilizing CRISPR/Cas9 to knockout a single gene of interest especially when
those studies have not profiled the cell lines globally, utilizing at least one omics technology
and/or utilizing two different guide RNA’s to knockout the gene thus constructing two knockout
cell lines for comparison. Great bias is introduced via the reductionist approach in those studies
and that bias may lead to naivety about additional mutations in samples.
As an example, in a study by Tsai et al. multiple CRISPR/Cas guide RNAs were used to
edit the gene VEGFA, on chromosome 6, to compare on-target and off-target mutations247. The
authors found the selected guide RNAs could also target genes on virtually every one of the other
22 human chromosomes. Although each CRISPR guide RNA had zero to a dozen or so predicted
off-target sites (by previously discussed web-based algorithms), neither algorithmic software used
(MIT CRISPR Design Tool243 and E-CRISP244) identified the vast majority of off-target sites247;
depending on the guide RNA, 0 to >150 off-target mutations were observed. Additionally, the offtarget sites had diverse sequences making prediction of where off-target effects occur rather
difficult. Without prediction of these off-target sites, scientists would have no idea where to look in
the genome for possible off-target mutations and no idea those errors were possible. This
example highlights the importance of global profiling (unbiased measurement of many aspects of
the global system) of CRISPR/Cas9 generated cell lines as well as the importance of including
cell lines generated with multiple different guide RNAs to be able to filter out off-target effects.
Notably, another study found that many off-target sites were mutated with frequencies
comparable to or even higher than the on-target site249.
Summary and Conclusions
The results from all experiments presented in this dissertation, 1. bioenergetics (Chapter
3), 2. metabolomics (Chapter 4), and 3. transcriptomics (Chapter 5), strongly suggest the
constructed MDA-MB-231 cell lines had differences in gene(s) other than NAT1 that were
unexpected. Without the sophisticated study design in which a global systems biology approach
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was utilized as well as multiple guide RNAs, I most likely would not have been aware that there
were additional differences between the cell lines. Additionally, it would have been nearly
impossible to parse out what effects were due to NAT1 and what effects were due to these
additional differences. These findings have especially great implications for researchers planning
to utilize CRISPR/Cas9 gene editing technology in humans; I assert that the potential for offtarget effects using CRISPR/Cas9 has been underappreciated and under-reported in the
literature due to the lack of global profiling. Currently, considerable research is being conducted
on ways to optimize CRISPR editing efficiency and decrease the number of off-target effects that
occur when utilizing CRISPR/Cas9 technology to edit genes250. Additionally, researchers in the
field are working on better ways to detect and/or predict off-target effects given both are still a
major challenge.

181

CHAPTER 8

SUMMARY AND CONCLUSIONS

Summary
This dissertation presents convincing evidence that NAT1, whether directly or through an
effect on acetyl-CoA levels, has a role in cellular metabolism and energetics in MDA-MB-231
breast cancer cells. Mitochondrial bioenergetics, specifically reserve capacity, maximal
respiration, and glycolytic reserve capacity were increased in the NAT1 knockout cell lines
(CRISPR 2-19 and CRISPR 5-50) while bioenergetics in the cell line with increased NAT1 Nacetylation activity (Up) were not significantly different from the cell lines with parental NAT1 Nacetylation activity (Parent and Scrambled). Additionally, in both the metabolomics and
transcriptomics experiments presented in this dissertation, metabolite abundances and gene
transcript expression were more dysregulated in the NAT1 knockout cell lines (CRISPR 2-19 and
CRISPR 5-50) than the cell line with increased NAT1 (Up) compared to the cell line with parental
NAT1 N-acetylation activity (Scrambled) suggesting the loss of NAT1 has a greater impact on
metabolism than its overexpression.
By utilizing a global systems biology approach, new directions for future research on
NAT1’s role in breast cancer cell metabolism have been generated that would not have been
considered otherwise. Systems biology allows a more unbiased view compared to traditional
reductionist approaches, thus enabling NAT1 research to be stimulated in a novel direction. The
data presented in this dissertation has also shown that the knockout of NAT1 induced more
changes bioenergetically, metabolically, and transcriptionally compared to the overexpression of
NAT1. As there is active research in the NAT field on the development of small molecule
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inhibitors of NAT1, it is important to understand how the knockout of NAT1 N-acetylation activity
and expression affects global cellular metabolism.
Strengths of This Work
The experimental design strategies and research presented in this dissertation have
several strengths that enabled many novel insights as well as the formulation of additional
hypotheses about NAT1’s role in breast cancer and, more generally, metabolism. The first major
strength I will discuss is the use of publicly available data to annotate previously undefined
relationships between NAT1, NAT2, & ESR1 in established breast cancer cell lines, primary
breast tumors, and normal breast tissue. For these analyses data was accessed and analyzed
(fairly quickly) without the need to do, what would have been, expensive wet-lab experiments.
Publicly available data repositories offer a wealth of knowledge but, until now, have been underutilized in NAT research. Additionally, the data repositories can be utilized to evaluate whether
the relationships observed in the datasets presented in this dissertation are also present in the
larger publicly available datasets.
A second strength of this work was the careful and thoughtful selection of samples. By
choosing a single breast cancer cell line and genetically modifying only NAT1 (theoretically) any
confounding factors that might be introduced when utilizing breast cancer cell lines with innately
different levels of NAT1 activity due to different genetic backgrounds and the presence of
additional unique mutations in each cell line have been eliminated. The MDA-MB-231 cell line
was chosen rather than an estrogen receptor positive cell line because cell lines with NAT1
knocked out as well as overexpressed were desired. To this end, a breast cancer cell line with an
approximate mid-level of NAT1 activity was selected. However, very few of the breast cancer cell
lines available for research (approximately 57 total) have been characterized for NAT1 Nacetylation activity. Therefore, RNA expression was used as a proxy for NAT1 N-acetylation
activity because publicly available data on NAT1 RNA expression of all 57 breast cancer cell lines
are available (discussed and utilized in Chapter 2). The MDA-MB-231 cell line expresses an
approximate mid-level of NAT1 RNA compared to the other 56 breast cancer cell lines.
Additionally, this cell line is frequently utilized in breast cancer research and has been utilized in
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previous studies looking at NAT1’s role in breast cancer thus allowing comparison of experiments
and observations more readily.
Additionally, during construction of the MDA-MB-231 breast cancer cell lines with varying
levels of NAT1 N-acetylation activity two different methods, siRNA and CRISPR/Cas9, were
utilized. This strategy helped to ensure any results or conclusions reported are truly due to
differences in NAT1 activity and not a result of the methodology utilized to modulate NAT1
expression. To this end, during construction of the complete NAT1 knockout cell lines via
CRISPR/Cas9 technology two unique NAT1 targeting guide RNAs were utilized, again ensuring
any results or conclusions reported are truly due to differences in NAT1 activity because guide
RNAs have been shown to cause off-target effects. In fact, as presented in Chapter 7, there is
strong evidence of additional differences other than NAT1 in the genetically modified cell lines;
without inclusion of NAT1 knockout cell lines constructed via different guide RNAs (CRISPR 2-19
and CRISPR 5-50) and cell lines constructed with the same guide RNA but that had different
levels of NAT1 N-acetylation activity (CRISPR 2-12 and CRISPR 2-19), this observation would
most likely have been missed and the results would be unknowingly confounded.
The third major advantage of the work presented in this dissertation is the systems
biology approach utilized to evaluate the dissertation hypothesis rather than the more traditional
reductionist approach. Notably, by using the exact same biological samples, collected and grown
at the exact same time in the metabolomics and transcriptomics experiments we integrated the
two resulting datasets on cells under identical biological conditions. Additionally, bioenergetics
and transcriptomics experiments were integrated by comparing mitochondrial gene expression. A
global systems biology approach has enabled stimulation of NAT1 research in new directions.
Caveats and Weaknesses
Although the work presented in this dissertation was well planned and executed there are
nevertheless caveats and weaknesses. The first caveat to acknowledge is that although this
dissertation asserts that a global analysis of the complete system was performed, that is not
entirely true. The field of metabolomics is limited by the number of metabolites that can be
detected analytically. Therefore, that assertion must be qualified to acknowledge that this study
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was a global metabolomics experiment in that data was collected on as many metabolites as was
feasible which still represents a small proportion of all metabolites present in the human
metabolome (Figure 8.1). Additionally, because metabolites were only isolated from cell pellets
and not the surrounding media, metabolites excreted from the cell that would be important in
understanding NAT1’s effects on cellular metabolism may have been missed. However, media
was collected and reserved during collection of cell pellet samples for possible future analyses.
Another caveat to acknowledge is the bias introduced by reliance on NAT1 N-acetylation
activity as a measure for NAT1 function. Although NAT1 N-acetylation is increased, decreased,
and not detectable in the constructed cell lines, it remains unknown if possible additional
functions/roles of NAT1 were not also affected and contribute to our overall observations in an as
yet uncharacterized manner. It will also be important for future studies to evaluate the findings
presented in this dissertation in additional breast cancer cell lines, untransformed (normal) breast
cell lines, and other cancers.
Notably, although sample choice was a major strength in this work it can also be viewed
as a weakness. The conclusions presented in this dissertation are based on results derived from
modulating NAT1 in a single breast cancer cell line; however, breast cancer is a very
heterogenous disease. The MDA-MB-231 breast cancer cell line may have unique mutations in
genes that are regulators, interactors, producing or metabolizing substrates for NAT1, or altering
metabolism independent of NAT1 status. It will be important for future work to conduct
experiments in other breast cancer cell lines and more generally, other cancer types where NAT1
is commonly overexpressed, to determine if our observations hold true. Although human breast
tumor samples would have been more biologically relevant, as the tumor microenvironment would
have been better represented, human samples would add more confounding factors when
interpreting results. Additionally, there is a great need to analyze data from human subjects to
see if these observations correlate with samples from a complete human system. Similarly, the
research presented here was conducted on samples that were already malignant in nature,
making inferences about NAT1’s role in breast cancer risk or tumorigenesis not possible. Results
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Figure 8.1
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Figure 8.1: Limitations of “Global” Metabolomics.
A Venn diagram depicting a significant issue in “global” metabolomics. Researchers are limited by
metabolite annotation, the ability to analytically detect metabolites, and the localization of
metabolites. When attempting to make inference about changes in metabolic pathways
metabolites in the intersection of the three circles are observed when the target metabolic
pathway is the entire rectangle. These difficulties limit the ability to obtain a true global view of
metabolism however there is abundant research being conducted in the field to improve all three.
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may be different if experiments were performed on non-malignant breast cells and further studies
in non-malignant cells are necessary.
Another weakness of the work presented here was the presence of differences other than
NAT1 in the constructed cell lines (presented in Chapter 7). These additional differences
complicated interpretations of the data. However, without a global systems biology approach, we
would not have realized there were additional differences and may have incorrectly attributed
results to the modulation of NAT1. It is the author’s opinion that other CRISPR/Cas9 studies also
have off-target effects. However, the measurements or observations that are made do not allow a
high-level global view so these off-target effects may be missed. Additionally, inclusion of two
NAT1 knockout cell lines that were generated using two different guide RNAs differences that
were truly due to the modulation of NAT1 to be focused on. In the future, whole genome
sequencing of the cell lines utilized in this study should be conducted to determine exactly which
genes these additional differences have occurred in. This may aide interpretation of some of the
results presented in this dissertation.
The final weakness of this work to be discussed was the inability to stably rescue NAT1
in the constructed NAT1 knockout cell lines. This rescue would have allowed greater confidence
that observations and results were truly due to the knockout of NAT1. It is predicted that any
observations truly due to NAT1 knockout would be reversed with the rescue of NAT1 activity and
conversely, predicted that any observations due to differences other than NAT1 would not be
reversed by the rescue of NAT1.
Future Directions
In addition to the results and conclusions that were presented in this dissertation, many
novel hypotheses about the role of NAT1 in breast cancer, and more generally cellular
metabolism, have been generated. As such, I propose numerous future directions to further
delineate the mechanism by which NAT1 affects breast cancer progression and the possible role
of NAT1 in cellular metabolism.
The first future direction, which is currently in progress, is to incubate the cell lines used
in this study with L-asparagine to measure how this supplementation affects cell growth and
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invasive ability, given the strong positive correlation between NAT1 N-acetylation activity and Nacetylasparagine and the recently proposed role of L-asparagine in breast cancer cell growth and
metastasis189,190. Although our lab currently does not have the ability to readily measure Lasparagine and/or N-acetylasparagine, the proposed experiments will help determine if cell lines
with varying NAT1 N-acetylation activities respond differently to L-asparagine supplementation. If
differences in growth and metastatic are observed based on NAT1 activity, that will add evidence
to the hypothesis that there is a relationship between NAT1 and L-asparagine. Additionally, our
lab is currently working with collaborators to develop an HPLC-fluorescence detection method to
detect N-acetylasparagine and L-asparagine. Once this method is optimized, recombinant human
NAT1 expressed in yeast lysates could be incubated with acetyl-CoA and L-asparagine to
evaluate if NAT1 is directly catalyzing the N-acetylation of L-asparagine more directly. Until then,
our lab is conducting competitive activity assays between PABA and L-asparagine to see if the
rate of N-acetylation of PABA is affected in the presence of L-asparagine in the reaction.
Similarly, studies using putrescine instead of L-asparagine could be performed given there is
evidence both biochemicals may be NAT1 substrates.
An additional area of future research will be further evaluating the mechanism by which
NAT2 transcripts are increased in NAT1 knockout cell lines (CRISPR 2-19 and CRISPR 5-50).
From the results of the transcriptomics data, a list of candidate genes that are predicted to
interact with NAT2 has been created. The candidate genes were chosen based on correlated
expression with NAT2 expression and also based on clustering with NAT2 in the WGCNA
analysis. While this phenomenon was observed in the constructed breast cancer cell lines, it is
unclear if this occurs in humans. I propose analyzing NAT1 and NAT2 gene expression data in
human subjects with no detectable NAT1 activity to see if the phenomenon is present. One
foreseeable limitation is the relatively rare occurrence of humans with no detectable NAT1
activity. While functional NAT2 N-acetylation activity was not observed in the NAT1 knockout cell
lines, investigating the mechanism by which NAT2 transcripts are produced will be an important
area of NAT research in the future. An additional area of research will be investigating miRNAs
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that possibly target NAT2 to help explain the observation of NAT2 transcripts but no NAT2 Nacetylation activity.
On the basis that many of our observations and results can be traced to reactions that
involve mitochondria, an additional future direction is to probe mitochondrial mass, biogenesis,
and morphology in our constructed cell lines. Additionally, reactive oxygen species (ROS) in
mitochondria can be evaluated. This will help determine if the observations presented in this
dissertation are related to changes in mitochondria biogenesis/number directly or dysregulation of
the reactions that occur in mitochondria.
Given the strong evidence of genetic differences in addition to NAT1 in the constructed
cell lines utilized in the studies presented in this dissertation, I propose performing WGS to
determine the exact location of the differences. This method is the only way to definitively
determine the genetic differences between the constructed cell lines. Once additional genetic
differences between the cell lines are determined, that information may be utilized to study those
genes. Additionally, the results of this proposed experiment will have great implications for past,
present, and future studies utilizing CRISPR/Cas9.
The final future direction proposed is integrating the three datasets presented in this
dissertation with the proteomics and acetylomics previously collected by our lab (collected only
for the complete NAT1 knockout cell lines, CRISPR 2-19 and CRISPR 5-50). As human
metabolism is a very highly regulated process and composed of many layers, combining these
datasets would add an additional level to the systems biology approach presented in this
dissertation. Combining the datasets will not be easy but improved methodology for combining
multi-omics datasets is currently a rich area of development (discussed in Chapter 6) in the
systems biology field.
Overall Conclusions
This dissertation has presented evidence that greater caution should be exercised in
interpretation of results from single gene knockout studies utilizing CRISPR/Cas9. The elegant
study design utilized in this dissertation enabled me to conclude CRISPR/Cas9 can cause offtarget effects in sites not predicted by web-based algorithms that would confound conclusions.

189

Furthermore, I have shown that publicly available datasets can be used to complement and
enhance wet-lab experiments very quickly and inexpensively.
I have presented strong evidence that NAT1, whether directly or through the effect of
NAT1 on acetyl-CoA levels, has an effect on acyl-CoA carnitine conjugates, lysine degradation,
and mitochondrial function (Figure 6.11). Saccharopine is the first product formed during lysine
degradation in mammals and was increased in cell lines with decreased levels and knockout
NAT1 (Down, CRISPR 2-12, CRISPR 2-19, and CRISPR 5-50). Notably, carnitine is
biosynthesized from methionine and lysine. Increases in saccharopine suggest more lysine is
degraded, leaving less lysine for carnitine biosynthesis. Fatty acyl-CoA carnitine conjugate
metabolites were decreased in the NAT1 knockout cell lines (CRISPR 2-19 and CRISPR 5-50)
and those metabolites were strongly correlated with carnitine abundance. In humans, fatty acylCoAs are conjugated to carnitine for transport to the mitochondria and subsequent beta oxidation
producing acetyl-CoA. The decrease in fatty acyl-CoA conjugates in the NAT1 knockout cell lines
(CRISPR 2-19 and CRISPR 5-50) suggest less acetyl-CoA is produced by this mitochondrial
pathway. It remains unknown whether this is a dysregulation of energetics or complex feedback
due to increased acetyl-CoA because of decreased NAT1 catalyzed hydrolysis of acetyl-CoA.
Overall, this dissertation describes the first studies to investigate the effect varying
human NAT1 activity has on the bioenergetics profile, metabolome, and transcriptome of a breast
cancer cell line. This dissertation has generated vast amounts of data that I foresee being utilized
for years to come as we learn more about NAT1 thus providing a valuable resource for future
studies. Additionally, I have used this data to generate novel hypotheses about the role of NAT1
in breast cancer, and more generally cellular metabolism. Furthermore, I have identified
biochemicals that are likely products of NAT1 N-acetylation, N-acetylasparagine and Nacetylputrescine, however further studies are needed to confirm this. While I have not identified
the exact mechanism by which NAT1 affects cellular metabolism or breast cancer progression,
the data presented in this dissertation add important pieces to the puzzle, putting NAT
researchers one step closer to that goal.
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ABBREVIATIONS

r

Spearman Correlation Coefficient

2-AF

2-aminoflourene

4-ABP

4-aminobiphenyl

3’UTR

3 Prime Untranslated Region

Acetyl-CoA

Acetyl Coenzyme A

ACS

American Cancer Society

ACY1

Aminoacylase 1

ALK

Anaplastic Lymphoma Receptor Tyrosine Kinase

AMPK

5' Adenosine Monophosphate-Activated Protein Kinase

ANOVA

Analysis of Variance

ASPA

Aminoacylase 2

ATCC

American Type Culture Collection

ATP

Adenosine Triphosphate

BRCA

Breast Invasive Cohort in TCGA

BRCA1

Breast Cancer 1, Early Onset

BRCA2

Breast Cancer 2, Early Onset

CCLE

Cancer Cell Line Encyclopedia

cDNA

Complementary Deoxyribose Nucleic Acid

CGeMM

Center for Genetics and Molecular Medicine

cKIT

KIT Proto-Oncogene Receptor Tyrosine Kinase

CRISPR

Clustered Regularly Interspaced Short Palindromic Repeats

CRISPR/Cas9 Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR Associated
Protein 9
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DMEM

Dulbecco's Modified Eagle Medium

DNA

Deoxyribonucleic Acid

ECAR

Extracellular Acidification Rate

EGFR

Epidermal Growth Factor Receptor

ER+

Estrogen Receptor Positive

ER-

Estrogen Receptor Negative

ER

Estrogen Receptor

ESR1

Estrogen Receptor 1

ESI

Electrospray Ionization

FA

Formic Acid

FCCP

Carbonyl Cyanide-p-trifluoromethoxyphenylhydrazone

FRT

Flippase Recognition Target

GFP

Green Fluorescent Protein

GI

Gastrointestinal

GNAQ/GNA11 G Protein Subunit Alpha Q/G Protein Subunit Alpha 11
gRNA(s)

Guide Ribonucleic Acid(s)

HER2

Human Epidermal Growth Factor Receptor 2

HESI

Heated Electrospray Ionization

HILIC

Hydrophilic Interaction Liquid Chromatography

HMDB

Human Metabolome Database

HPLC

High Performance Liquid Chromatography

HUGO

Human Genome Organization

IDLVs

Integrase-Defective Lentiviral Vectors

IGV

Integrative Genomics Viewer

IQR

Interquartile Range

KBRIN

Kentucky Biomedical Research Infrastructure Network

KEGG

Kyoto Encyclopedia of Genes and Genomes

KO

Knockout
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LIMS

Laboratory Information Management System

MATCH

Molecular Analysis for Therapy Choice

MET

Hepatocyte Growth Factor Receptor

MIT

Massachusetts Institute of Technology

MR1

Methylthioribose-1-Phosphate Isomerase

mRNA

Messenger Ribonucleic Acid

MS

Mass Spectrometry

MTAP

Methylthioadenosine Phosphorylase

mTOR

Mechanistic Target of Rapamycin Kinase

MTT

3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide

m/z

Mass to Charge Ratio

NAT1

arylamine N-acetyltransferase 1

NAT2

arylamine N-acetyltransferase 2

NATs

arylamine N-acetyltransferases

NCI

National Cancer Institute

NTRK

Neurotrophic Tyrosine Kinase

OCR

Oxygen Consumption Rate

ORF

Open Reading Frame

PABA

p-aminosalicylate

pABG

p-aminobenzoylglutamate

PAS

p-aminosalicylate

PBS

Phosphate Buffered Saline

PC1

Principal Component 1

PCR

Polymerase Chain Reaction

PCA

Principal Component Analysis

PFPA

Perfluoropentanoic Acid

PR

Progesterone Receptor

QA/QC

Quality Assessment/Quality Control
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QC

Quality Control

qPCR

Quantitative Polymerase Chain Reaction

r

Pearson Correlation Coefficient

RI

Retention Index

RNA

Ribonucleic Acid

RNA-Seq

Ribonucleic Acid Sequencing

ROS1

ROS Proto-Oncogene 1, Receptor Tyrosine Kinase

RP

Reverse Phase

RPKM

Reads Per Kilobase of Transcript per Million Mapped Reads

RSD

Relative Standard Deviation

RSEM

RNA-Seq by Expectation- Maximization

RT-PCR

Reverse Transcription-Polymerase Chain Reaction

RT-qPCR

Reverse Transcription-Quantitative Polymerase Chain Reaction

SAT1

Spermidine/Spermine N1-Acetyltransferase 1

SAT2

Spermidine/Spermine N1-Acetyltransferase 2

SEM

Standard Error of the Mean

shRNA

Short Hairpin Ribonucleic Acid

siRNA

Silencing Ribonucleic Acid

SMO/PTCH1

Smoothened, Frizzled Class Receptor/Patched 1

SMZ

Sulfamethazine

SNPs

Single Nucleotide Polymorphisms

sPLS-DA

Sparse Partial Least Squares-Discriminant Analysis

STR

Short Tandem Repeat

TCA

Citric Acid Cycle

TCGA

The Cancer Genome Atlas

TNBC

Triple Negative Breast Cancer

TSC1

Tuberous Sclerosis Complex Subunit 1

TSC2

Tuberous Sclerosis Complex Subunit 2
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UPLC

Ultra Performance Liquid Chromatography

UPLC- MS/MS Ultra Performance Liquid Chromatography- Tandem Mass Spectrometry
VEGFA

Vascular Endothelial Growth Factor A

WGCNA

Weighted Gene Co-expression Network Analysis

WGS

Whole Genome Sequencing

WPGMA

Weighted Pair Group Method with Arithmetic Mean
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